
<html lang="en"     class="pb-page"  data-request-id="cf5299b2-7404-46c4-9c70-fef12e194535"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm301658d;issue:issue:10.1021/jmcmar.2013.56.issue-5;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery and Optimization of a Novel Series of Potent Mutant B-RafV600E Selective Kinase Inhibitors" /></meta><meta name="dc.Creator" content="Melissa M.  Vasbinder" /></meta><meta name="dc.Creator" content="Brian  Aquila" /></meta><meta name="dc.Creator" content="Martin  Augustin" /></meta><meta name="dc.Creator" content="Huawei  Chen" /></meta><meta name="dc.Creator" content="Tony  Cheung" /></meta><meta name="dc.Creator" content="Donald  Cook" /></meta><meta name="dc.Creator" content="Lisa  Drew" /></meta><meta name="dc.Creator" content="Benjamin P.  Fauber" /></meta><meta name="dc.Creator" content="Steve  Glossop" /></meta><meta name="dc.Creator" content="Michael  Grondine" /></meta><meta name="dc.Creator" content="Edward  Hennessy" /></meta><meta name="dc.Creator" content="Jeffrey  Johannes" /></meta><meta name="dc.Creator" content="Stephen  Lee" /></meta><meta name="dc.Creator" content="Paul  Lyne" /></meta><meta name="dc.Creator" content="Mario  Mörtl" /></meta><meta name="dc.Creator" content="Charles  Omer" /></meta><meta name="dc.Creator" content="Sangeetha  Palakurthi" /></meta><meta name="dc.Creator" content="Timothy  Pontz" /></meta><meta name="dc.Creator" content="Jon  Read" /></meta><meta name="dc.Creator" content="Li  Sha" /></meta><meta name="dc.Creator" content="Minhui  Shen" /></meta><meta name="dc.Creator" content="Stefan  Steinbacher" /></meta><meta name="dc.Creator" content="Haixia  Wang" /></meta><meta name="dc.Creator" content="Allan  Wu" /></meta><meta name="dc.Creator" content="Minwei  Ye" /></meta><meta name="dc.Description" content="B-Raf represents an attractive target for anticancer therapy and the development of small molecule B-Raf inhibitors has delivered new therapies for metastatic melanoma patients. We have discovered ..." /></meta><meta name="Description" content="B-Raf represents an attractive target for anticancer therapy and the development of small molecule B-Raf inhibitors has delivered new therapies for metastatic melanoma patients. We have discovered ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 27, 2013" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm301658d" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm301658d" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm301658d" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm301658d" /></link>
        
    
    

<title>Discovery and Optimization of a Novel Series of Potent Mutant B-RafV600E Selective Kinase Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm301658d" /></meta><meta property="og:title" content="Discovery and Optimization of a Novel Series of Potent Mutant B-RafV600E Selective Kinase Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0001.jpeg" /></meta><meta property="og:description" content="B-Raf represents an attractive target for anticancer therapy and the development of small molecule B-Raf inhibitors has delivered new therapies for metastatic melanoma patients. We have discovered a novel class of small molecules that inhibit mutant B-RafV600E kinase activity both in vitro and in vivo. Investigations into the structure–activity relationships of the series are presented along with efforts to improve upon the cellular potency, solubility, and pharmacokinetic profile. Compounds selectively inhibited B-RafV600E in vitro and showed preferential antiproliferative activity in mutant B-RafV600E cell lines and exhibited selectivity in a kinase panel against other kinases. Examples from this series inhibit growth of a B-RafV600E A375 xenograft in vivo at a well-tolerated dose. In addition, aminoquinazolines described herein were shown to display pERK elevation in nonmutant B-Raf cell lines in vitro." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm301658d"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm301658d">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm301658d&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm301658d&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm301658d&amp;href=/doi/10.1021/jm301658d" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 1996-2015</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm301652t" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm3016816" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Optimization of a Novel Series of Potent Mutant B-Raf<sup>V600E</sup> Selective Kinase Inhibitors</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Melissa+M.++Vasbinder">Melissa M. Vasbinder</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian++Aquila">Brian Aquila</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Augustin">Martin Augustin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Huawei++Chen">Huawei Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tony++Cheung">Tony Cheung</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Donald++Cook">Donald Cook</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lisa++Drew">Lisa Drew</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Benjamin+P.++Fauber">Benjamin P. Fauber</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steve++Glossop">Steve Glossop</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Grondine">Michael Grondine</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Edward++Hennessy">Edward Hennessy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey++Johannes">Jeffrey Johannes</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephen++Lee">Stephen Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Lyne">Paul Lyne</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mario++M%C3%B6rtl">Mario Mörtl</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Charles++Omer">Charles Omer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sangeetha++Palakurthi">Sangeetha Palakurthi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Timothy++Pontz">Timothy Pontz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jon++Read">Jon Read</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Li++Sha">Li Sha</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Minhui++Shen">Minhui Shen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stefan++Steinbacher">Stefan Steinbacher</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Haixia++Wang">Haixia Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Allan++Wu">Allan Wu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Minwei++Ye">Minwei Ye</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Oncology iMED and <sup>‡</sup>Discovery Sciences, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div><div class="aff-info" id="aff3"><span class="aff-text"><sup>§</sup>Discovery Sciences and <sup>∥</sup>Oncology iMED, AstraZeneca R&D Alderley Park, Cheshire, Macclesfield SK10 4TG, U.K.</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">⊥</span> <span class="aff-text">Proteros Biostructures GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried, Germany</span></div><div class="corresp-info"><strong>*</strong>Phone: 1-781-839-4886. Fax: 1-781-839-4230. E-mail: <a href="/cdn-cgi/l/email-protection#8ce1e9e0e5ffffeda2faedffeee5e2e8e9feccedfff8feedf6e9e2e9efeda2efe3e1"><span class="__cf_email__" data-cfemail="2a474f464359594b045c4b594843444e4f586a4b595e584b504f444f494b04494547">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm301658d&amp;href=/doi/10.1021%2Fjm301658d" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 1996–2015</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 11, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>9 November 2012</li><li><span class="item_label"><b>Published</b> online</span>27 February 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 March 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm301658d" title="DOI URL">https://doi.org/10.1021/jm301658d</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1996%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMelissa%2BM.%2BVasbinder%252C%2BBrian%2BAquila%252C%2BMartin%2BAugustin%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D5%26contentID%3Djm301658d%26title%3DDiscovery%2Band%2BOptimization%2Bof%2Ba%2BNovel%2BSeries%2Bof%2BPotent%2BMutant%2BB-RafV600E%2BSelective%2BKinase%2BInhibitors%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2015%26publicationDate%3DMarch%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm301658d"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3130</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">22</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm301658d" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Optimization of a Novel Series of Potent Mutant B-RafV600E Selective Kinase Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Melissa&quot;,&quot;last_name&quot;:&quot;M. Vasbinder&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;Aquila&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Augustin&quot;},{&quot;first_name&quot;:&quot;Huawei&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Tony&quot;,&quot;last_name&quot;:&quot;Cheung&quot;},{&quot;first_name&quot;:&quot;Donald&quot;,&quot;last_name&quot;:&quot;Cook&quot;},{&quot;first_name&quot;:&quot;Lisa&quot;,&quot;last_name&quot;:&quot;Drew&quot;},{&quot;first_name&quot;:&quot;Benjamin&quot;,&quot;last_name&quot;:&quot;P. Fauber&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;Glossop&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Grondine&quot;},{&quot;first_name&quot;:&quot;Edward&quot;,&quot;last_name&quot;:&quot;Hennessy&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;Johannes&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Lyne&quot;},{&quot;first_name&quot;:&quot;Mario&quot;,&quot;last_name&quot;:&quot;Mörtl&quot;},{&quot;first_name&quot;:&quot;Charles&quot;,&quot;last_name&quot;:&quot;Omer&quot;},{&quot;first_name&quot;:&quot;Sangeetha&quot;,&quot;last_name&quot;:&quot;Palakurthi&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;Pontz&quot;},{&quot;first_name&quot;:&quot;Jon&quot;,&quot;last_name&quot;:&quot;Read&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Sha&quot;},{&quot;first_name&quot;:&quot;Minhui&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;Steinbacher&quot;},{&quot;first_name&quot;:&quot;Haixia&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Allan&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Minwei&quot;,&quot;last_name&quot;:&quot;Ye&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;1996-2015&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm301658d&quot;},&quot;abstract&quot;:&quot;B-Raf represents an attractive target for anticancer therapy and the development of small molecule B-Raf inhibitors has delivered new therapies for metastatic melanoma patients. We have discovered a novel class of small molecules that inhibit mutant B-RafV600E kinase activity both in vitro and in vivo. Investigations into the structure–activity relationships of the series are presented along with efforts to improve upon the cellular potency, solubility, and pharmacokinetic profile. Compounds selectively inhibited B-RafV600E in vitro and showed preferential antiproliferative activity in mutant B-RafV600E cell lines and exhibited selectivity in a kinase panel against other kinases. Examples from this series inhibit growth of a B-RafV600E A375 xenograft in vivo at a well-tolerated dose. In addition, aminoquinazolines described herein were shown to display pERK elevation in nonmutant B-Raf cell lines in vitro.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301658d&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301658d" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301658d&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301658d" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301658d&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301658d" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm301658d&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301658d&amp;href=/doi/10.1021/jm301658d" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm301658d" /></input><a href="/doi/pdf/10.1021/jm301658d" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm301658d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm301658d%26sid%3Dliteratum%253Aachs%26pmid%3D23398453%26genre%3Darticle%26aulast%3DVasbinder%26date%3D2013%26atitle%3DDiscovery%2Band%2BOptimization%2Bof%2Ba%2BNovel%2BSeries%2Bof%2BPotent%2BMutant%2BB-RafV600E%2BSelective%2BKinase%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D5%26spage%3D1996%26epage%3D2015%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jmcmar.2013.56.issue-5/production/jmcmar.2013.56.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">B-Raf represents an attractive target for anticancer therapy and the development of small molecule B-Raf inhibitors has delivered new therapies for metastatic melanoma patients. We have discovered a novel class of small molecules that inhibit mutant B-Raf<sup>V600E</sup> kinase activity both in vitro and in vivo. Investigations into the structure–activity relationships of the series are presented along with efforts to improve upon the cellular potency, solubility, and pharmacokinetic profile. Compounds selectively inhibited B-Raf<sup>V600E</sup> in vitro and showed preferential antiproliferative activity in mutant B-Raf<sup>V600E</sup> cell lines and exhibited selectivity in a kinase panel against other kinases. Examples from this series inhibit growth of a B-Raf<sup>V600E</sup> A375 xenograft in vivo at a well-tolerated dose. In addition, aminoquinazolines described herein were shown to display pERK elevation in nonmutant B-Raf cell lines in vitro.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div class="extra-info-sec articleNote withdrawn"><h4><span></span> Accession Codes</h4><p class="last">PDB ID for <b>3</b>−EphB4 complex, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4bb4">4bb4</a>; PDB ID for the <b>48</b>−B-Raf complex, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4H58">4H58</a>.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77622" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77622" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The Raf family of intracellular serine/threonine protein kinases is involved in the transmission of proliferative signals from cell surface receptors to the cell nucleus through the mitogen-activated protein kinase (MAPK) pathway.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The RAS/RAF/MEK/ERK pathway plays a key role in many cancers and is activated in approximately 30% of all human tumors.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> B-Raf somatic missense mutations have been reported in 66% of malignant melanomas and in a lower occurrence in a wide range of human cancers, with the most prevalent mutation V600E found to be constitutively active in carcinoma cells.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Selectively targeting the mutant form of B-Raf with small molecule inhibitors has been of great interest as a potential therapeutic strategy. The 2011 FDA approval of vemurafenib (PLX4032/RG7204, Plexxikon/Roche)<a onclick="showRef(event, 'ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7">(4-7)</a> for the treatment of metastatic melanoma bearing the B-Raf<sup>V600E</sup> mutation confirmed the importance of B-Raf within the MAPK pathway and advanced the treatment options for melanoma patients. Numerous other clinical and preclinical small molecule inhibitors have been published contributing to this field, further supporting the interest by many in the broader therapeutic potential for B-Raf inhibitors.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8-10)</a></div><div class="NLM_p">We have reported previously an amidoheteroaryl class of compounds to be potent inhibitors of mutant B-Raf<sup>V600E</sup> with in vivo activity.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Compound <b>1</b> represents one such example that potently inhibits B-Raf<sup>V600E</sup> both in vitro (B-Raf <sup>V600E</sup> IC<sub>50</sub> = 16 nM and A375 pERK IC<sub>50</sub> = 40 nM, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) and in vivo. We also identified additional compounds such as <b>2</b> (AZ628)<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> to be potent inhibitors of mutant B-Raf<sup>V600E</sup> (B-Raf <sup>V600E</sup> IC<sub>50</sub> = 34 nM and A375 pERK IC<sub>50</sub> = 15 nM, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), and <b>2</b> has been reported by us and others for its ability to modulate the MAPK pathway.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Examples such as <b>1</b> and <b>2</b> are believed to bind to mutant B-Raf<sup>V600E</sup> in its DFG-out conformation.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> As part of our screening efforts within AstraZeneca to identify inhibitors of B-Raf, we screened a subset of our collection which was biased toward small molecules known or expected to contain kinase inhibitors. Aminoquinazoline <b>3</b> was identified as a singleton hit from this effort and displayed reasonable biochemical (B-Raf <sup>V600E</sup> IC<sub>50</sub> = 77 nM) and cellular potency (A375 pERK IC<sub>50</sub> = 190 nM), as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>. In contrast to previous inhibitors <b>1</b> and <b>2</b>, the hit <b>3</b> was at least 5-fold less potent based on pERK cellular potency. However, we did believe <b>3</b> represented an excellent starting point for further optimization.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. AstraZeneca B-Raf inhibitors <b>1</b>–<b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In this paper, we describe our efforts to further expand and optimize the aminoquinazoline hit <b>3</b> into a DFG-in binding inhibitor of mutant B-Raf<sup>V600E</sup>. Examples from this inhibitor class were optimized for cellular potency, physical properties, and rat pharmacokinetics, resulting in examples with potent in vivo activity in A375 xenograft models. We likewise found that the aminoquinazoline compounds represented herein exhibited a mutant B-Raf<sup>V600E</sup> selective profile based on biochemical activity and preferential cell panel antiproliferative activity over a range of cell lines. The B-Raf<sup>V600E</sup> selective nature of the compounds was found to elevate pERK in nonmutant B-Raf cell lines in vitro, a phenomenon which has been previously documented by others in the literature as resulting from Raf dimerization events.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Aminoquinazolines presented herein represent a new class of B-Raf<sup>V600E</sup> selective inhibitors that provide a complementary profile to those we had previously reported (<b>1</b> and <b>2</b>), thus serving as additional B-Raf<sup>V600E</sup> selective tool compounds to further interrogate the important role of mutant B-Raf within the MAPK pathway.</div><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Synthetic Chemistry</h3><div class="NLM_p">Aminoquinazolines were readily accessed using the following synthetic route (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). Commercially available aldehyde <b>4</b> was converted to 6-bromoaminoquinazoline <b>5</b> by treatment with guanidine carbonate heating in DMA followed by Suzuki coupling with a variety of boronic acids to afford amino derivatives <b>6</b>–<b>16</b>. Palladium-catalyzed coupling with the corresponding aryl bromides generated the final aminoquinazoline analogs <b>3</b> and <b>24</b>–<b>39</b> (Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0011.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Aminoquinazolines <b>3</b> and <b>24</b>–<b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) guanidine carbonate, DMA, 140 °C; (b) Pd(PPh<sub>3</sub>)<sub>4</sub> (20 mol %), K<sub>2</sub>CO<sub>3</sub>, ArB(OH)<sub>2</sub>, DME/water, 90 °C; (c) <b>17</b>–<b>23</b>, Pd<sub>2</sub>(dba)<sub>3</sub> (5 mol %), BINAP (10 mol %), Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 100 °C.</p></p></figure><div class="NLM_p">As described in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>, benzyl amine analogs <b>48</b>–<b>50</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) were generated via the corresponding aminoquinazoline aldehyde <b>40</b>, followed by reductive amination with commercially available amines. A variety of aryl bromides were utilized to generate additional target analogs, including those containing ethers (<b>51</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>), reversed amides (<b>52</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>), and α-methyl benzyl amines and amides (<b>53</b>–<b>58</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Aryl bromides were either commercially available or readily synthesized by standard conditions (see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>).</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0012.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Aminoquinazolines <b>48</b>–<b>50</b> and <b>51</b>–<b>58</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd<sub>2</sub>(dba)<sub>3</sub> (10 mol %), BINAP (20 mol %), Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 100 °C; (b) amine (1.1 equiv), MeOH, 3 Å MS, HOAc (catalytic amount), NaBH<sub>3</sub>CN (1.6 equiv), rt, 12 h then 1 N NaOH; (c) <b>41–47</b>, Xantphos (10 mol %), Cs<sub>2</sub>CO<sub>3</sub> (3.0 equiv), dioxane, Pd(OAc)<sub>2</sub>,160 °C, microwave. For preparation of <b>51</b> and <b>53</b>, see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. 1-[2-(4-Bromophenoxy)ethyl]pyrrolidine was commercially available.</p></p></figure><div class="NLM_p">An alternative route to access similar aminoquinazoline compounds containing either ethers (<b>67</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>), reversed amides (<b>68</b>–<b>70</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>), or <i>N</i>-linked anilines (<b>71</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>) was accomplished, as reported in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Readily accessible 6-bromo-2-chloroquinazoline<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> was treated under either microwave or thermal conditions (method A or B, respectively) with a variety of anilines to afford bromides <b>62</b>–<b>66</b>, which were then subjected to palladium-catalyzed Suzuki coupling conditions with 4-pyridinylboronic acid to afford <b>67</b>–<b>71</b>.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0013.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Aminoquinazolines <b>67</b>–<b>71</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) method A or B [method A, <i>N</i>-(4-aminophenyl)-<i>N</i>-methylacetamide or <i>N</i>-(4-aminophenyl)acetamide (1.5 equiv), MeCN, 125 °C, microwave, 30 min; method B, <b>59–61</b>, propan-2-ol, 100 °C, 2 h]; (b) 4-pyridinylboronic acid (1.5 equiv), Cs<sub>2</sub>CO<sub>3</sub> or K<sub>2</sub>CO<sub>3</sub> (3.0 equiv), dioxane/water or DME/water (4/1), Pd(PPh<sub>3</sub>)<sub>4</sub>or PdCI<sub>2</sub>(dppf)-CH<sub>2</sub>CI<sub>2</sub> (0.1 equiv), 100 °C.</p></p></figure><div class="NLM_p">Additional efforts to explore the effects of further diversifying the α-methyl benzyl motif led to the generation of α-methyl amine intermediate <b>73</b>, which was readily synthesized by palladium-catalyzed coupling of <b>6</b> and <b>72</b> followed by BOC-group deprotection. As described in Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>, intermediate <b>73</b> served as a key building block for rapid synthesis of various α-methyl amides and vinylogous amides such as <b>75</b>–<b>84</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). The α-methyl amides (<b>75</b>–<b>80</b>) were prepared from coupling of the corresponding carboxylic acids with amine <b>73</b> followed by any required deprotection of BOC protecting groups to generate the desired analogs. Compounds <b>81</b> and <b>82</b> were generated by reacting <b>73</b> with cyclic 1,3-diketones such as cyclohexane-1,3-dione or cyclopentane-1,3-dione with a catalytic amount of acid or under microwave conditions in the presence of piperidine-2,4-dione to yield <b>83</b>. Vinylogous amide analog <b>84</b> was synthesized by reduction of commercially available 3,5-dimethoxypyridine followed by protection to afford intermediate <b>74</b>. Treatment of <b>74</b> in the presence of amine <b>73</b> under acid-mediated conditions followed by deprotection of the carbonylbenzyloxy protecting group generated the target compound <b>84</b> (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>).</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0014.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Aminoquinazoline Analogues <b>75</b>–<b>84</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) <b>72</b>, Xantphos (10 mol %), Cs<sub>2</sub>CO<sub>3</sub> (3.0 equiv), dioxane, Pd(OAc)<sub>2</sub> (5 mol %), 100 °C, 4 h; (ii) 2 N HCl in ether. (b) For compounds <b>75</b>–<b>76</b> and <b>78–80</b>, (i) carboxylic acid, DIPEA, HATU, DMF, 60 °C; (ii) 4 M HCl in dioxane or 2 N HCl in ether, rt; for compounds <b>81</b>, <b>82</b>, cyclohexane- or cyclopentane-1,3-dione (3 equiv), HOAc, DIPEA, MeOH, 60 °C, 12 h; for compound <b>83</b>, piperidine-2,4-dione, DMF, microwave, 150 °C; for preparation of <b>77</b>, see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. (c) (i) NaBH<sub>4</sub> (1.8 equiv), MeCN, benzyl carbonochloridate (1.2 equiv), 0 °C, dioxane; (ii) 4 M HCl in dioxane, rt. (d) (i) <b>73</b>, HOAc, NMP, 105 °C, 6 h; (ii) Pearlman’s catalyst (15 mol %), MeOH, rt, H<sub>2</sub>, 1 atm.</p></p></figure><div class="NLM_p">The chemistry we employed to probe substitution at the 7- and 8-positions of the aminoquinazoline is described in Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>. Readily accessible bromo chloride and amino intermediates such as <b>88</b>–<b>90</b> were generated in accordance with known literature procedures.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Treatment of aniline <b>85</b> with 6-bromo-2-chloro-8-methoxyquinazoline in the presence of refluxing propan-2-ol followed by base generated <b>86</b>, which after Suzuki coupling afforded <b>87</b>. Alternatively, the sequence of Suzuki coupling (generating <b>91</b>–<b>93</b>) followed by palladium-catalyzed coupling, deprotection of the BOC group, and acetylation led to the desired analogs (<b>97</b>–<b>99</b>). Further derivatization of <b>95</b> (R<sub>1</sub> = Cl, R = H) and <b>96</b> (R<sub>1</sub> = H, R = Cl) by coupling with methyl boronic acid followed by deprotection of the BOC group and acetylation resulted in <b>100</b> and <b>101</b>.</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0015.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Preparation of Aminoquinazolines <b>87</b> and <b>97</b>–<b>101</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>85</b>, propan-2-ol, reflux, 3 h then DIPEA, reflux. (b) Pd(PPh<sub>3</sub>)<sub>4</sub>, Cs<sub>2</sub>CO<sub>3</sub>, 4-pyridinylboronic acid, dioxane/water (2/1), 90 °C. (c) <b>72</b>, Pd(OAc)<sub>2</sub> (5 mol %), Xantphos (10 mol %), Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 100 °C. (d) (i) HCl/THF or 4 N HCl/dioxane; (ii) NEt<sub>3</sub>, Ac<sub>2</sub>O, rt. (e) (i) <b>95</b>, <b>96</b>, methyl boronic acid, K<sub>2</sub>CO<sub>3</sub> (3.0 equiv), dioxane, Pd(OAc)<sub>2</sub>(4 mol %), PCy<sub>3</sub>-HBF<sub>4</sub> (10 mol %), 100 °C, 12 h; (ii) HCl/THF; (iii) NEt<sub>3</sub>, Ac<sub>2</sub>O, rt.</p></p></figure></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53804" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53804" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Initial Hypothesis of Binding and Approach for Compound Design and Optimization</h3><div class="NLM_p">We obtained a cocrystal of compound <b>3</b> in kinase EphB4, which was used as a surrogate protein due to the high binding site homology to B-Raf<sup>V600E</sup>. The structure confirmed <b>3</b> binding in a DFG-in manner, making the canonical hydrogen-bond interactions with the hinge region of the protein via the N3 of the quinazoline ring and the aniline hydrogen.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The binding mode oriented the 6-position 4-pyridyl group in the selectivity pocket at the back of the ATP site and the 4-substituent of the aniline ring directed into the solvent channel of the ATP site (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A).</div><figure id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Cocrystallization of <b>3</b> in EphB4, which was used as a surrogate to mutant B-Raf, illustrates the compound binding in a DFG-in manner in the ATP site of the kinase domain of the protein. The structure has been deposited in the Protein Data Bank (reference code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4bb4">4bb4</a>). (B) Proposed plan for aminoquinazoline exploration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">On the basis of the knowledge of the binding mode of <b>3</b> in EphB4, the chemistry plan was focused on exploring the SAR of this class of compounds. Our approach was 3-fold and examined exploration of the A-, B-, and C-rings (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B). We prioritized A- and C-ring exploration, as we believed these regions of the molecule would influence most the cellular pERK potency and physical properties without interfering with the B-ring of the molecule, which was responsible for making the key interactions to the hinge region of the protein.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> SAR Development</h3><div class="NLM_p">We began our exploration with modifications to the A-ring and found that a variety of steric and electronic changes to the 4-pyridyl ring resulted in a significant loss in cell potency (<b>24</b>–<b>27</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Likewise, replacing the 4-pyridyl with a phenyl group led to a much less potent compound (<b>28</b>, A375 pERK IC<sub>50</sub> = 3.80 μM). We discovered that a 4-methyl-3-pyridyl group led to improvements in both biochemical and cell potency (<b>30</b>, B-Raf<sup>V600E</sup> IC<sub>50</sub> = 0.023 μM, A375 pERK IC<sub>50</sub> = 0.089 μM), achieving a 2-fold improvement in cell potency vs the initial hit <b>3</b>. However, a 3-pyridyl or substituted 3-pyridyl ring was not tolerated (<b>29</b>, <b>31</b>, <b>32</b>). Further examples that explored the effects of various other nitrogen-containing six-membered ring heterocycles also resulted in a loss of cell potency, such as pyrimidine <b>33</b> (A375 pERK IC<sub>50</sub> = 6.40 μM). Thus, while we identified tight SAR around the 6-position of the aminoquinazoline in the initial A-ring exploration, we were pleased to uncover the improvement in cell potency (i.e, <b>30</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. A-Ring Exploration</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0016.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0017.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Measured at <i>K</i><sub>m</sub> ATP concentration. For experimental details, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">All values are an average of at least two independent dose–response curves. For experimental details, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div></div><div></div></div><div class="NLM_p">We profiled the most potent analogs of this series (<b>3</b> and <b>30</b>) early on to better understand the kinase selectivity profile. Both compounds were screened against a Millipore panel of 83 kinases.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> We concluded the selectivity profile of <b>3</b> to be superior to that of <b>30</b>, as demonstrated by visualization of inhibition profiles and <i>S</i>(10) selectivity scores of 0.01 and 0.11, respectively (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). The results revealed that the 4-pyridyl ring led to an overall more selective profile, in particular against other tyrosine and serine/threonine kinases. Therefore, based on the more promiscuous nature of <b>30</b>, we chose to continue our SAR optimization keeping the 4-pyridyl A-ring constant.</div><figure id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Millipore KinaseProfiler selectivity screening of a diverse kinase set (<i>n</i> = 83) at 1 μM of <b>3</b> and <b>30</b>, with hits overlaid on the kinome phylogenetic tree. Red circles indicate active hits ≤35% of control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition to assessing the kinase selectivity profile, we also studied the biochemical and cell proliferation profile of <b>3</b>.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> We hypothesized on the basis of our findings from both biochemical and cell proliferation data that aminoquinazoline <b>3</b> afforded a different profile to previous inhibitors such as <b>2</b>. Aminoquinazoline <b>3</b> was found to inhibit mutant B-Raf<sup>V600E</sup> but was much less potent against C-Raf<sup>WT</sup> or inactive against B-Raf<sup>WT</sup> under saturated ATP conditions (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A), pointing to evidence for a more mutant B-Raf<sup>V600E</sup> selective profile. Compound <b>2</b> resulted in a different biochemical profile affording a near equal inhibition of B-Raf<sup>V600E</sup> and C-Raf and a drop off in the B-Raf<sup>WT</sup> potency. We obtained similar results after comparing the cell proliferation profile of compounds <b>2</b> and <b>3</b> against a panel of various cell lines. Aminoquinazoline <b>3</b> resulted in preferential antiproliferative activity in the presence of mutant B-Raf<sup>V600E</sup> cell lines (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B). Compound <b>2</b>, when treated under identical cell lines and conditions, inhibited additional nonmutant B-Raf cell lines. Thus, we identified early on the potential for the aminoquinazoline series to provide a different yet complementary profile to the previous inhibitors such as <b>2</b> that we had discovered.</div><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Biochemical inhibitory profile of <b>2</b> and <b>3</b>. For a more detailed description of the biochemical differences of <b>2</b> and <b>3</b> with regard to substrate ATP concentration, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>. (B) Antiproliferative activity of B-Raf inhibitors <b>2</b> and <b>3</b> against a panel of various cell lines. Cells were incubated with DMSO or compounds <b>2</b> or <b>3</b> for 72 h and cell growth was determined by MTS assay, represented as log mean GI<sub>50</sub> (average of three replicates). Cell lines denoted with an asterisk (*) harbor the B-Raf<sup>V600E</sup> mutation. For a complete listing of cell line type, further observations around the proliferation profile, and additional MTS assay details, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further exploration of the C-ring SAR involved modifications toward the solvent channel, a region of the molecule that would allow for optimization of the overall properties of the series. The solubility for <b>3</b> was found to be 3 μM, so a key focus of our optimization and SAR generation was around improving solubility. Meta-substitution of the amido group was not tolerated on the basis of the cellular potency; however, methyl or fluoro substitution adjacent to the <i>p</i>-amido group was acceptable, albeit with no improvement in solubility (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, <b>34</b>–<b>36</b>). We incorporated various basic amines, both acyclic and cyclic, into the amide to serve as solubilizing groups. These changes significantly improved the solubility; however, they resulted in a slight decrease in potency (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, analog <b>39</b>, A375 pERK IC<sub>50</sub> = 330 nM) or had no effect on potency (such as <b>37</b> and <b>38</b>, with similar cellular potency to <b>3</b>). In order to better understand the functional group tolerance at the 2-position of the quinazoline, we investigated other groups in addition to amido-substituted phenyl. Diversifying beyond phenyl amides to benzyl amine derivatives <b>48</b>–<b>50</b>, while improving solubility, led to reduced potency, in particular with example <b>50</b>. Ethers such as <b>51</b> and <b>67</b> did not afford much benefit to potency, though improved solubility could be achieved with the inclusion of basic groups such as the pyrrolidine in <b>51</b>. We also explored reversing the amide with <i>N</i>-linked compounds such as <b>52</b> and <b>68</b>–<b>70</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) or removing the amide altogether with <i>N</i>-linked analog <b>71</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). While not all of these changes led to favorable improvements in cell potency, we were able to find some examples where cell potency below 100 nM was achieved and resulted in modest evidence for desirable solubility (<b>52</b>, A375 pERK IC<sub>50</sub> = 45 nM, solubility 40 μM; <b>69</b>, A375 pERK IC<sub>50</sub> 63 nM, solubility 7 μM; Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). It appeared from the SAR that <i>N</i>-methyl amides were >6-fold more potent in the A375 pERK cellular assay vs their desmethylated matched pairs (i.e., <b>52</b> vs <b>68</b> and <b>69</b> vs <b>70</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). In contrast, <i>N</i>-methyl linked analogs such as <b>71</b> were not tolerated on the basis of much weaker cell potency (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, A375 pERK IC<sub>50</sub> = 855 nM). From our initial exploration varying the functionality at the C-ring, we were able to identify compounds with good solubility and improved potency compared to initial hit <b>3</b>. Next, we further explored analogs <b>52</b> and <b>69</b> with the goal of maintaining the improvements in potency while increasing the solubility.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. C-Ring Modifications</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0018.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0019.gif" alt="" id="fx4" /></img><div></div></div><div class="NLM_p">We were successful in obtaining a cocrystal structure of <b>48</b> in B-Raf<sup>V600E</sup>, and our initial hypotheses from the cocrystallization of <b>3</b> in EphB4 were confirmed (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). The structure revealed binding to the kinase domain in a DFG-in conformation, making the canonical hydrogen bond interaction to the N–H of C531 via the N3 of the quinazoline ring and the backbone carbonyl of E532 via the aniline hydrogen. The 4-substituent of the aniline ring was directed into the solvent channel of the ATP site, and the quinazoline and aniline rings were stacked against the indole side chain of W530. The 6-position 4-pyridyl group was located in the selectivity pocket at the back of the ATP site, above the T528 gatekeeper residue. We speculated on the basis of the structure that our observation of the 4-methyl-3-pyridyl analog (<b>30</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), which resulted in significantly more potent activity as compared to the desmethyl analog (<b>29</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), could be due to anchoring of the methyl group over the T528 gatekeeper residue to capitalize on a lipophilic interaction, thus locking into place the 6-position 3-pyridyl ring into the selectivity pocket. We also hypothesized that the preorganization gained by the lipophilic interaction of the T528 methyl and methyl group of the pyridyl ring in the selectivity pocket contributed to the broader kinase activity of analogs such as <b>30</b>, in particular by other threonine-containing gatekeeper kinases. The X-ray crystal structure of <b>48</b> thus helped support our plans to continue exploring the C-ring substituents in the solvent channel. The X-ray structure also suggested that additional exploration around the B-ring at either the 7- or 8-position of the quinazoline would be tolerated.</div><figure id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0007.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray structure of <b>48</b> bound to the kinase domain of mutant B-Raf<sup>V600E</sup>. The structure has been deposited in the Protein Data Bank (reference code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4H58">4H58</a>), and detailed protein preparation, crystallization, and freezing protocols are included in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Additional exploration of what else could be tolerated in the solvent channel was instrumental to the optimization of this series. We expanded on our prior knowledge that <i>N</i>-methyl amides such as <b>52</b> and <b>69</b> improved potency while retaining modest solubility. We were also concerned that analogs such as <b>52</b> and <b>69</b> could carry a potential mutagenic liability due to the aromatic aniline functionality, and we sought to prioritize design ideas to remove this functionality.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> We found that incorporating an additional atom between the arene and the nitrogen was tolerated, such as α-methyl amino derivative <b>53</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, A375 pERK IC<sub>50</sub> = 49 nM). This compound had improved solubility (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, solubility 830 μM and human plasma protein binding 9.4% free) as compared to the hit <b>3</b> (solubility 3 μM and human plasma protein binding 1.7% free).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Further expanding this theme to other α-methyl amides led to additional examples with promising cell potency. Analogs <b>54</b>–<b>58</b> highlight the stereochemical preference of the α-methyl group with respect to cellular potency. We discovered retention of potency in the (<i>R</i>)-enantiomer of each example (<b>55</b> and <b>58</b>, A375 pERK IC<sub>50</sub> = 60 and 34 nM, respectively); however, these analogs suffered from poor physical properties (solubility <10 μM and human protein binding <2.3% free). On average, the (<i>R</i>)-enantiomers of both <b>54</b> and <b>57</b> were found to be 2–5 times more potent than the corresponding (<i>S</i>)-enantiomers (i.e., <b>56</b> vs <b>55</b>, A375 pERK IC<sub>50</sub> = 160 vs 60 nM).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> We were optimistic about the pharmacokinetic profiles of the α-methyl benzylic amino analogs because examples <b>53</b>, <b>55</b>, and <b>58</b> had favorable rat liver hepatocyte stabilities (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, rat hepatocyte CL<sub>int</sub> 16, 11, and 6 μL/min/1E6, respectively). Likewise, human microsomal stabilities for <b>53</b> and <b>58</b> were in a desirable range (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Encouraged by these results, we expanded upon the (<i>R</i>)-α-methyl amide motif.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Additional C-Ring Modifications</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0020.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0021.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Measured at <i>K</i><sub>m</sub> ATP concentration. For experimental details, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">All values are an average of at least two independent dose–response curves. For experimental details, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">Human PPB, rat hepatocyte, and human microsomal stability details can be found in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div></div><div></div></div><div class="NLM_p">Plans to improve upon the physical properties of analogs such as <b>55</b> and <b>58</b> centered around expanding the diversity of the (<i>R</i>)-α-methyl benzyl amides by incorporating solubilizing groups. We explored basic groups off the amide functionality in an attempt to improve solubility while the potency and in vitro PK profile that we believed would be desirable were maintained. We found amides containing cyclic amines to be most promising. A variety of ring sizes were explored, and positioning of the nitrogen was key for maintaining desirable cellular potency and solubility. For example, 4-piperidino carboxamide <b>79</b> resulted in a significant loss in cell potency (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, A375 pERK IC<sub>50</sub> = 688 nM), whereas the 2-piperidino carboxamide <b>75</b> maintained desirable cell potency (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, A375 pERK IC<sub>50</sub> = 45 nM). Compound <b>75</b> likewise had excellent solubility (>940 μM), human plasma protein binding (5.1% free), and moderate in vitro rat clearance. The 2-substituted piperidino carboxamide <b>75</b> was also found to be more potent than the 3-piperidino analog <b>78</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, A375 pERK IC<sub>50</sub> = 140 nM), whereas the 2-pyrrolidino carboxamide <b>80</b> was of similar cellular potency to <b>75</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, A375 pERK IC<sub>50</sub> = 74 nM).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> We also explored further elaboration of <b>75</b> with various substituents to probe the importance of the free amine and build upon the SAR. We believed attenuation of the basic amine p<i>K</i><sub>a</sub> could be a strategy to address pharmacokinetic liabilities that may arise in vivo.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Methyl substitution as in <b>76</b> was tolerated, yielding an identical potency to <b>75</b> with reduced solubility (65 μM).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Substitution to generate what we believed would be a less basic moiety in hydroxyethyl analog <b>77</b> afforded a potent inhibitor (A375 pERK IC<sub>50</sub> = 25 nM) though with poor solubility and higher predicted clearance as indicated by both rat liver hepatocytes and human liver microsomal data (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Amide Modifications</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0022.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0023.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Measured at 5 mM ATP concentration. For experimental details, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">All values are an average of at least two independent dose–response curves. For experimental details, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">Hu PPB, rat hepatocyte, and Hu microsomal stability details can be found in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="footnote" id="t4fn4"><sup>Table d</sup><p class="last"><b>76</b> represents a mixture of diastereomers at the piperidinyl chiral center as the diasteromers proved to be inseparable after various attempts at separation.</p></div><div class="footnote" id="t4fn5"><sup>Table e</sup><p class="last">Denotes not tested.</p></div></div><div></div></div><div class="NLM_p">Inspired by reports of vinylogous amide pharmacophores in a series of pyrrolidine ether hNK<sub>1</sub> antagonists,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> we found the carboxamide could be replaced by a vinylogous amide and derivatives such as <b>81</b> and <b>82</b> resulted in single digit nanomolar cell potency (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, <b>81</b>–<b>82</b> A375 pERK IC<sub>50</sub> = 4–5 nM). Both five- and six-membered rings were equally promising; however, both resulted in poor solubility (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, 4 μM). We hypothesized the design and synthesis of close analogs such as dihydropyridinones <b>83</b> and <b>84</b> incorporating nitrogen atoms into the ring would improve the solubility with the expectation of maintaining single digit nanomolar cell potency. We discovered that analog <b>83</b> maintained potency however did little to improve upon the solubility of prior compounds (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). Analog <b>84</b> was designed to combine features of the 2- and 3-piperidino carboxamide profiles of <b>75</b> and <b>78</b> with the vinylogous amide motif. Our hypothesis was that a combination of both features would maintain a desirable potency and solubility profile. However, <b>84</b> resulted in a less potent and still poorly soluble analog (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, A375 pERK IC<sub>50</sub> = 63 nM, solubility 10 μM). Our strategy to diversify beyond the (<i>R</i>)-α-methyl benzyl amides to uncover analogs such as piperidino carboxamide <b>75</b> and vinylogous amides <b>81</b> and <b>82</b> led to identification of promising leads with in vitro PK profiles that we believed would translate into an acceptable in vivo PK profile.</div><div class="NLM_p">Modifications to the core aminoquinazoline B-ring were also examined to probe the SAR of this region. On the basis of our knowledge of the aminoquinazoline binding mode, we believed substitution at either the 7- or 8-position of the quinazoline would be tolerated. These positions were oriented away from the hinge binding region, whereas substitution of the aminoquinazoline at the 4- and 5-positions was expected to interfere with hinge binding. We explored the electronic distribution of the quinazoline ring as this might play a key role in modulating PK. A limited number of groups representing electron-donating and -withdrawing potential were investigated at the 7- and 8-positions of the aminoquinazoline. We discovered 7-substitution with chloro and methyl (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>, <b>98</b> and <b>100</b>, A375 pERK IC<sub>50</sub> = 430 and 573 nM, respectively) were detrimental to pERK cell potency, resulting in a greater than 20-fold loss in potency as compared to their 8-substituted matched pairs (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>, <b>99</b> and <b>101</b>, respectively). Interestingly, both the 8- and 7-methoxy substitutions were tolerated and resulted in potency similar to that of <b>58</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>, <b>87</b> and <b>97</b>, A375 pERK IC<sub>50</sub> = 10 and 25 nM, respectively). These core substitutions did not lead to a desirable solubility range, as most analogs had <10 μM solubility and high human protein binding. Most examples exhibited acceptable rat hepatocyte and human microsomal intrinsic clearance values.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. B-Ring Core Modifications</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0024.gif" alt="" id="fx9" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">CL<sub>int</sub></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">B-Raf<sup>V600E</sup><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">A375 pERK<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">solubility (μM) pH 7.4</th><th class="colsep0 rowsep0" align="center">Hu PPB Fu (%)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">rat Hep (μL/min/1E6)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">Hu Mic (μL/min/mg)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>87</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.057</td><td class="colsep0 rowsep0" align="left">0.01</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">3.4</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>97</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">0.14</td><td class="colsep0 rowsep0" align="left">0.025</td><td class="colsep0 rowsep0" align="left"><1</td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left"><4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>98</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">2.29</td><td class="colsep0 rowsep0" align="left">0.43</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left"><1</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>99</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.187</td><td class="colsep0 rowsep0" align="left">0.02</td><td class="colsep0 rowsep0" align="left"><1</td><td class="colsep0 rowsep0" align="left"><1</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>100</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left">0.573</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>101</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.081</td><td class="colsep0 rowsep0" align="left">0.025</td><td class="colsep0 rowsep0" align="left"><1</td><td class="colsep0 rowsep0" align="left"><1</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">17</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Measured at 5 mM ATP concentration. For experimental details, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">All values are an average of at least two independent dose–response curves. For experimental details, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Hu PPB, rat hepatocyte, and human microsomal stability details can be found in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Pharmacokinetic Properties of Leads</h3><div class="NLM_p">Aminoquinazolines with desirable pERK cell potency (typically IC<sub>50</sub> < 50 nM) and in vitro rat hepatocyte and human microsomal stability which should be predictive of modest clearance were progressed into in vivo rat PK studies. We were encouraged to find that the most potent analogs had low in vivo clearance and good bioavailability (<b>52</b> and <b>58</b>, F = 60 and 100%, respectively, Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). However, a trend of short half-life and low volume of distribution was also seen, a profile that might not achieve the sustained exposure we would require to achieve target inhibition in vivo. Analogs such as benzyl amine <b>53</b>, which demonstrated improved solubility and desirable potency, showed moderate–high clearance in a manner similar to analog <b>84</b>. Interestingly, carboxamide <b>75</b> did lead to a desirable in vivo rat PK profile with a longer half-life over a 24 h iv dosing period and larger volume of distribution, though moderate clearance (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). We believed compounds <b>58</b> and <b>75</b> were excellent candidates for additional in vivo evaluation.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Rat PK of Lead Compounds<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compd</th><th class="colsep0 rowsep0" align="center" char=".">CL<sub>obs</sub>(mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>dss</sub>(L/kg)</th><th class="colsep0 rowsep0" align="center">F (%)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub><b>1/2</b></sub> (h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>52</b></td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="char" char=".">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>53</b></td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="char" char=".">4.9</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>58</b></td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">0.8</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>75</b></td><td class="colsep0 rowsep0" align="char" char=".">43</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="char" char=".">4.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>81</b></td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">0.67</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>84</b></td><td class="colsep0 rowsep0" align="char" char=".">120</td><td class="colsep0 rowsep0" align="char" char=".">7.9</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">0.42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>97</b></td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">0.67</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">0.61</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Han Wistar rat male; 10 mg/kg po (0.1% HPMC); 3 mg/kg iv (40% DMA/40% TEG/20% saline). <i>t</i><sub>1/2</sub> represents the iv half-life.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Denotes not tested as a po dose, so F (%) was not determined.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Mutant B-Raf<sup>V600E</sup> Selective Cell Profile Results in pERK Elevation in Nonmutant B-Raf Cells</h3><div class="NLM_p">Additional experiments to understand the effects of the mutant B-Raf<sup>V600E</sup> selective profile are highlighted in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>. An A549 cell line with B-Raf<sup>WT</sup> KRAS mutant background was evaluated for pERK response to aminoquinazolines <b>3</b>, <b>58</b>, <b>69</b>, <b>75</b>, <b>81</b>, and <b>87</b>. Upon treatment of compounds at 0.1-, 1-, 10-, and 100-fold the A375 pERK IC<sub>50</sub>, a dose-dependent elevation of pERK was seen with no clear margin to this effect, irrespective of the aminoquinazoline chosen. This observation is in stark contrast to the effects seen after a 75 min treatment with either <b>2</b> or Pfizer’s known selective MEK1/2 inhibitor PD0325901 (<b>102</b>),<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> both of which resulted in a decreased pERK in a dose-dependent manner (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>).</div><figure id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0008.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Evaluation of pERK in A549 cell lines. Cells were collected following a 75 min treatment with DMSO or compound at the indicated doses (0.1-, 1-, 10-, and 100-fold the A375 pERK IC<sub>50</sub>). pERK refers to phospho-ERK levels and tERK represents total-ERK levels. Western blotting analyses were performed using antibodies against the indicated proteins. <b>102</b> was used as a positive control in this study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We wanted to understand how general this trend for elevated pERK was in a variety of other B-Raf<sup>WT</sup> and KRAS cellular contexts, and thus selected lead aminoquinazoline <b>58</b> for additional studies. Both cancer (melanoma, lung, and breast), normal, and fibroblast cell lines were treated with <b>58</b> at 1-, 10-, and 100-fold the A375 pERK IC<sub>50</sub>. Elevation of pERK was observed in all cell lines after a 75 min treatment with <b>58</b>. No clear margin to the elevation of pERK in nonmutant B-Raf cell lines, relative to decrease in pERK in A375 cell lines, was seen over the range of doses investigated (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). In contrast to aminoquinazoline compounds, <b>2</b> did not show pERK elevation in any of the cell lines tested. MEK1/2 inhibitor <b>102</b> led to an expected decrease, or near complete inhibition, of pERK in all cell lines. Consistent with observations by others in this field, there are differences in the ability of the various classes of B-Raf<sup>V600E</sup> inhibitors to lead to elevated pERK and MAPK pathway activation in nonmutant B-Raf cells, an observation now well documented to result from Raf dimerization.<a onclick="showRef(event, 'ref15 ref29'); return false;" href="javascript:void(0);" class="ref ref15 ref29">(15, 29)</a></div><figure id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0009.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vitro pERK evaluation in multiple nonmutant B-Raf cell lines. Cells were collected following 75 min treatment with DMSO or compound at the indicated doses (1-, 10-, and 100-fold the A375 pERK IC<sub>50</sub>). Western blotting analysis was performed using antibodies against the indicated proteins. pERK refers to phospho-ERK levels and tERK represents total-ERK levels. <b>102</b> was used as a positive control in this study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> In Vivo Activity of Lead Aminoquinazolines</h3><div class="NLM_p">Lead compound <b>58</b> was progressed for additional in vivo profiling. A dose-dependent decrease in pERK was observed in an A375 mouse xenograft PD study with <b>58</b> starting at the 10 mg/kg dose as observed by Western blot and quantitation of the percent reduction in pERK (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>A,B). In addition, a dose-dependent increase in drug concentration in the plasma was observed (see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). Compound <b>58</b> was progressed further into an in vivo efficacy study in an A375 mutant B-Raf<sup>V600E</sup> xenograft model dosed 25 mg/kg orally twice daily for 10.5 days. <b>58</b> demonstrated significant tumor growth inhibition (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>C) and displayed excellent tolerability with no significant body weight loss.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><figure id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0010.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) A375 xenograft dose–response mouse PD of compound <b>58</b> at 2 h post po single dose. Tumors and plasma were harvested 2 h after dosing. Western blotting was performed on tumor samples to determine pERK inhibition. An equal amount of protein was loaded into each well and total ERK (tERK) was used for further normalization. (B) Percent reduction in pERK from the A375 xenograft dose–response mouse PD. For additional details including plasma concentration information, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>. (C) A375 mouse xenograft tumor growth inhibition study with <b>58</b> (<i>n</i> = 5) dosed at 25 mg/kg po BID for 10.5 days. The vehicle group (<i>n</i> = 8) received 0.5% HPMC. Tumor volume and body weights were measured twice weekly. For additional details, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11644" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11644" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The aminoquinazoline DFG-in class of compounds were shown to be potent and selective B-Raf<sup>V600E</sup> inhibitors that evolved from a singleton hit identified from a kinase subset screening effort. Aminoquinazolines were optimized for B-Raf<sup>V600E</sup> cellular potency, physical properties, and in vivo rat pharmacokinetics. We have demonstrated that a lead compound from this series, <b>58</b>, exhibits in vivo tumor growth inhibition in an A375 xenograft model. A key finding from this class of compounds was the B-Raf<sup>V600E</sup> selective profile, which, similar to previous reports by others in the field, resulted in the elevation of pERK, thus highlighting the potential for multiple novel chemotypes to generate such a profile. Compounds such as the aminoquinazoline series described herein, in addition to the complementary profile afforded by analogs such as <b>2</b>, provide useful tools to further interrogate the important role of B-Raf within the MAPK pathway.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24630" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24630" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Chemistry</h3><div class="NLM_p last"><sup>1</sup>H NMR spectra were recorded on either Bruker 300 or 400 MHz NMR spectrometers using deuterated DMSO (DMSO-<i>d</i><sub>6</sub>) unless otherwise stated. Temperatures are given in degrees Celsius (°C); operations were carried out at room temperature or ambient temperature, that is, in the range 18–25 °C. Chemical shifts are expressed in parts per million (ppm, δ units). Coupling constants are given in units of hertz (Hz). Splitting patterns describe apparent multiplicities and are designated as s (singlet), d (doublet), dd (doublet–doublet), t (triplet), q (quartet), m (multiplet), and br s (broad singlet). Mass spectroscopy analyses were performed with an Agilent 1100 equipped with Waters columns (Atlantis T3, 2.1 × 50 mm, 3 μm or Atlantis dC18, 2.1 × 50 mm, 5 μm) eluted with a gradient mixture of H<sub>2</sub>O–acetonitrile with formic acid or ammonium acetate. The purity determination of all reported compounds was performed with an Agilent 1100 equipped with Waters columns (Atlantis T3, 2.1 × 50 mm, 3 μm; or Atlantis dC18, 2.1 × 50 mm, 5 μm) eluted for >10 min with a gradient mixture of H<sub>2</sub>O–acetonitrile with formic or trifluoroacetic acid at wavelengths of 220, 254, and 280 nm. All final compounds analyzed were >95% pure unless otherwise indicated. Reverse-phase chromatography was performed with Gilson systems using a YMC-AQC18 reverse-phase HPLC column with dimension 20 mm/100 and 50 mm/250 in water/MeCN with 0.1% TFA, 0.1% ammonium acetate, or 0.1% formic acid as mobile phase. Most of the reactions described were monitored by thin-layer chromatography on 0.25 mm E. Merck silica gel plates (60F-254), visualized with UV light or LC–MS. Flash column chromatography was performed on an ISCO system MPLC Combi-flash systems (4700 Superior Street, Lincoln, NE) unless otherwise mentioned using silica gel cartridges.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>N</i>-(2-Methoxyethyl)-4-[(6-pyridin-4-ylquinazolin-2-yl)amino]benzamide (<b>3</b>)</h3><div class="NLM_p last">6-Pyridin-4-ylquinazolin-2-amine (<b>6</b>, 50 mg, 0.225 mmol), 4-bromo-<i>N</i>-(2-methoxyethyl)benzamide (<b>17</b>, 58 mg, 0.225 mmol), Cs<sub>2</sub>CO<sub>3</sub> (220 mg, 0.675 mmol, 3.0 equiv), and BINAP (14 mg, 0.023 mmol, 10 mol %) in dioxane (2 mL) were treated with Pd<sub>2</sub>(dba)<sub>3</sub> (11 mg, 0.012 mmol, 5 mol %). The reaction mixture was heated to 100 °C for 12 h. The reaction was then quenched with 10% NaOH (aq) and extracted with EtOAc. The organics were dried with NaCl (satd) and then Na<sub>2</sub>SO<sub>4</sub> (solid). The solvent was removed under reduced pressure and the resulting solid was purified by a Gilson HPLC (0.1% TFA in CH<sub>3</sub>CN and water) to afford 60 mg (52%) of the title compound. <sup>1</sup>H NMR: 10.38 (s, 1H), 9.45 (s, 1H), 8.86 (d, 2H), 8.61 (d, 1H), 8.38 (m, 2H), 8.22 (d, 2H), 8.07 (d, 2H), 7.87 (m, 3H), 3.44 (m, 4H), 3.27 (s, 3H). LC–MS: <i>m</i>/<i>z</i> 400.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 6-Bromoquinazolin-2-amine (<b>5</b>)</h3><div class="NLM_p last">2-Fluoro-5-bromobenzaldehyde (<b>4</b>, 1.0 g, 4.9 mmol) and guanidine carbonate (1.3 g, 7.4 mmol, 1.5 equiv) were dissolved in DMA and heated to 140 °C for 5 h. The reaction was treated with H<sub>2</sub>O and the resulting precipitate was collected by vacuum filtration. LC–MS: <i>m</i>/<i>z</i> 225.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 6-Pyridin-4-ylquinazolin-2-amine (<b>6</b>)</h3><div class="NLM_p">6-Bromoquinazolin-2-amine (<b>5</b>, 200 mg, 0.89 mmol), 4-pyridinylboronic acid (165 mg, 1.34 mmol, 1.5 equiv), and K<sub>2</sub>CO<sub>3</sub> (370 mg, 2.68 mmol, 3.0 equiv) in DME/H<sub>2</sub>O (5:1, 4 mL) were treated with Pd(Ph<sub>3</sub>P)<sub>4</sub> (206 mg, 0.179 mmol, 20 mol %). The reaction was stirred at 90 °C for 12 h. The reaction was quenched with 10% NaOH and extracted with EtOAc. The combined organics were dried with NaCl (satd) and then Na<sub>2</sub>SO<sub>4</sub> (s). The solvents were removed under reduced pressure. The crude product was purified by column chromatography utilizing an ISCO system (EtOAc–MeOH) to yield 100 mg (51%) of the title compound. LC–MS: <i>m</i>/<i>z</i> 223.</div><div class="NLM_p last">Following a similar procedure to that of <b>6</b>, <b>7</b>–<b>16</b> were synthesized.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 6-(2-Methylpyridin-4-yl)quinazolin-2-amine (<b>7</b>)</h3><div class="NLM_p last">The title compound was synthesized from 6-bromoquinazolin-2-amine (<b>5</b>) and (2-methylpyridin-4-yl)boronic acid. LC–MS: <i>m/</i>z 237.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 6-(3-Methoxypyridin-4-yl)quinazolin-2-amine (<b>8</b>)</h3><div class="NLM_p last">The title compound was synthesized from 6-bromoquinazolin-2-amine (<b>5</b>) and (3-methoxypyridin-4-yl)boronic acid. LC–MS: <i>m/</i>z 253.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 6-(3-Methylpyridin-4-yl)quinazolin-2-amine (<b>9</b>)</h3><div class="NLM_p last">The title compound was synthesized from 6-bromoquinazolin-2-amine (<b>5</b>) and (3-methylpyridin-4-yl)boronic acid. LC–MS: <i>m/</i>z 237.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 6-(3-Chloropyridin-4-yl)quinazolin-2-amine (<b>10</b>)</h3><div class="NLM_p last">The title compound was synthesized from 6-bromoquinazolin-2-amine (<b>5</b>) and (3-chloropyridin-4-yl)boronic acid. <sup>1</sup>H NMR: 7.71–7.65 (m, 4H), 7.58–7.45 (m, 5H).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 6-Phenylquinazolin-2-amine (<b>11</b>)</h3><div class="NLM_p last">The title compound was synthesized from 6-bromoquinazolin-2-amine (<b>5</b>) and phenyl boronic acid. LC–MS: <i>m/</i>z 222.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 6-Pyridin-3-ylquinazolin-2-amine (<b>12</b>)</h3><div class="NLM_p last">The title compound was synthesized from 6-bromoquinazolin-2-amine (<b>5</b>) and pyridin-3-ylboronic acid. LC–MS: <i>m</i>/<i>z</i> 223.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 6-(4-Methylpyridin-3-yl)quinazolin-2-amine (<b>13</b>)</h3><div class="NLM_p last">The title compound was synthesized from 6-bromoquinazolin-2-amine (<b>5</b>) and (4-methylpyridin-3-yl)boronic acid. LC–MS: <i>m/</i>z 237.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 6-(6-Methoxypyridin-3-yl)quinazolin-2-amine (<b>14</b>)</h3><div class="NLM_p last">The title compound was synthesized from 6-bromoquinazolin-2-amine (<b>5</b>) and (6-methoxypyridin-3-yl)boronic acid. LC–MS: <i>m/</i>z 253.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 6-(6-Fluoropyridin-3-yl)quinazolin-2-amine (<b>15</b>)</h3><div class="NLM_p last">The title compound was synthesized from 6-bromoquinazolin-2-amine (<b>5</b>) and (6-fluoropyridin-3-yl)boronic acid. LC–MS: <i>m/</i>z 256.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 6-(Pyrimidin-5-yl)quinazolin-2-amine (<b>16</b>)</h3><div class="NLM_p last">The title compound was synthesized from 6-bromoquinazolin-2-amine (<b>5</b>) and pyrimidin-5-ylboronic acid. LC–MS: <i>m</i>/<i>z</i> 224.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 4-Bromo-<i>N</i>-(2-methoxyethyl)benzamide (<b>17</b>)</h3><div class="NLM_p last">2-Methoxyethylamine (10 mL) at 0 °C was treated with 4-bromobenzoyl chloride (2.0 g, 9.1 mmol). After 15 min, 10% HCl was added to the reaction mixture. The resulting white solid (2.00 g, 85%) was collected by vacuum filtration. <sup>1</sup>H NMR: 8.59 (t, 1H), 7.78 (d, 2H), 7.66 (d, 2H), 3.42 (m, 4H), 3.25 (s, 3H).</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 3-Bromo-<i>N</i>-(2-methoxyethyl)benzamide (<b>18</b>)</h3><div class="NLM_p last">2-Methoxyethylamine (0.435 mL, 5.0 mmol), 3-bromobenzoic acid (1.00 g, 5.0 mmol), and DIPEA (1.31 mL, 7.5 mmol) were dissolved in DMF (10 mL) followed by the addition of HATU (2.85 g, 7.5 mmol). The reaction mixture was stirred for 12 h at rt whereupon the mixture was extracted with saturated NH<sub>4</sub>Cl solution and washed with EtOAc three times. The organic layers were dried over magnesium sulfate, filtered, and concentrated in vacuo to afford the crude mixture that after purification using an ISCO system (EtOAc–MeOH) provided the title compound. LC–MS: <i>m</i>/<i>z</i> 259.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 4-Bromo-<i>N-</i>(2-methoxyethyl)-2-methylbenzamide (<b>19</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4-bromo-2-methylbenzoic acid and 2-methoxyethylamine using a method analogous to that of <b>18</b>. LC–MS: <i>m</i>/<i>z</i> 273.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 4-Bromo-2-fluoro-<i>N-</i>(2-methoxyethyl)benzamide (<b>20</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4-bromo-2-fluorobenzoic acid and 2-methoxyethylamine using a method analogous to that of <b>18</b>. LC–MS: <i>m</i>/<i>z</i> 277.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 4-Bromo-<i>N-</i>[2-(dimethylamino)ethyl]benzamide (<b>21</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4-bromobenzoyl chloride and <i>N,N-</i>dimethylethane-1,2-diamine using a method analogous to that of <b>17</b>. LC–MS: <i>m</i>/<i>z</i> 272.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 4-Bromo-<i>N-</i>[2-(1-methylpyrrolidin-2-yl)ethyl]benzamide (<b>22</b>)</h3><div class="NLM_p last">The title compoumd was synthesized from 4-bromobenzoyl chloride and [2-(1-methylpyrrolidin-2-yl)ethyl]amine using a method analogous to that of <b>17</b>. LC–MS: <i>m</i>/<i>z</i> 312.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 4-Bromo-<i>N-</i>(2-pyrrolidin-1-ylethyl)benzamide (<b>23</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4-bromobenzoic acid and (2-pyrrolidin-1-ylethyl)amine using a method analogous to that of <b>18</b>. LC–MS: <i>m</i>/<i>z</i> 298.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> <i>N-</i>(2-Methoxyethyl)-4-{[6-(2-methylpyridin-4-yl)quinazolin-2-yl]amino}benzamide (<b>24</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4-bromo-<i>N</i>-(2-methoxyethyl)benzamide (<b>17</b>) and 6-(2-methylpyridin-4-yl)quinazolin-2-amine (<b>7</b>) following a similar procedure to that of <b>3</b>. <sup>1</sup>H NMR: 10.30 (s, 1H), 9.42 (s, 1H), 8.54 (d, 1H), 8.44 (s, 1H), 8.38 (m, 1H), 8.27 (d, 1H), 8.08 (m, 2H), 7.84 (m, 2H), 7.72 (s, 1H), 7.62 (m, 2H), 3.44 (m, 4H), 3.27 (s, 3H), 2.56 (s, 3H). LC–MS: <i>m</i>/<i>z</i> 414. Purity: 94%.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> <i>N-</i>(2-Methoxyethyl)-4-{[6-(3-methoxypyridin-4-yl)quinazolin-2-yl]amino}benzamide (<b>25</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4-bromo-<i>N</i>-(2-methoxyethyl)benzamide (<b>17</b>) and 6-(3-methoxypyridin-4-yl)quinazolin-2-amine (<b>8</b>) following a similar procedure to that of <b>3</b>. <sup>1</sup>H NMR: 10.27 (s, 1H), 9.41 (s, 1H), 8.52 (s, 1H), 8.38 (m, 1H), 8.33 (d, 1H), 8.19 (m, 1H), 8.07 (d, 3H), 7.85 (d, 2H), 7.78 (d, 1H), 7.49 (d, 1H), 3.94 (s, 3H), 3.44 (m, 4H), 3.27 (s, 3H). LC–MS: <i>m</i>/<i>z</i> 430.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> <i>N</i>-(2-Methoxyethyl)-4-{[6-(3-methylpyridin-4-yl)quinazolin-2-yl]amino}benzamide (<b>26</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4-bromo-<i>N</i>-(2-methoxyethyl)benzamide (<b>17</b>) and 6-(3-methylpyridin-4-yl)quinazolin-2-amine (<b>9</b>) following a similar procedure to that of <b>3</b>. <sup>1</sup>H NMR: 10.28 (s, 1H), 9.41 (s, 1H), 8.55 (s, 1H), 8.50 (d, 1H), 8.42–8.35 (m, 1H), 8.10–8.02 (m, 3H), 7.93–7.78 (m, 4H), 7.36 (d, 1H), 3.47–3.41 (m, 4H), 3.27 (s, 3H), 2.32 (s, 3H). LC–MS: <i>m</i>/<i>z</i> 414.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 4-{[6-(3-Chloropyridin-4-yl)quinazolin-2-yl]amino}-<i>N</i>-(2-methoxyethyl)benzamide (<b>27</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4-bromo-<i>N</i>-(2-methoxyethyl)benzamide (<b>17</b>) and 6-(3-chloropyridin-4-yl)quinazolin-2-amine (<b>10</b>) following a similar procedure to that of <b>3</b>. <sup>1</sup>H NMR: 10.34 (s, 1H), 9.47 (s, 1H), 8.80 (s, 1H), 8.65 (d, 1H), 8.46–8.35 (m, 1H), 8.22–8.15 (m, 1H), 8.09 (d, 2H), 8.01 (dd, 1H), 7.91–7.81 (m, 3H), 7.64 (d, 1H), 3.50–3.40 (m, 4H), 3.28 (s, 3H). LC–MS: <i>m</i>/<i>z</i> 434. Purity: 90%.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> N-(2-Methoxyethyl)-4-(6-phenylquinazolin-2-ylamino)benzamide (<b>28</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4-bromo-<i>N</i>-(2-methoxyethyl)benzamide (<b>17</b>) and 6-phenylquinazolin-2-amine (<b>11</b>) following a similar procedure to that of <b>3</b>. <sup>1</sup>H NMR: 10.23 (s, 1H), 9.42 (s, 1H), 8.37 (m, 1H), 8.28 (m, 1H), 8.21 (m, 1H), 8.08 (d, 2H), 7.87–7.80 (m, 5H), 7.53 (t, 2H), 7.42 (t, 1H), 3.44 (m, 4H), 3.28 (s, 3H). LC–MS: <i>m</i>/<i>z</i> 399.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <i>N-</i>(2-Methoxyethyl)-4-[(6-pyridin-3-ylquinazolin-2-yl)amino]benzamide (<b>29</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4-bromo-<i>N</i>-(2-methoxyethyl)benzamide (<b>17</b>) and 6-pyridin-3-ylquinazolin-2-amine (<b>12</b>) following a similar procedure to that of <b>3</b>. <sup>1</sup>H NMR: 10.29 (s, 1H), 9.42 (s, 1H), 9.03 (s, 1H), 8.61 (m, 1H), 8.40 (m, 1H), 8.36 (m, 1H), 8.23 (m, 2H), 8.08 (d, 2H), 7.84 (m, 3H), 7.54 (m, 1H), 3.44 (m, 4H), 3.27 (s, 3H). LC–MS: <i>m</i>/<i>z</i> 400.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>N</i>-(2-Methoxyethyl)-4-{[6-(4-methylpyridin-3-yl)quinazolin-2-yl]amino}benzamide (<b>30</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4-bromo-<i>N</i>-(2-methoxyethyl)benzamide (<b>17</b>) and 6-(4-methylpyridin-3-yl)quinazolin-2-amine (<b>13</b>) following a similar procedure to that of <b>3</b>. <sup>1</sup>H NMR: 10.26 (s, 1H), 9.40 (s, 1H), 8.47 (m, 2H), 8.38 (m, 1H), 8.07 (m, 2H), 8.00 (s, 1H), 7.84 (m, 4H), 7.37 (d, 1H), 3.44 (m, 4H), 3.27 (s, 3H), 2.32 (s, 3H). LC–MS: <i>m</i>/<i>z</i> 414.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> <i>N-</i>(2-Methoxyethyl)-4-{[6-(6-methoxypyridin-3-yl)quinazolin-2-yl]amino}benzamide (<b>31</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4-bromo-<i>N</i>-(2-methoxyethyl)benzamide (<b>17</b>) and 6-(6-methoxypyridin-3-yl)quinazolin-2-amine (<b>14</b>) following a similar procedure to that of <b>3</b>. <sup>1</sup>H NMR: 10.23 (s, 1H), 9.38 (s, 1H), 8.61 (m, 1H), 8.37 (m, 1H), 8.25 (m, 1H), 8.16 (m, 2H), 8.08 (m, 2H), 7.83 (m, 3H), 6.98 (d, 1H), 3.91 (s, 3H), 3.45 (m, 4H), 3.27 (s, 3H). LC–MS: <i>m</i>/<i>z</i> 430.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 4-{[6-(6-Fluoropyridin-3-yl)quinazolin-2-yl]amino}-<i>N-</i>(2-methoxyethyl)benzamide (<b>32</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4-bromo-<i>N</i>-(2-methoxyethyl)benzamide (<b>17</b>) and 6-(6-fluoropyridin-3-yl)quinazolin-2-amine (<b>15</b>) following a similar procedure to that of <b>3</b>. <sup>1</sup>H NMR: 10.27 (s, 1H), 9.40 (s, 1H), 8.69 (bs, 1H), 8.38 (m, 3H), 8.21 (m, 1H), 8.06 (d, 2H), 7.84 (m, 3H), 7.35 (m, 1H), 3.45 (m, 4H), 3.27 (s, 3H). LC–MS: <i>m</i>/<i>z</i> 418.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> N-(2-Methoxyethyl)-4-(6-(pyrimidin-5-yl)quinazolin-2-ylamino)benzamide (<b>33</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4<b>-</b>bromo-<i>N</i>-(2-methoxyethyl)benzamide (<b>17</b>) and 6-(pyrimidin-5-yl)quinazolin-2-amine (<b>16</b>) following a similar procedure to that of <b>3</b>. <sup>1</sup>H NMR: 10.33 (s, 1H), 9.42 (s, 1H), 9.29 (s, 2H), 9.23 (s, 1H), 8.47 (m, 1H), 8.33 (m, 1H), 8.07 (m, 2H), 7.87 (m, 3H), 3.46 (m, 4H), 3.28 (s, 3H). LC–MS: <i>m</i>/<i>z</i> 401.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> <i>N-</i>(2-Methoxyethyl)-3-[(6-pyridin-4-ylquinazolin-2-yl)amino]benzamide (<b>34</b>)</h3><div class="NLM_p last">The title compound was synthesized from 6-pyridin-4-ylquinazolin-2-amine (<b>6</b>) and 3-bromo-<i>N</i>-(2-methoxyethyl)benzamide (<b>18</b>) following a similar procedure to that of <b>3</b>. <sup>1</sup>H NMR: 10.17 (s, 1H), 9.41 (s, 1H), 8.68 (d, 2H), 8.45 (m, 3H), 8.29 (d, 1H), 8.16 (d, 1H), 7.84 (d, 2H), 7.78 (d, 1H), 7.44 (m, 2H), 3.58 (m, 4H), 3.29 (s, 3H). LC–MS: <i>m</i>/<i>z</i> 400.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> <i>N-</i>(2-Methoxyethyl)-2-methyl-4-[(6-pyridin-4-ylquinazolin-2-yl)amino]benzamide (<b>35</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4-bromo-<i>N-</i>(2-methoxyethyl)-2-methylbenzamide (<b>19</b>) and 6-pyridin-4-ylquinazolin-2-amine (<b>6</b>) following a similar procedure to that of <b>3</b>. <sup>1</sup>H NMR: 10.12 (s, 1H), 9.41 (s, 1H), 8.68 (d, 2H), 8.44 (m, 1H), 8.28 (d, 1H), 8.16 (m, 1H), 7.92 (d, 1H), 7.83 (m, 4H), 7.33 (d, 1H), 3.45 (m, 4H), 3.28 (s, 3H), 2.38 (s, 3H). LC–MS: <i>m</i>/<i>z</i> 414.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 2-Fluoro-<i>N-</i>(2-methoxyethyl)-4-[(6-pyridin-4-ylquinazolin-2-yl)amino]benzamide (<b>36</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4-bromo-2-fluoro-<i>N-</i>(2-methoxyethyl)benzamide (<b>20</b>) and 6-pyridin-4-ylquinazolin-2-amine (<b>6</b>) following a similar procedure to that of <b>3</b>. <sup>1</sup>H NMR: 10.52 (s, 1H), 9.47 (s, 1H), 8.69 (d, 2H), 8.48 (s, 1H), 8.33 (d, 1H), 8.16 (d, 1H), 8.02 (m, 1H), 7.86 (m, 3H), 7.71 (m, 2H), 3.44 (m, 4H), 3.27 (s, 3H). LC–MS: <i>m</i>/<i>z</i> 418.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> <i>N-</i>[2-(Dimethylamino)ethyl]-4-[(6-pyridin-4-ylquinazolin-2-yl)amino]benzamide (<b>37</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4-bromo-<i>N-</i>[2-(dimethylamino)ethyl]benzamide (<b>21</b>) and 6-pyridin-4-ylquinazolin-2-amine (<b>6</b>) following a similar procedure to that of <b>3</b>. <sup>1</sup>H NMR: 10.31 (s, 1H), 9.43 (s, 1H), 8.68 (d, 2H), 8.46 (m, 1H), 8.28 (m, 2H), 8.07 (m, 2H), 7.84 (m, 5H), 3.36 (m, 2H), 2.39 (m, 2H), 2.17 (s, 6H). LC–MS: <i>m</i>/<i>z</i> 413.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> <i>N-</i>[2-(1-Methylpyrrolidin-2-yl)ethyl]-4-[(6-pyridin-4-ylquinazolin-2-yl)amino]benzamide (<b>38</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4-bromo-<i>N-</i>[2-(1-methylpyrrolidin-2-yl)ethyl]benzamide (<b>22</b>) and 6-pyridin-4-ylquinazolin-2-amine (<b>6</b>) following a similar procedure to that of <b>3</b>. <sup>1</sup>H NMR: 10.30 (s, 1H), 9.43 (s, 1H), 8.69 (d, 2H), 8.46 (s, 1H), 8.30 (m, 2H), 8.07 (d, 2H), 7.85 (m, 5H), 3.27 (m, 2H), 2.92 (m, 1H), 2.20 (s, 3H), 2.00 (m, 4H), 1.62 (m, 2H), 1.44 (m, 2H). LC–MS: <i>m</i>/<i>z</i> 453.</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 4-[(6-Pyridin-4-ylquinazolin-2-yl)amino]-<i>N-</i>(2-pyrrolidin-1-ylethyl)benzamide (<b>39</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4-bromo-<i>N-</i>(2-pyrrolidin-1-ylethyl)benzamide (<b>23</b>) and 6-pyridin-4-ylquinazolin-2-amine (<b>6</b>) following a similar procedure to that of <b>3</b>. <sup>1</sup>H NMR: 10.31 (s, 1H), 9.43 (s, 1H), 8.69 (d, 2H), 8.46 (s, 1H), 8.28 (m, 2H), 8.07 (d, 2H), 7.84 (m, 5H), 3.35 (m, 2H), 2.41–2.53 (m, 4H), 1.67 (m, 6H). LC–MS: <i>m</i>/<i>z</i> 439.</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 4-[(6-Pyridin-4-ylquinazolin-2-yl)amino]benzaldehyde (<b>40</b>)</h3><div class="NLM_p last">6-Pyridin-4-ylquinazolin-2-amine (<b>6</b>, 2 g, 9.0 mmol), 4-bromobenzaldehyde (1.83 g, 9.9 mmol), Cs<sub>2</sub>CO<sub>3</sub> (8.8 g, 27 mmol, 3.0 equiv), and BINAP (1.12 g, 1.8 mmol, 0.2 equiv) in dioxane (60 mL) were treated with Pd<sub>2</sub>(dba)<sub>3</sub> (825 mg, 0.9 mmol). The reaction mixture was heated to 100 °C for 3 h. The reaction was cooled and filtered. The crude mixture was purified on an ISCO system (EtOAc/Et<sub>3</sub>N) to yield 1.5 g (51%) of the title compound. <sup>1</sup>H NMR: 10.61 (s, 1H), 9.87 (s, 1H), 9.48 (s, 1H), 8.69 (m, 2H), 8.49 (m, 1H), 8.33 (m, 1H), 8.25 (d, 2H), 7.87 (m, 5H). LC–MS: <i>m</i>/<i>z</i> 327.</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> <i>N</i>-(4-Bromophenyl)-3-methoxy-<i>N</i>-methylpropanamide (<b>41</b>)</h3><div class="NLM_p last">The title compound was synthesized from 3-methoxypropanoic acid and (4-bromophenyl)methylamine using a method analogous to that of <b>18</b>. LC–MS: <i>m</i>/<i>z</i> 273.</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> [1-(4-Bromophenyl)ethyl](2-methoxyethyl)amine (<b>42</b>)</h3><div class="NLM_p last">To a solution of 1-(4-bromophenyl)ethanone (500 mg, 2.51 mmol) and (2-methoxyethyl)amine (188 mg, 2.51 mmol) in toluene (13 mL) were added diethyl 2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (907 mg, 3.51 mmol), thiourea (19 mg, 0.25 mmol), and 5 Å molecular sieves (∼5 g). The reaction was heated at 50 °C under nitrogen for approximately 40 h. The reaction mixture was filtered, solvent was evaporated under reduced pressure, and the residue was purified by an ISCO system (EtOAc/hexane, TLC with I<sub>2</sub>) to give 120 mg of a colorless oil (19% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.39 (d, 2H), 7.17 (d, 2H), 3.69 (m, 1H), 3.41 (m, 2H), 3.30 (s, 3H), 2.59 (m, 2H), 1.29 (d, 3H).</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> <i>N</i>-(1-(4-Bromophenyl)ethyl)-3-methoxypropanamide (<b>43</b>)</h3><div class="NLM_p last">The title compound was synthesized from 1-(4-bromophenyl)ethylamine and 3-methoxypropanoyl chloride using a method analogous to that of <b>17</b>. LC–MS: <i>m</i>/<i>z</i> 287.</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> <i>N</i>-[(1<i>R</i>)-1-(4-Bromophenyl)ethyl]-3-methoxypropanamide (<b>44</b>)</h3><div class="NLM_p last">The title compound was synthesized from [(1<i>R</i>)-1-(4-bromophenyl)ethyl]amine and 3-methoxypropanoic acid using a method analogous to that of <b>18</b>. LC–MS: <i>m</i>/<i>z</i> 287.</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> <i>N</i>-[(1<i>S</i>)-1-(4-Bromophenyl)ethyl]-3-methoxypropanamide (<b>45</b>)</h3><div class="NLM_p last">The title compound was synthesized from [(1<i>S</i>)-1-(4-bromophenyl)ethyl]amine and 3-methoxypropanoic acid using a method analogous to that of <b>18</b>. LC–MS: <i>m</i>/<i>z</i> 287.</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> <i>N</i>-(1-(4-Bromophenyl)ethyl)acetamide (<b>46</b>)</h3><div class="NLM_p last">The title compound was synthesized from 1-(4-bromophenyl)ethanamine and acetyl chloride using a method analogous to that of <b>17</b>. LC–MS: <i>m</i>/<i>z</i> 243.</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> (<i>R</i>)-<i>N</i>-(1-(4-Bromophenyl)ethyl)acetamide (<b>47</b>)</h3><div class="NLM_p last">The title compound was synthesized from (<i>R</i>)-1-(4-bromophenyl)ethanamine and acetyl chloride using a method analogous to that of <b>17</b>. LC–MS: <i>m</i>/<i>z</i> 243.</div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> <i>N</i>-(4-{[(2-Methoxyethyl)amino]methyl}phenyl)-6-pyridin-4-ylquinazolin-2-amine (<b>48</b>)</h3><div class="NLM_p">4-[(6-Pyridin-4-ylquinazolin-2-yl)amino]benzaldehyde (<b>40</b>, 70 mg, 0.21 mmol) and (2-methoxyethyl)amine (18 mg, 0.24 mmol) in 5 mL of MeOH (with 3 Å molecular sieves) were stirred at room temperature, whereupon a few drops of acetic acid were added. NaBH<sub>3</sub>CN (22 mg, 1.6 equiv) was then added and the reaction mixture was stirred at room temperature overnight followed by quenching with NaOH (1 N, aq, ∼5 mL). The reaction mixture was extracted with EtOAc, and the water layers were then extracted with EtOAc three times. The combined organic layers were washed with water and brine, evaporated, and purified by Gilson HPLC (0.1% 10 mM ammonium acetate in CH<sub>3</sub>CN and water) to give 25 mg (95%) of the title compound. <sup>1</sup>H NMR: 9.99 (s, 1H), 9.36 (s, 1H), 8.67 (d, 2H), 8.41 (d, 1H), 8.25 (m, 1H), 7.91 (d, 2H), 7.83 (d, 2H), 7.75 (d, 1H), 7.27 (d, 2H), 3.66 (s, 2H), 3.39 (m, 2H), 3.23 (s, 3H), 2.63 (m, 2H). LC–MS: <i>m</i>/<i>z</i> 384 (M–H).</div><div class="NLM_p last">Compounds <b>49</b> and <b>50</b> were prepared following a similar procedure to that of <b>48</b>.</div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> <i>N-</i>(4-{[(2-Methoxyethyl)(methyl)amino]methyl}phenyl)-6-pyridin-4-ylquinazolin-2-amine (<b>49</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4-[(6-pyridin-4-ylquinazolin-2-yl)amino]benzaldehyde (<b>40</b>) and (2-methoxyethyl)methylamine. <sup>1</sup>H NMR: 10.01 (s, 1H), 9.37 (s, 1H), 8.67 (d, 2H), 8.41 (d, 1H), 8.25 (m, 1H), 8.18 (s, 1H), 7.92 (d, 2H), 7.83 (d, 2H), 7.75 (d, 1H), 7.24 (d, 2H), 3.66 (s, 2H), 3.47 (m, 2H), 3.20 (s, 3H), 2.66 (m, 2H), 2.27 (s, 3H). LC–MS: <i>m</i>/<i>z</i> 422 (M + Na).</div></div><div id="sec4_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> <i>N,N-</i>Dimethyl-<i>N</i>′-{4-[(6-pyridin-4-ylquinazolin-2-yl)amino]benzyl}ethane-1,2-diamine (<b>50</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4-[(6-pyridin-4-ylquinazolin-2-yl)amino]benzaldehyde (<b>40</b>) and <i>N,N-</i>dimethylethane-1,2-diamine. <sup>1</sup>H NMR: 10.00 (s, 1H), 9.38 (s, 1H), 8.69 (d, 2H), 8.43 (d, 1H), 8.26 (m, 1H), 7.92 (d, 2H), 7.84 (d, 2H), 7.76 (d, 1H), 7.28 (d, 2H), 3.67 (s, 2H), 2.54 (m, 2H), 2.33 (m, 2H), 2.12 (s, 6H). LC–MS: <i>m</i>/<i>z</i> 397 (M – H).</div></div><div id="sec4_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 6-Pyridin-4-yl-<i>N-</i>[4-(2-pyrrolidin-1-ylethoxy)phenyl]quinazolin-2-amine (<b>51</b>)</h3><div class="NLM_p last">The title compound was synthesized from 6-pyridin-4-ylquinazolin-2-amine (<b>6</b>) and 1-[2-(4-bromophenoxy)ethyl]pyrrolidine (commercially available) using a method analogous to the preparation of <b>3</b>. <sup>1</sup>H NMR: 9.86 (s, 1H), 9.33 (s, 1H), 8.67 (d, 2H), 8.39 (s, 1H), 8.21 (m, 1H), 7.83 (m, 4H), 7.70 (d, 1H), 6.95 (d, 2H), 4.04 (m, 2H), 2.79 (m, 2H), 2.53 (m, 4H), 1.68 (m, 4H). LC–MS: <i>m</i>/<i>z</i> 412. Purity: 90%.</div></div><div id="sec4_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 3-Methoxy-<i>N-</i>methyl-<i>N-</i>(4-(6-(pyridin-4-yl)quinazolin-2-ylamino)phenyl)propanamide (<b>52</b>)</h3><div class="NLM_p last">The title compound was synthesized from <i>N</i>-(4-bromophenyl)-3-methoxy-<i>N</i>-methylpropanamide (<b>41</b>) and 6-pyridin-4-ylquinazolin-2-amine (<b>6</b>) using a method analogous to the preparation of <b>3</b>, except with Xantphos and palladium(II) acetate and by heating in a microwave at 160 °C for 1 h. <sup>1</sup>H NMR: 10.2 (s, 1H), 9.41 (s, 1H), 8.68 (d, 2H), 8.44 (s, 1H), 8.28 (d, 1H), 8.06 (d, 2H), 7.83 (m, 3H), 7.28 (d, 2H), 3.48 (t, 2H), 3.14 (m, 6H), 2.27 (t, 2H). LC–MS: <i>m</i>/<i>z</i> 414.</div></div><div id="sec4_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> <i>N</i>-(4-{1-[(2-Methoxyethyl)amino]ethyl}phenyl)-6-pyridin-4-ylquinazolin-2-amine (<b>53</b>)</h3><div class="NLM_p last">The title compound was synthesized from [1-(4-bromophenyl)ethyl](2-methoxyethyl)amine (<b>42</b>) and 6-pyridin-4-ylquinazolin-2-amine (<b>6</b>) using a method analogous to the preparation of <b>3</b>. <sup>1</sup>H NMR: 9.97 (s, 1H), 9.36 (s, 1H), 8.67 (d, 2H), 8.41 (d, 1H), 8.25 (m, 2H), 7.90 (d, 2H), 7.83 (d, 2H), 7.74 (d, 1H), 7.27 (d, 2H), 3.68 (m, 1H), 3.34 (m, 2H), 3.21 (s, 3H), 2.43 (m, 2H), 1.25 (d, 3H). LC–MS: <i>m</i>/<i>z</i> 422 (M + Na).</div></div><div id="sec4_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 3-Methoxy-<i>N</i>-(1-{4-[(6-pyridin-4-ylquinazolin-2-yl)amino]phenyl}ethyl)propanamide (<b>54</b>)</h3><div class="NLM_p">The title compound was synthesized from <i>N</i>-(1-(4-bromophenyl)ethyl)-3-methoxypropanamide (<b>43</b>) and 6-pyridin-4-ylquinazolin-2-amine (<b>6</b>) using a method analogous to the preparation of <b>3</b>, using Xantphos and palladium(II) acetate and by heating in a microwave at 160 °C for 1 h. <sup>1</sup>H NMR: 9.98 (s, 1H), 9.36 (s, 1H), 8.68 (d, 2H), 8.42 (s, 1H), 8.25 (d, 2H), 7.89 (d, 2H), 7.84 (d, 2H), 7.76 (d, 1H), 7.27 (d, 2H), 4.9 (m, 1H), 3.52 (t, 2H), 3.21 (s, 3H), 2.35 (t, 2H), 1.34 (s, 3H). LC–MS: <i>m</i>/<i>z</i> 428. Purity: 93%.</div><div class="NLM_p last">The following compounds <b>55</b>–<b>58</b> were prepared in a similar fashion as <b>54</b>.</div></div><div id="sec4_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> 3-Methoxy-<i>N-</i>((1<i>R</i>)-1-{4-[(6-pyridin-4-ylquinazolin-2-yl)amino]phenyl}ethyl)propanamide (<b>55</b>)</h3><div class="NLM_p last">The title compound was synthesized from <i>N</i>-[(1<i>R</i>)-1-(4-bromophenyl)ethyl]-3-methoxypropanamide (<b>44</b>) and 6-pyridin-4-ylquinazolin-2-amine (<b>6</b>). <sup>1</sup>H NMR: 9.98 (s, 1H), 9.36 (s, 1H), 8.67 (d, 2H), 8.41 (s, 1H), 8.24 (d, 2H), 7.89 (d, 2H), 7.83 (d, 2H), 7.75 (d, 1H), 7.27 (d, 2H), 4.90 (m, 1H), 3.52 (t, 2H), 3.21 (s, 3H), 2.35 (t, 2H), 1.34 (d, 3H). LC–MS: <i>m</i>/<i>z</i> 428.</div></div><div id="sec4_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 3-Methoxy-<i>N-</i>((1<i>S</i>)-1-{4-[(6-pyridin-4-ylquinazolin-2-yl)amino]phenyl}ethyl)propanamide (<b>56</b>)</h3><div class="NLM_p last">The title compound was synthesized from <i>N</i>-[(1<i>S</i>)-1-(4-bromophenyl)ethyl]-3-methoxypropanamide (<b>45</b>) and 6-pyridin-4-ylquinazolin-2-amine (<b>6</b>). <sup>1</sup>H NMR: 9.98 (s, 1H), 9.36 (s, 1H), 8.67 (d, 2H), 8.41 (s, 1H), 8.25 (d, 2H), 7.89 (d, 2H), 7.83 (d, 2H), 7.74 (d, 1H), 7.27 (d, 2H), 4.9 (m, 1H), 3.52 (t, 2H), 3.21 (s, 3H), 2.35 (t, 2H), 1.3 (d, 3H). LC–MS: <i>m</i>/<i>z</i> 428.</div></div><div id="sec4_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> <i>N-</i>(1-(4-(6-(Pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethyl)acetamide (<b>57</b>)</h3><div class="NLM_p last">The title compound was synthesized from <i>N</i>-(1-(4-bromophenyl)ethyl)acetamide (<b>46</b>) and 6-pyridin-4-ylquinazolin-2-amine (<b>6</b>). <sup>1</sup>H NMR: 9.98 (s, 1H), 9.36 (s, 1H), 8.67 (d, 2H), 8.41 (s, 1H), 8.25 (m, 2H), 7.90 (d, 2H), 7.83 (d, 2H), 7.75 (d, 1H), 7.27 (d, 2H), 4.88 (m, 1H), 1.83 (s, 3H), 1.33 (d, 3H). LC–MS: <i>m</i>/<i>z</i> 384. Purity: 90%.</div></div><div id="sec4_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> (<i>R</i>)-<i>N-</i>(1-(4-(6-(Pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethyl)acetamide (<b>58</b>)</h3><div class="NLM_p last">The title compound was synthesized from (<i>R</i>)-<i>N</i>-(1-(4-bromophenyl)ethyl)acetamide (<b>47</b>) and 6-pyridin-4-ylquinazolin-2-amine (<b>6</b>). <sup>1</sup>H NMR: 9.98 (s, 1H), 9.36 (s, 1H), 8.67 (d, 2H), 8.41 (s, 1H), 8.25 (m, 2H), 7.90 (d, 2H), 7.83 (d, 2H), 7.76 (d, 1H), 7.27 (d, 2H), 4.88 (m, 1H), 1.83 (s, 3H), 1.33 (d, 3H). LC–MS: <i>m</i>/<i>z</i> 384.</div></div><div id="sec4_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> [4-(2-Methoxyethoxy)phenyl]amine (<b>59</b>)</h3><div class="NLM_p last">4-Aminophenol (2.2 g, 19.8 mmol) and potassium carbonate (5.5 g, 39.6 mmol) were dissolved in DMF. To the reaction mixture was added 1-chloro-2-methoxyethane (2 mL, 21.8 mmol) and the mixture was stirred overnight at 80 °C. The resulting solids were filtered, and the filtrate was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated under reduced pressure, and purified by an ISCO system (50–100% EtOAc in hexanes) to afford 538 mg of the title compound (16% yield). LC–MS: <i>m</i>/<i>z</i> 168.</div></div><div id="sec4_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> <i>N</i>-(4-Aminophenyl)-3-methoxypropanamide (<b>60</b>)</h3><div class="NLM_p last">The title compound was synthesized from deprotection of <i>tert</i>-butyl {4-[3-methoxypropanoyl)amino]phenyl}carbamate intermediate, which was synthesized in analogy to <b>18</b> from <i>tert</i>-butyl (4-aminophenyl)carbamate and 3-methoxypropanoic acid and was carried forward crude into the BOC group deprotection using standard acid mediated conditions. LC–MS: <i>m</i>/<i>z</i> 403.</div></div><div id="sec4_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> <i>N</i>-(2-Methoxyethyl)-<i>N</i>-methylbenzene-1,4-diamine (<b>61</b>)</h3><div class="NLM_p last">To a solution of <i>N</i>-(2-methoxyethyl)-<i>N</i>-methyl-4-nitroaniline (prepared from 1-bromo-4-nitrobenzene and 2-methoxyethylamine using a method analogous to the preparation of <b>3</b>, 700 mg, 3.3 mmol) in ethanol (8 mL) was added SnCl<sub>2</sub>·H<sub>2</sub>O (1.8 g, 8.3 mmol), and the reaction was stirred overnight at 70 °C. To the reaction mixture was then added 4.0 M NaOH. The mixture was extracted (2×) with EtOAc, and the combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to afford 505 mg of a green oil, which was taken on crude immediately to the next reaction.</div></div><div id="sec4_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> 6-Bromo-<i>N</i>-[4-(2-methoxyethoxy)phenyl]quinazolin-2-amine (<b>62</b>)</h3><div class="NLM_p last">To [4-(2-methoxyethoxy)phenyl]amine (<b>59</b>, 100 mg, 0.598 mmol) in propan-2-ol (3 mL) was added 6-bromo-2-chloroquinazoline (prepared in analogy to ref <a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">16</a>; 131 mg, 0.538 mmol). The reaction mixture was stirred for 2 h at 100 °C and then allowed to cool to room temperature. The title compound was formed as a precipitate from the solution yielding 123 mg (56% yield). LC–MS: <i>m</i>/<i>z</i> 388.</div></div><div id="sec4_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> <i>N</i>-(4-(6-Bromoquinazolin-2-ylamino)phenyl)-3-methoxypropanamide (<b>63</b>)</h3><div class="NLM_p last">The title compound was synthesized from 6-bromo-2-chloroquinazoline (prepared in analogy to ref <a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">16</a>) and <i>N</i>-(4-aminophenyl)-3-methoxypropanamide (<b>60</b>) using a method analogous to <b>62</b>. LC–MS: <i>m</i>/<i>z</i> 403.</div></div><div id="sec4_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> <i>N-</i>{4-[(6-Bromoquinazolin-2-yl)amino]phenyl}-<i>N-</i>methylacetamide (<b>64</b>)</h3><div class="NLM_p last">6-Bromo-2-chloroquinazoline (prepared in analogy to ref <a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">16</a>; 100 mg, 0.412 mmol, 1.0 equiv), <i>N-</i>(4-aminophenyl)-<i>N-</i>methylacetamide (101 mg, 0.617 mmol, 1.5 equiv), and acetonitrile (5.0 mL) were added to a microwave vial which was heated in a microwave at 125 °C for 30 min. The reaction was then concentrated to afford a crude solid that was purified by an ISCO system (100% hexanes to 100% EtOAc) to obtain a yellow solid. LC–MS: <i>m</i>/<i>z</i> 372.</div></div><div id="sec4_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> <i>N-</i>{4-[(6-Bromoquinazolin-2-yl)amino]phenyl}acetamide (<b>65</b>)</h3><div class="NLM_p last">The title compound was synthesized from 6-bromo-2-chloroquinazoline (prepared in analogy to ref <a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">16</a>) and <i>N-</i>(4-aminophenyl)acetamide using a method similar to that of <b>64</b>. LC–MS: <i>m</i>/<i>z</i> 372.</div></div><div id="sec4_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> <i>N</i>′-(6-Bromoquinazolin-2-yl)-<i>N</i>-(2-methoxyethyl)-<i>N</i>-methylbenzene-1,4-diamine (<b>66</b>)</h3><div class="NLM_p last">The title compound was synthesized from 6-bromo-2-chloroquinazoline (prepared in analogy to ref <a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">16</a>) and <i>N</i>-(2-methoxyethyl)- <i>N</i>-methylbenzene-1,4-diamine (<b>61</b>) prepared by a method similar to that of <b>62</b>. LC–MS: <i>m</i>/<i>z</i> 389.</div></div><div id="sec4_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> <i>N-</i>[4-(2-Methoxyethoxy)phenyl]-6-pyridin-4-ylquinazolin-2-amine (<b>67</b>)</h3><div class="NLM_p last">The title compound was synthesized from 4-pyridinylboronic acid and 6-bromo-<i>N</i>-[4-(2-methoxyethoxy)phenyl]quinazolin-2-amine (<b>62</b>) using a procedure analogous to that of <b>6</b>. <sup>1</sup>H NMR: 9.88 (s, 1H), 9.32 (s, 1H), 8.66 (s, 2H), 8.39 (s, 1H), 8.22 (d, 1H), 7.90–7.80 (m, 3H), 7.75–7.64 (m, 2H), 6.94 (d, 2H), 4.10–4.03 (m, 2H), 3.65 (t, 2H), 3.31 (s, 3H). LC–MS: <i>m</i>/<i>z</i> 373.</div></div><div id="sec4_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> 3-Methoxy-<i>N</i>-(4-(6-(pyridin-4-yl)quinazolin-2-ylamino)phenyl)propanamide (<b>68</b>)</h3><div class="NLM_p last">The title compound was synthesized from <i>N</i>-(4-(6-bromoquinazolin-2-ylamino)phenyl)-3-methoxypropanamide (<b>63</b>) and 4-pyridinylboronic acid using a method similar to that of <b>6</b>, except with PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> as catalyst. Purification was performed by Gilson HPLC (0.1% ammonium acetate in CH<sub>3</sub>CN and water) to yield a yellow solid (16 mg, 0.04 mmol, 30.6% yield). <sup>1</sup>H NMR: 10.17 (s, 1H), 9.98 (s, 1H), 9.39 (s, 1H), 8.99 (d, 2H), 8.72 (s, 1H), 8.50 (d, 2H), 8.43 (d, 1H), 7.90 (d, 2H), 7.81 (d, 1H), 7.62–7.55 (m, 2H), 3.61 (t, 2H), 3.24 (s, 3H), 2.54 (t, 2H). LC–MS: <i>m</i>/<i>z</i> 400.</div></div><div id="sec4_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> <i>N-</i>Methyl-<i>N-</i>{4-[(6-pyridin-4-ylquinazolin-2-yl)amino]phenyl}acetamide (<b>69</b>)</h3><div class="NLM_p last">The title compound was synthesized from <i>N-</i>{4-[(6-bromoquinazolin-2-yl)amino]phenyl}-<i>N-</i>methylacetamide (<b>64</b>) and 4-pyridinylboronic acid using a similar method to that of <b>68</b>, except with cesium carbonate as base, dioxane/water (4:1) as solvent, and with reaction temperature of 80 °C. Purification was performed by Gilson HPLC (0.1% ammonium acetate in CH<sub>3</sub>CN and water). <sup>1</sup>H NMR: 10.20 (s, 1H), 9.41 (s, 1H), 8.68 (d, 2H), 8.45 (s, 1H), 8.28 (m, 1H), 8.06 (d, 2H), 7.82 (m, 3H), 7.29 (d, 2H), 3.14 (s, 3H), 1.78 (s, 3H). LC–MS: <i>m</i>/<i>z</i> 370.</div></div><div id="sec4_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> <i>N-</i>{4-[(6-Pyridin-4-ylquinazolin-2-yl)amino]phenyl}acetamide (<b>70</b>)</h3><div class="NLM_p last">The title compound was synthesized from <i>N-</i>{4-[(6-bromoquinazolin-2-yl)amino]phenyl}acetamide (<b>65</b>) and 4-pyridinylboronic acid using a similar method to that of <b>69</b>. <sup>1</sup>H NMR: 9.96 (s, 1H), 9.87 (s, 1H), 9.35 (s, 1H), 8.68 (m, 2H), 8.40 (s, 1H), 8.25 (m, 1H), 7.86 (m, 5H), 7.53 (m, 2H), 2.02 (s, 3H). LC–MS: <i>m</i>/<i>z</i> 356.</div></div><div id="sec4_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> <i>N-</i>(2-Methoxyethyl)-<i>N-</i>methyl-<i>N</i>′-(6-pyridin-4-ylquinazolin-2-yl)benzene-1,4-diamine (<b>71</b>)</h3><div class="NLM_p last">The title compound was synthesized from <i>N</i>′-(6-bromoquinazolin-2-yl)-<i>N</i>-(2-methoxyethyl)-<i>N</i>-methylbenzene-1,4-diamine (<b>66</b>) and 4-pyridinylboronic acid using a similar method to that of<b> 69</b>. <sup>1</sup>H NMR: 9.86 (s, 1H), 9.30 (s, 1H), 8.78 (d, 2H), 8.49 (s, 1H), 8.28 (d, 1H), 8.08 (d, 2H), 7.80 (s, 2H), 7.69 (d, 1H), 6.83 (s, 2H), 3.48 (bs, 7H), 2.94 (s, 3H). LC–MS: <i>m</i>/<i>z</i> 386.</div></div><div id="sec4_70" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> (<i>R</i>)-<i>tert</i>-Butyl 1-(4-Bromophenyl)ethylcarbamate (<b>72</b>)</h3><div class="NLM_p last">(<i>R</i>)-1-(4-Bromophenyl)ethanamine (5 g, 24.99 mmol), BOC anhydride (6.00 g, 27.94 mmol), and THF (50 mL) were stirred at room temperature for 12 h. The resulting reaction mixture was concentrated under reduced pressure to afford a white solid which was used directly in the next step. <sup>1</sup>H NMR: 7.50 (m, 2H), 7.24 (m, 2H), 4.48–4.66 (m, 1H), 1.35 (s, 9 H), 1.27 (d, <i>J</i> = 7.16 Hz, 3H). LC–MS: <i>m</i>/<i>z</i> 200 (M + H – BOC).</div></div><div id="sec4_71" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> (<i>R</i>)-<i>N</i>-(4-(1-Aminoethyl)phenyl)-6-(pyridin-4-yl)quinazolin-2-amine Hydrochloride (<b>73</b>)</h3><div class="NLM_p last">The title compound was synthesized from (<i>R</i>)-<i>tert</i>-butyl 1-(4-bromophenyl)ethylcarbamate (<b>72</b>) and 6-pyridin-4-ylquinazolin-2-amine (<b>6</b>) using a method analogous to the preparation of <b>3</b>, with Xantphos and palladium(II) acetate and by heating at 100 °C for 4 h. Purification on an ISCO system (100% hexanes to 100% ethyl acetate) afforded (<i>R</i>)-<i>tert</i>-butyl 1-(4-(6-(pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethylcarbamate, which was carried forward and treated with 2 N HCl in ether solution followed by concentration under reduced pressure to afford the title compound. <sup>1</sup>H NMR: 10.20–10.43 (m, 1H), 9.44 (s, 1H), 8.97 (d, <i>J</i> = 5.27 Hz, 2H), 8.65–8.76 (m, 1H), 8.25–8.49 (m, 6H), 8.03 (m, 2H), 7.85 (d, <i>J</i> = 8.67 Hz, 1H), 7.49 (m, 2H), 4.39 (m, 1H), 1.52 (d, <i>J</i> = 6.59 Hz, 3H). LC–MS: <i>m</i>/<i>z</i> 342.</div></div><div id="sec4_72" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> Benzyl 3-Hydroxy-5-oxo-5,6-dihydropyridine-1(2<i>H</i>)-carboxylate (<b>74</b>)</h3><div class="NLM_p last">To a 50 mL round-bottomed flask was added 3,5-dimethoxypyridine (0.983 g, 7.06 mmol) and NaBH<sub>4</sub> (0.481 g, 12.72 mmol) in acetonitrile (20.54 mL) to give a colorless suspension. Benzyl carbonochloridate (1.256 mL, 8.48 mmol) was added, dropwise, at 0 °C over 20 min to produce a milky mixture. The reaction mixture was stirred for an additional 30 min at 0 °C (whereby LC–MS indicated the consumption of starting material) and then poured into 1 M aqueous NaOH (20 mL). The reaction was extracted with EtOAc (3 × 20 mL), the organic fractions were combined and rinsed with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to yield an oily mixture. Exposure of the mixture to MeOH produced small crystals, which were isolated via vacuum filtration. The resulting filtrate was concentrated under reduced pressure, exposed to MeOH (5 mL), cooled at 0 °C for 30 min, and the resulting solid was isolated via vacuum-filtration. The filtrate was concentrated via reduced pressure to yield the dimethyl enol ether intermediate, which was subsequently dissolved in 1,4-dioxane (20 mL). Then 4 M aqueous HCl was added (10 mL) and reaction mixture was stirred at 23 °C for 3 h. The reaction was then extracted with EtOAc (3 × 20 mL), and the organic extracts were combined, rinsed with brine (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to yield the title compound (75% purity by LC–MS), which was taken forward as the crude material to the next step. LC–MS: <i>m</i>/<i>z</i> 248.</div></div><div id="sec4_73" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> (<i>R</i>)-<i>N</i>-((<i>R</i>)-1-(4-(6-(Pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethyl)piperidine-2-carboxamide Hydrochloride (<b>75</b>)</h3><div class="NLM_p last">In a 10 mL vial, (<i>R</i>)-<i>N</i>-(4-(1-aminoethyl)phenyl)-6-(pyridin-4-yl)quinazolin-2-amine hydrochloride (<b>73</b>, 5.567 g, 12.35 mmol), (<i>R</i>)-1-(<i>tert</i>-butoxycarbonyl)piperidine-2-carboxylic acid hydrochloride (3.94 g, 14.82 mmol), DIPEA (9.71 mL, 55.57 mmol), and HATU (9.39 g, 24.70 mmol) were combined in DMF (61.7 mL) to give a yellow solution. The reaction was stirred for 18 h at 60 °C, poured into 10% aqueous K<sub>2</sub>HPO<sub>4</sub> (60 mL), and extracted with EtOAc (3 × 40 mL). The organic extracts were combined and rinsed with saturated NH<sub>4</sub>Cl (3 × 30 mL) and brine (40 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to yield a yellow foam. HCl (4 M) in dioxane (31.2 mL, 125 mmol) and MeOH (6.24 mL) were added to afford a yellow solution. The reaction was stirred for 4 h at 23 °C and then evaporated to dryness, followed by addition of toluene, concentration under reduced pressure, and then drying under high vacuum to yield the title compound. <sup>1</sup>H NMR: 9.99 (s, 1H), 9.37 (s, 1H), 8.68 (d, <i>J</i> = 5.09 Hz, 2H), 8.42 (s, 1H), 8.26 (d, <i>J</i> = 7.35 Hz, 1 H), 7.67–8.01 (m, 6H), 7.28 (d, <i>J</i> = 8.29 Hz, 2H), 4.90 (m, 1H), 3.06 (d, <i>J</i> = 8.85 Hz, 1H), 2.92 (d, <i>J</i> = 12.43 Hz, 1H), 2.10–2.24 (m, 1H), 1.73 (d, <i>J</i> = 9.42 Hz, 2H), 1.17–1.53 (m, 7H). LC–MS: <i>m</i>/<i>z</i> 453.</div></div><div id="sec4_74" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> 1-Methyl-<i>N</i>-((<i>R</i>)-1-(4-(6-(pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethyl)piperidine-2-carboxamide Hydrochloride (<b>76</b>)</h3><div class="NLM_p last">The title compound was synthesized from 1-methylpiperidine-2-carboxylic acid and (<i>R</i>)-<i>N</i>-(4-(1-aminoethyl)phenyl)-6-(pyridin-4-yl)quinazolin-2-amine hydrochloride (<b>73</b>) using a method analogous to the preparation of <b>75</b>. <sup>1</sup>H NMR (MeOH-<i>d</i><sub>4</sub>), reported as a mixture of diastereomers: 9.23 (s, 1H), 8.49–8.64 (m, 2H), 8.24 (m, 1H), 8.15 (m, 1H), 7.67–7.91 (m, 5 H), 7.22–7.40 (m, 2H), 4.96–5.10 (m, 1H), 3.13–3.18 (m, 2H), 2.74–3.03 (m, 1H), 2.58–2.72 (m, 1H), 2.46–2.54 (m, 3H), 1.97–2.07 (m, 1H), 1.80 (m, 2H), 1.57–1.74 (m, 2H), 1.41–1.55 (m, 3H). LC–MS: <i>m</i>/<i>z</i> 467.</div></div><div id="sec4_75" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> (<i>R</i>)-1-(2-Hydroxyethyl)-<i>N</i>-((R)-1-(4-(6-(pyridin-4-yl)quinazolin-2 ylamino)phenyl)ethyl)piperidine-2-carboxamide (<b>77</b>)</h3><div class="NLM_p last">In a 10 mL vial, (<i>R</i>)-<i>N</i>-((<i>R</i>)-1-(4-(6-(pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethyl)piperidine-2-carboxamide hydrochloride (<b>75</b>, 0.463 g, 0.82 mmol), 2-(<i>tert</i>-butyldimethylsilyloxy)acetaldehyde (0.158 g, 0.91 mmol), acetic acid (0.047 mL, 0.82 mmol), and DIPEA (0.460 mL, 2.64 mmol) were combined in MeOH (4.12 mL) to afford a yellow solution. Sodium cyanoborohydride (0.078 g, 1.24 mmol) was added and the reaction was stirred for 4 h at 23 °C. LC–MS indicated that the TBDMS group was cleaved under the reaction conditions, and all of the starting material was consumed. The reaction was poured into 1 M aq NaOH (30 mL) and extracted with EtOAc (3 × 20 mL). The organic extracts were combined and rinsed with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to yield a pale yellow solid which was purified via an ISCO system (10% MeOH/DCM) to yield the title compound. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub> with a drop of MeOH added for dissolution): 9.32 (s, 1H), 8.58–8.70 (m, 2H), 8.34 (br s, 1H), 8.20 (dd, <i>J</i> = 8.85, 2.07 Hz, 1H), 7.89 (m, <i>J</i> = 8.48 Hz, 2H), 7.71–7.83 (m, 3H), 7.30 (m, <i>J</i> = 8.48 Hz, 2H), 4.88 (q, <i>J</i> = 6.91 Hz, 1H), 3.37–3.64 (m, 2H), 2.69–2.82 (m, 1H), 2.56–2.65 (m, 1H), 2.13–2.31 (m, 1H), 1.96–2.13 (m, 1H), 1.59–1.81 (m, 2H), 1.42–1.59 (m, 3H), 1.37 (d, <i>J</i> = 6.97 Hz, 3H), 1.12–1.33 (m, 2H). LC–MS: <i>m</i>/<i>z</i> 497.</div></div><div id="sec4_76" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> (<i>S</i>)-<i>N</i>-((<i>R</i>)-1-(4-(6-(Pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethyl)piperidine-3-carboxamide Hydrochloride (<b>78</b>)</h3><div class="NLM_p last">The title compound was synthesized from (<i>S</i>)-1-(<i>tert</i>-butoxycarbonyl)piperidine-3-carboxylic acid and (<i>R</i>)-<i>N</i>-(4-(1-aminoethyl)phenyl)-6-(pyridin-4-yl)quinazolin-2-amine hydrochloride (<b>73</b>) using a method similar to that of <b>75</b> except using 2 N HCl in ether for BOC group deprotection. <sup>1</sup>H NMR: 10.17 (s, 1H), 9.40 (m, 2H), 8.98 (m, 2H), 8.70 (m, 1H), 8.46 (m, 2H), 7.91 (m, 5H), 7.28 (m, 2H), 4.88 (m, 1H), 3.67 (m, 2H), 2.94 (m, 2H), 1.95 (m, 1H), 1.73 (m, 2H), 1.58 (m, 2H), 1.37 (m, 3H). LC–MS: <i>m</i>/<i>z</i> 453.</div></div><div id="sec4_77" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> (<i>R</i>)-<i>N</i>-(1-(4-(6-(Pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethyl)piperidine-4-carboxamide Hydrochloride (<b>79</b>)</h3><div class="NLM_p last">The title compound was synthesized from 1-(<i>tert-</i>butoxycarbonyl)piperidine-4-carboxylic acid and (<i>R</i>)-<i>N</i>-(4-(1-aminoethyl)phenyl)-6-(pyridin-4-yl)quinazolin-2-amine hydrochloride (<b>73</b>) using a method similar to that of <b>75</b>. <sup>1</sup>H NMR: 10.21 (s, 1H), 9.41 (s, 1H), 9.24 (d, <i>J</i> = 9.80 Hz, 1H), 9.00 (d, <i>J</i> = 6.97 Hz, 2H), 8.69–8.86 (m, 2H), 8.52 (d, <i>J</i> = 6.97 Hz, 2H), 8.45 (dt, <i>J</i> = 8.76, 2.03 Hz, 2H), 7.89 (m, 2H), 7.80 (d, <i>J</i> = 9.04 Hz, 1H), 7.29 (m, 2H), 4.89 (m, 1H), 3.59–3.75 (m, 1H), 3.39–3.54 (m, 1H), 3.17–3.31 (m, 2H), 2.73–2.94 (m, 2H), 1.63–1.94 (m, 3H), 1.36 (d, <i>J</i> = 6.97 Hz, 3 H). LC–MS: <i>m</i>/<i>z</i> 453.</div></div><div id="sec4_78" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> (<i>R</i>)-<i>N</i>-((<i>R</i>)-1-(4-(6-(Pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethyl)pyrrolidine-2-carboxamide Hydrochloride (<b>80</b>)</h3><div class="NLM_p last">The title compound was synthesized from BOC-<span class="smallcaps smallerCapital">d</span>-proline and (<i>R</i>)-<i>N</i>-(4-(1-aminoethyl)phenyl)-6-(pyridin-4-yl)quinazolin-2-amine hydrochloride (<b>73</b>) using a method similar to that of <b>75</b>. <sup>1</sup>H NMR: 10.21 (br s, 1H), 10.07 (s, 1H), 9.34–9.42 (m, 1H), 9.10–9.23 (m, 1H), 8.80 (d, <i>J</i> = 5.27 Hz, 2H), 8.41–8.58 (m, 2H), 8.32 (dd, <i>J</i> = 9.04, 2.07 Hz, 1H), 8.05–8.13 (m, 2H), 7.95 (s, 1H), 7.77 (d, <i>J</i> = 8.85 Hz, 1H), 7.31 (d, <i>J</i> = 8.67 Hz, 2H), 4.95 (quin, 1H), 4.15–4.32 (m, 1H), 3.63–3.76 (m, 1H), 3.41–3.54 (m, 1H), 2.30–2.43 (m, 1H), 1.69–1.96 (m, 3H), 1.43 (d, <i>J</i> = 6.97 Hz, 3 H). LC–MS: <i>m</i>/<i>z</i> 439.</div></div><div id="sec4_79" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> (<i>R</i>)-3-(1-(4-(6-(Pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethylamino)cyclohex-2-enone (<b>81</b>)</h3><div class="NLM_p last">To (<i>R</i>)-<i>N</i>-(4-(1-aminoethyl)phenyl)-6-(pyridin-4-yl)quinazolin-2-amine hydrochloride (<b>73</b>, 0.298 g, 0.66 mmol) and cyclohexane-1,3-dione (0.222 g, 1.98 mmol), acetic acid (0.038 mL, 0.66 mmol), and DIPEA (0.358 mL, 2.05 mmol) was added MeOH (3.31 mL) to give a yellow solution. The reaction was stirred for 12 h at 60 °C. The reaction was quenched with 1 M aqueous NaOH (30 mL). The resulting thick oil was triturated with a mixture of MTBE (10 mL) and EtOAc (6 mL). The resultant yellow solid was isolated via vacuum filtration, rinsed with MTBE (2 × 5 mL), and dried under high-vacuum to yield the title compound. <sup>1</sup>H NMR: 10.01 (s, 1H), 9.31–9.40 (m, 1H), 8.63–8.75 (m, 2H), 8.42 (d, <i>J</i> = 2.07 Hz, 1H), 8.26 (dd, <i>J</i> = 8.85, 2.26 Hz, 1H), 7.92 (m, 2H), 7.81–7.87 (m, 2H), 7.77 (d, <i>J</i> = 8.85 Hz, 1H), 7.40 (d, <i>J</i> = 6.78 Hz, 1H), 7.27 (m, 2H), 4.67 (s, 1H), 4.42 (quin, 1H), 2.39 (m, 2H), 2.01 (m, 2H), 1.73–1.86 (m, 2H), 1.41 (d, <i>J</i> = 6.78 Hz, 3H). LC–MS: <i>m</i>/<i>z</i> 436.</div></div><div id="sec4_80" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> (<i>R</i>)-3-(1-(4-(6-(Pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethylamino)cyclopent-2-enone (<b>82</b>)</h3><div class="NLM_p last">The title compound was synthesized from (<i>R</i>)-<i>N</i>-(4-(1-aminoethyl)phenyl)-6-(pyridin-4-yl)quinazolin-2-amine hydrochloride (<b>73</b>) and cyclopentane-1,3-dione using a method analogous to the preparation of <b>81</b>. <sup>1</sup>H NMR: 10.02 (s, 1H), 9.38 (s, 1H), 8.65–8.72 (m, 2H), 8.42 (d, <i>J</i> = 2.07 Hz, 1H), 8.26 (dd, <i>J</i> = 8.76, 2.17 Hz, 1H), 8.01 (d, <i>J</i> = 6.97 Hz, 1H), 7.93 (m, 2H), 7.81–7.86 (m, 2H), 7.77 (d, <i>J</i> = 8.85 Hz, 1H), 7.30 (m, 2H), 4.67 (s, 1H), 4.41 (quin, 1H), 2.52–2.58 (m, 2H), 2.04–2.15 (m, 2H), 1.44 (d, <i>J</i> = 6.78 Hz, 3H). LC–MS: <i>m</i>/<i>z</i> 422.</div></div><div id="sec4_81" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> (<i>R</i>)-4-(1-(4-(6-(Pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethylamino)-5,6-dihydropyridin-2(1<i>H</i>)-one (<b>83</b>)</h3><div class="NLM_p last">The title compound was synthesized from (<i>R</i>)-<i>N</i>-(4-(1-aminoethyl)phenyl)-6-(pyridin-4-yl)quinazolin-2-amine (<b>73</b>-free base) and piperidine-2,4-dione using a method analogous to the preparation of <b>81</b>, except using DMF as solvent and heating in a microwave at 150 °C for 30 min. Compound was purified by an ISCO system (0–40% methanol/ethyl acetate gradient). <sup>1</sup>H NMR (MeOH-<i>d</i><sub>4</sub>): 7.48 (s, 1H), 6.89–6.95 (m, 2H), 6.46 (d, <i>J</i> = 2.02 Hz, 1H), 6.40 (dd, <i>J</i> = 8.84, 2.27 Hz, 1H), 6.19 (d, <i>J</i> = 8.59 Hz, 2H), 6.06–6.11 (m, 2H), 6.02 (d, <i>J</i> = 8.84 Hz, 1H), 5.65 (d, <i>J</i> = 8.59 Hz, 2H), 2.88 (s, 1H), 2.82 (q, <i>J</i> = 6.65 Hz, 1H), 1.72–1.75 (m, 2H), 0.89 (t, <i>J</i> = 6.95 Hz, 2H), −0.13 (d, <i>J</i> = 6.82 Hz, 3H). LC–MS: <i>m</i>/<i>z</i> 437. Purity: 90%.</div></div><div id="sec4_82" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> (<i>R</i>)-5-(1-(4-(6-(Pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethylamino)-1,2-dihydropyridin-3(6<i>H</i>)-one (<b>84</b>)</h3><div class="NLM_p last">(i) (<i>R</i>)-<i>N</i>-(4-(1-Aminoethyl)phenyl)-6-(pyridin-4-yl)quinazolin-2-amine (<b>73</b>-free base, 1.016 g, 2.98 mmol), benzyl 3-hydroxy-5-oxo-5,6-dihydropyridine-1(2<i>H</i>)-carboxylate (<b>74</b>, 0.883 g, 3.57 mmol), and acetic acid (0.170 mL, 2.98 mmol) were combined in NMP (6.97 mL) to give a yellow solution. The reaction was heated at 105 °C for 6 h, cooled to ambient temperature, and poured into saturated aq NH<sub>4</sub>Cl (40 mL). The mixture was extracted with EtOAc (3 × 30 mL), and the organic fractions were combined, rinsed with 1 M aqueous NaOH (30 mL) and brine (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to yield a dark orange oil which was purified via column chromatography (SiO<sub>2</sub>, 10% MeOH/DCM) to yield (<i>R</i>)-benzyl-5-oxo-3-(1-(4-(6-(pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethylamino)-5,6-dihydropyridine-1(2<i>H</i>)-carboxylate which was carried forward crude into the next step. LC–MS: <i>m</i>/<i>z</i> 570. (ii) In a 20 mL round-bottomed flask, (<i>R</i>)-benzyl 5-oxo-3-(1-(4-(6-(pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethylamino)-5,6-dihydropyridine-1(2<i>H</i>)-carboxylate (0.380 g, 0.53 mmol) and Pearlman’s catalyst (0.056 g, 0.08 mmol) were combined in MeOH (2.66 mL) to give a yellow suspension. The reaction was stirred for 18 h at 23 °C under a hydrogen balloon (1 atm). The reaction was filtered, and the filtrate was concentrated over Celite and subjected to column chromatography (SiO<sub>2</sub>, 18% MeOH/DCM) to yield the title compound as a yellow solid. <sup>1</sup>H NMR (MeOH-<i>d</i><sub>4</sub>): 8.94–9.12 (m, 1H), 8.40–8.59 (m, 2H), 8.08 (m, 2H), 7.48–7.86 (m, 5H), 7.26 (m, 2H), 5.06 (s, 1H), 4.30–4.59 (m, 1H), 3.42–3.62 (m, 2H), 3.14–3.25 (m, 2H), 1.50 (m, 3H). LC–MS: <i>m</i>/<i>z</i> 437.</div></div><div id="sec4_83" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> (<i>R</i>)-<i>N</i>-(1-(4-Aminophenyl)ethyl)acetamide (<b>85</b>)</h3><div class="NLM_p last">(i) (<i>R</i>)-1-(4-Bromophenyl)ethanamine (25 g, 0.125 mol) was treated with acetic anhydride (100 mL). The reaction mixture was heated to 50 °C for 4 h. The organics were removed under reduced pressure to afford (<i>R</i>)-<i>N</i>-(1-(4-bromophenyl)ethyl)acetamide (30 g, 99% yield), which was used directly in the next step. (ii) A solution of (<i>R</i>)-<i>N</i>-(1-(4-bromophenyl)ethyl)acetamide (30 g, 120 mmol), diphenylmethanimine (27.2 g, 150 mmol, 1.3 equiv), Pd<sub>2</sub>(dba)<sub>3</sub>-CH<sub>2</sub>Cl<sub>2</sub> (6.5 g, 6.3 mmol, 0.53 equiv), 2-(dicyclohexylphosphino)-2′,4′,6′-triisopropyl-1,1′-biphenyl (X-Phos, 6.1 g, 8.2 mmol, 0.068 equiv), and Cs<sub>2</sub>CO<sub>3</sub> (122 g, 375 mmol, 3 equiv) in 1,4-dioxane (1.5 L) was heated to 100 °C for 12 h. The reaction mixture was cooled to 25 °C and poured into water, followed by extraction with EtOAc. The organics were dried over Na<sub>2</sub>SO<sub>4</sub> (s) and removed under reduced pressure. The resulting product was purified by silica gel chromatography (petroleum ether/ethyl acetate, 1:1) to afford (<i>R</i>)-<i>N</i>-(1-(4-(Diphenylmethyleneamino)phenyl)ethyl)acetamide (33.6 g, 78% yield). LC–MS: <i>m</i>/<i>z</i> 343. (iii) (<i>R</i>)-<i>N</i>-(1-(4(diphenylmethyleneamino)phenyl)ethyl)acetamide (33.5 g, 97.8 mmol) in Et<sub>2</sub>O (300 mL) was treated with 1 N HCl (300 mL). The reaction mixture was stirred at 25 °C for 12 h. The reaction mixture was concentrated under reduced pressure and the resulting residue was triturated with Et<sub>2</sub>O. The resulting solid was dissolved in a mixture of 10% w/v aq K<sub>2</sub>HPO<sub>4</sub> and EtOAc. The organics were washed with NaCl (satd) and then dried with Na<sub>2</sub>SO<sub>4</sub> (s). The organics were removed under reduced pressure to afford the title compound (17.2 g, 98% yield). LC–MS: <i>m</i>/<i>z</i> 179.</div></div><div id="sec4_84" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> (<i>R</i>)-<i>N</i>-(1-(4-(6-Bromo-8-methoxyquinazolin-2-ylamino)phenyl)ethyl)acetamide (<b>86</b>)</h3><div class="NLM_p last">6-Bromo-2-chloro-8-methoxyquinazoline (prepared as described in ref <a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">17</a>; 100 mg, 0.366 mmol) and (<i>R</i>)-<i>N</i>-(1-(4-aminophenyl)ethyl)acetamide (<b>85</b>, 98 mg, 0.549 mmol, 1.5 equiv) were dissolved in 2-propanol (20 mL), and the mixture was heated to reflux for 3 h. DIPEA (0.140 mL, 0.805 mmol, 2.2 equiv) was then added and the mixture was heated at reflux for 12 h. The crude mixture was then concentrated under reduced pressure. The resulting suspension was washed with methanol, and the solid was collected by filtration and then dried under high vacuum to afford the title compound (110 mg, 73% yield), which was carried forward crude into the next step.</div></div><div id="sec4_85" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> (<i>R</i>)-<i>N</i>-(1-(4-(8-Methoxy-6-(pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethyl)acetamide (<b>87</b>)</h3><div class="NLM_p last">The title compound was synthesized from (<i>R</i>)-<i>N</i>-(1-(4-(6-bromo-8-methoxyquinazolin-2-ylamino)phenyl)ethyl)acetamide (<b>86</b>) and 4-pyridinylboronic acid using a method analogous to the preparation of <b>6</b>, except using Cs<sub>2</sub>CO<sub>3</sub> as base and 1,4-dioxane/water (2:1) as solvent. The crude product was purified by column chromatography (DCM/MeOH) to afford 80 mg (80%) of the title compound. <sup>1</sup>H NMR: 10.01 (s, 1H), 9.32 (s, 1H), 8.68 (s, 2H), 8.23 (d, 1H), 7.97 (m, 5H), 7.64 (s, 1H), 7.23 (m, 2H), 4.90 (m, 1H), 4.08 (s, 3H), 1.83 (s, 3H), 1.33 (d, 3H). LC–MS: <i>m</i>/<i>z</i> 414.</div></div><div id="sec4_86" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> 6-Bromo-7-methoxyquinazolin-2-amine (<b>88</b>)</h3><div class="NLM_p last">2-Amino-5-bromo-4-methoxybenzaldehyde (prepared as described in ref <a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">17</a>; 180 mg, 0.78 mmol) was dissolved in decalin (5 mL). Guanidine carbonate (0.4 g, 2.2 mmol) was added, and the mixture was heated at 210 °C for 3 h. The mixture was allowed to cool and was purified by silica gel chromatography to give the product as a yellow solid (110 mg, 55%). <sup>1</sup>H NMR: 8.90 (s, 1H), 8.05 (s, 1H) 3.92 (s, 3H), 6.87 (s, 1H). LC–MS: <i>m</i>/<i>z</i> 254.</div></div><div id="sec4_87" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> 6-Bromo-7-chloroquinazolin-2-amine (<b>89</b>)</h3><div class="NLM_p last">To 2-amino-5-bromo-4-chlorobenzaldehyde (prepared as described in ref <a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">17</a>; 6.44 g, 27.5 mmol) and guanidine carbonate (7.45 g, 41.35 mmol) was added DMA (55 mL), and the resulting mixture was placed in a 140 °C oil bath. After 4 h, the reaction was allowed to cool and was then diluted with H<sub>2</sub>O (200 mL), precipitating an orange-colored amorphous solid that was isolated by suction-filtration. The filter cake was washed with H<sub>2</sub>O and dried in air to give a yellow solid (6.54 g) which was suspended in refluxing MeOH (100 mL) for 16 h. The resulting mixture was allowed to cool and was suction-filtered, washed with MeOH, and dried in air to give the product as a yellow solid (4.73 g, 67%). <sup>1</sup>H NMR: 9.11 (s, 1H), 8.27 (s, 1H), 7.63 (s, 1H), 7.20 (s, 2H). LC–MS: <i>m</i>/<i>z</i> 259.</div></div><div id="sec4_88" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> 6-Bromo-8-chloroquinazolin-2-amine (<b>90</b>)</h3><div class="NLM_p last">The title compound was synthesized from 2-amino-5-bromo-3-chlorobenzaldehyde (prepared as described in ref <a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">17</a>) using a method analogous to the preparation of <b>89</b>, to afford a yellow solid (7.38 g, 84% yield). <sup>1</sup>H NMR: 9.13 (s, 1H), 7.99–8.11 (m, 2H), 7.38 (br. s., 2H); <i>m</i>/<i>z</i> 259.</div></div><div id="sec4_89" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> 7-Methoxy-6-(pyridin-4-yl)quinazolin-2-amine (<b>91</b>)</h3><div class="NLM_p last">The title compound was synthesized from 6-bromo-7-methoxyquinazolin-2-amine (<b>88</b>) and 4-pyridinylboronic acid using a method analogous to the preparation of <b>87</b>, but with Cs<sub>2</sub>CO<sub>3</sub> and dioxane/water (2/1) as solvent (94% yield). LC–MS: <i>m</i>/<i>z</i> 253.</div></div><div id="sec4_90" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> 7-Chloro-6-(pyridin-4-yl)quinazolin-2-amine (<b>92</b>)</h3><div class="NLM_p last">The title compound was synthesized from 6-bromo-7-chloroquinazolin-2-amine (<b>89</b>) using a method analogous to the preparation of <b>6</b>, except with (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub> (4.0 mol %) as catalyst and dioxane/water (2/1) as solvent (3.42 g, 77%). <sup>1</sup>H NMR: 9.18 (s, 1H), 8.64–8.75 (m, 2H), 7.94 (s, 1H), 7.60 (s, 1H), 7.48–7.58 (m, 2H), 7.21 (s, 2H). LC–MS: <i>m</i>/<i>z</i> 257.</div></div><div id="sec4_91" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> 8-Chloro-6-(pyridin-4-yl)quinazolin-2-amine (<b>93</b>)</h3><div class="NLM_p last">The title compound was synthesized from 6-bromo-8-chloroquinazolin-2-amine (<b>90</b>) following the procedure described for the preparation of <b>92</b>, to afford the title compound as a yellow solid (3.41 g, 99%) that was contaminated with a minor amount of the bis-4-pyridyl product derived from coupling at both the bromo and chloro positions, which was used without further purification. LC–MS: <i>m</i>/<i>z</i> 257.</div></div><div id="sec4_92" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> (<i>R</i>)-<i>tert</i>-Butyl 1-(4-(7-Methoxy-6-(pyridin-4-yl)quinazolin-2 ylamino)phenyl)ethylcarbamate (<b>94</b>)</h3><div class="NLM_p last">The title compound was synthesized from (<i>R</i>)-<i>tert</i>-butyl 1-(4-bromophenyl)ethylcarbamate (<b>72</b>) and 7-methoxy-6-(pyridin-4-yl)quinazolin-2-amine (<b>91</b>) using a method analogous to the preparation of <b>3</b>, with Xantphos and palladium(II) acetate followed by purification on an ISCO system (CH<sub>2</sub>Cl<sub>2</sub>:MeOH = 30:1) to afford the title compound (0.41 g, 73%). <sup>1</sup>H NMR: 10.07 (s, 1H), 9.14 (s, 1H), 8.60–8.62 (m, 2H), 7.93 (s, 1H), 7.85–7.88 (m, 2H), 7.56–7.58 (m, 2H), 7.22–7.25 (m, 2H), 7.15 (s, 1H), 4.52–4.61 (m, 1H), 3.96 (s, 3H), 1.35 (s, 9H), 1.29 (d, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_93" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> (<i>R</i>)-<i>tert</i>-Butyl 1-(4-(7-Chloro-6-(pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethylcarbamate (<b>95</b>)</h3><div class="NLM_p last">The title compound was synthesized from 7-chloro-6-(pyridin-4-yl)quinazolin-2-amine (<b>92</b>) using a method analogous to the preparation of <b>3</b>, with Xantphos and heating at 90 °C followed by purification on an ISCO system (CH<sub>2</sub>Cl<sub>2</sub>:MeOH = 30:1) to afford the product (2.73 g, 49%). <sup>1</sup>H NMR: 10.07 (s, 1 H), 9.35 (s, 1H), 8.67–8.76 (m, 2H), 8.05 (s, 1H), 7.82–7.94 (m, 3H), 7.52–7.61 (m, 2H), 7.31–7.38 (m, 1H), 7.23–7.30 (m, 2H), 4.54–4.65 (m, 1H), 1.38 (s, 9H), 1.31 (d, <i>J</i> = 7.1 Hz, 3H). LC–MS: <i>m</i>/<i>z</i> 476.</div></div><div id="sec4_94" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> (<i>R</i>)-<i>tert</i>-Butyl 1-(4-(8-Chloro-6-(pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethylcarbamate (<b>96</b>)</h3><div class="NLM_p last">The title compound was synthesized from 8-chloro-6-(pyridin-4-yl)quinazolin-2-amine (<b>93</b>) using a method analogous to the preparation of <b>95</b> (2.92 g, 51%). <sup>1</sup>H NMR: 10.29 (s, 1H), 9.41 (s, 1H), 8.66–8.72 (m, 2H), 8.46–8.49 (m, 1H), 8.41–8.45 (m, 1H), 8.02–8.12 (m, 2H), 7.84–7.90 (m, 2H), 7.25–7.40 (m, 3H), 4.55–4.67 (m, 1H), 1.37 (s, 9H), 1.32 (d, <i>J</i> = 7.07 Hz, 3H). LC–MS: <i>m</i>/<i>z</i> 476.</div></div><div id="sec4_95" class="NLM_sec NLM_sec_level_2"><div id="ac_i117" class="anchor-spacer"></div><h3 class="article-section__title" id="_i117"> (<i>R</i>)-<i>N</i>-(1-(4-(7-Methoxy-6-(pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethyl)acetamide (<b>97</b>)</h3><div class="NLM_p last">(i) (<i>R</i>)-<i>tert</i>-Butyl 1-(4-(7-methoxy-6-(pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethylcarbamate (<b>94</b>, 0.40 g, 0.8 mmol) was added to HCl/THF (50 mL) and the mixture was allowed to stir at room temperature overnight. The mixture was concentrated, and the solid residue was washed with hexanes to afford (<i>R</i>)-<i>N</i>-(4-(1-aminoethyl)phenyl)-7-methoxy-6-(pyridin-4-yl)quinazolin-2-amine dihydrochloride (0.34 g, 98%, <i>m</i>/<i>z</i> 373), which was carried forward into the next step. (ii) (<i>R</i>)-<i>N</i>-(4-(1-Aminoethyl)phenyl)-7-methoxy-6-(pyridin-4-yl)quinazolin-2-amine dihydrochloride (102 mg, 0.23 mmol) was added to EtOAc (5 mL) and triethylamine (300 μL, 2.2 mmol) followed by acetic anhydride (100 μL, 1.1 mmol). The resulting mixture was allowed to stir at room temperature. After 1 h, MeOH (1 mL) was added to the heterogeneous mixture to improve overall solubility. After stirring at room temperature overnight, the mixture was diluted with H<sub>2</sub>O (10 mL). The biphasic, heterogeneous mixture was suction-filtered, and the filter cake was washed with EtOAc and H<sub>2</sub>O to afford the title compound (40 mg, 42%). <sup>1</sup>H NMR: 9.82 (s, 1H), 9.16 (s, 1H), 8.61–8.68 (m, 2H), 8.21–8.27 (m, 1H), 7.95 (s, 1H), 7.87–7.93 (m, 2H), 7.56–7.62 (m, 2H), 7.23–7.30 (m, 2H), 7.16 (s, 1H), 4.84–4.93 (m, 1H), 3.97 (s, 3H), 1.84 (s, 3H), 1.35 (d, <i>J</i> = 6.8 Hz, 3H). LC–MS: <i>m</i>/<i>z</i> 414.</div></div><div id="sec4_96" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118"> (<i>R</i>)-<i>N</i>-(1-(4-(7-Chloro-6-(pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethyl)acetamide (<b>98</b>)</h3><div class="NLM_p last">The title compound was synthesized from (<i>R</i>)-<i>tert</i>-butyl 1-(4-(7-chloro-6-(pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethylcarbamate (<b>95</b>) using a method similar to that for the preparation of <b>97</b>, except with 4 N HCl/dioxane for BOC group deprotection, followed by treatment with acetic anhydride as described for the preparation of <b>97</b>. <sup>1</sup>H NMR: 10.09 (s, 1H), 9.35 (s, 1H), 8.68–8.74 (m, 2H), 8.21–8.28 (m, 1 H), 8.06 (s, 1H), 7.85–7.94 (m, 3H), 7.55–7.58 (m, 2H), 7.25–7.30 (m, 2H), 4.84–4.94 (m, 1 H), 1.84 (s, 3H), 1.34 (d, <i>J</i> = 7.1 Hz, 3H). LC–MS: <i>m</i>/<i>z</i> 418.</div></div><div id="sec4_97" class="NLM_sec NLM_sec_level_2"><div id="ac_i119" class="anchor-spacer"></div><h3 class="article-section__title" id="_i119"> (<i>R</i>)-<i>N</i>-(1-(4-(8-Chloro-6-(pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethyl)acetamide (<b>99</b>)</h3><div class="NLM_p last">The title compound was synthesized from (<i>R</i>)-<i>tert</i>-butyl 1-(4-(8-chloro-6-(pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethylcarbamate (<b>96</b>) using a method similar to that for the preparation of <b>98</b>. <sup>1</sup>H NMR: 10.29 (s, 1 H), 9.41 (s, 1 H), 8.65–8.73 (m, 2H), 8.45–8.49 (m, 1H), 8.41–8.44 (m, 1H), 8.20–8.26 (m, 1H), 8.03–8.13 (m, 2H), 7.84–7.90 (m, 2H), 7.27–7.33 (m, 2H), 4.85–4.95 (m, 1H), 1.85 (s, 3H), 1.35 (d, <i>J</i> = 6.8 Hz, 3H). LC–MS: <i>m</i>/<i>z</i> 418.</div></div><div id="sec4_98" class="NLM_sec NLM_sec_level_2"><div id="ac_i120" class="anchor-spacer"></div><h3 class="article-section__title" id="_i120"> (<i>R</i>)-<i>N</i>-(1-(4-(7-Methyl-6-(pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethyl)acetamide (<b>100</b>)</h3><div class="NLM_p last">(i) A test tube equipped with a stir bar was charged with (<i>R</i>)-<i>tert</i>-butyl 1-(4-(7-chloro-6-(pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethylcarbamate (<b>95</b>, 238 mg, 0.50 mmol), methylboronic acid (63 mg, 1.05 mmol), Pd(OAc)<sub>2</sub> (4.4 mg, 3.9 mol %), PCy<sub>3</sub>·HBF<sub>4</sub>(19.3 mg, 10.5 mol %), and potassium carbonate (281 mg, 2.03 mmol). The tube was evacuated and back-filled with N<sub>2</sub>, and then dioxane (1.5 mL) and water (0.5 mL) were added. The mixture was allowed to stir at room temperature for a few minutes and was then placed in a 100 °C oil bath. After heating for 12 h, the reaction was allowed to cool, and the mixture was partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc, and the combined organics were concentrated under reduced pressure. The resulting solid residue was used without further purification in the next step. LC–MS: <i>m</i>/<i>z</i> 456. (ii and iii) BOC-deprotection and acylation were accomplished using a method analogous to the preparation of <b>97</b>. <sup>1</sup>H NMR: 9.87 (s, 1H), 9.27 (s, 1H), 8.65–8.71 (m, 2H), 8.21–8.27 (m, 1H), 7.87–7.93 (m, 2H), 7.81 (s, 1H), 7.62 (s, 1H), 7.46–7.53 (m, 2H), 7.23–7.29 (m, 2H), 4.83–4.93 (m, 1H), 2.41 (s, 3H), 1.84 (s, 3H), 1.34 (d, <i>J</i> = 7.1 Hz, 3H). LC–MS: <i>m</i>/<i>z</i> 398.</div></div><div id="sec4_99" class="NLM_sec NLM_sec_level_2"><div id="ac_i121" class="anchor-spacer"></div><h3 class="article-section__title" id="_i121"> (<i>R</i>)-<i>N</i>-(1-(4-(8-Methyl-6-(pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethyl)acetamide (<b>101</b>)</h3><div class="NLM_p last">The title compound was synthesized from (<i>R</i>)-<i>tert</i>-butyl 1-(4-(8-chloro-6-(pyridin-4-yl)quinazolin-2-ylamino)phenyl)ethylcarbamate (<b>96</b>) using a method analogous to the preparation of <b>100</b>. <sup>1</sup>H NMR: 10.01 (s, 1H), 9.34 (s, 1H), 8.64–8.71 (m, 2H), 8.19–8.29 (m, 2H), 8.17 (s, 1H), 7.96–8.04 (m, 2H), 7.79–7.86 (m, 2H), 7.24–7.33 (m, 2H), 4.85–4.95 (m, 1H), 2.69 (s, 3H), 1.84 (s, 3H), 1.35 (d, <i>J</i> = 7.1 Hz, 3H). LC–MS: <i>m</i>/<i>z</i> 398.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i122"><a href="/doi/suppl/10.1021/jm301658d">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81677" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81677" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Tables SI1–SI4, Figure SI1, protein expression, purification, crystallization, and structure determination for <b>3</b> and <b>48</b>, biological and DMPK assay details, pharmacodynamic protocol, and A375 mouse xenograft assay protocol details. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm301658d/suppl_file/jm301658d_si_001.pdf">jm301658d_si_001.pdf (571.51 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm301658d" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68484" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68484" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melissa M. Vasbinder</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#96fbf3faffe5e5f7b8e0f7e5f4fff8f2f3e4d6f7e5e2e4f7ecf3f8f3f5f7b8f5f9fb"><span class="__cf_email__" data-cfemail="7a171f161309091b540c1b091813141e1f083a1b090e081b001f141f191b54191517">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian Aquila</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Augustin</span> - <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huawei Chen</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tony Cheung</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donald Cook</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisa Drew</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Benjamin P. Fauber</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve Glossop</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Grondine</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Edward Hennessy</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey Johannes</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen Lee</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Lyne</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mario Mörtl</span> - <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charles Omer</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sangeetha Palakurthi</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy Pontz</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jon Read</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Sha</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Minhui Shen</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan Steinbacher</span> - <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haixia Wang</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Allan Wu</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Minwei Ye</span> - <span class="hlFld-Affiliation affiliation">†Oncology
iMED and ‡Discovery Sciences, AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451,
United States</span>; 
    <span class="hlFld-Affiliation affiliation">§Discovery
Sciences and ∥Oncology iMED, AstraZeneca R&D Alderley
Park, Cheshire, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Proteros Biostructures
GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried,
Germany</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d281e5854-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i126">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37420" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37420" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to thank Mukta Bagul, Robert Godin, Geraldine Hamilton, Erika Keeton, and Mali Wald for their early contributions to this work and to Claudio Chuaqui, Corinne Reimer, and David Scott for useful discussions and assistance during the preparation of the manuscript.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i127" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i127"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i128" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i128"> Abbreviations Used</h2><tr><td class="NLM_term">BINAP</td><td class="NLM_def"><p class="first last">2,2′-bis(diphenylphosphino)-1,1′-binaphthyl</p></td></tr><tr><td class="NLM_term">CL<sub>int</sub></td><td class="NLM_def"><p class="first last">in vitro intrinsic clearance</p></td></tr><tr><td class="NLM_term">CL<sub>obs</sub></td><td class="NLM_def"><p class="first last">measured in vivo clearance</p></td></tr><tr><td class="NLM_term">DFG</td><td class="NLM_def"><p class="first last">sequence of the three amino acids aspartic acid-phenylalanine-glycine</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DME</td><td class="NLM_def"><p class="first last">ethylene glycol dimethyl ether</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">Fu</td><td class="NLM_def"><p class="first last">fraction unbound</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">(Dimethylamino)-<i>N</i>,<i>N</i>-dimethyl(3<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyridin-3-yloxy)methaniminium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">Hep</td><td class="NLM_def"><p class="first last">hepatocytes</p></td></tr><tr><td class="NLM_term">HOAc</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">HPMC</td><td class="NLM_def"><p class="first last">hydroxypropyl methylcellulose</p></td></tr><tr><td class="NLM_term">Hu</td><td class="NLM_def"><p class="first last">human</p></td></tr><tr><td class="NLM_term">LC–MS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">Mic</td><td class="NLM_def"><p class="first last">microsomes</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">molecular sieves</p></td></tr><tr><td class="NLM_term">MPLC</td><td class="NLM_def"><p class="first last">medium-pressure liquid chromatography</p></td></tr><tr><td class="NLM_term">mut</td><td class="NLM_def"><p class="first last">mutant</p></td></tr><tr><td class="NLM_term">Pd<sub>2</sub>(dba)<sub>3</sub></td><td class="NLM_def"><p class="first last">tris(dibenzylideneacetone)dipalladium</p></td></tr><tr><td class="NLM_term">Pd(OAc)<sub>2</sub></td><td class="NLM_def"><p class="first last">palladium(II) acetate</p></td></tr><tr><td class="NLM_term">PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub></td><td class="NLM_def"><p class="first last">1,1′-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex</p></td></tr><tr><td class="NLM_term">PCy<sub>3</sub>·HBF<sub>4</sub></td><td class="NLM_def"><p class="first last">tricyclopentyl phosphine tetrafluoroborate</p></td></tr><tr><td class="NLM_term">satd</td><td class="NLM_def"><p class="first last">saturated</p></td></tr><tr><td class="NLM_term">TBDMS</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyldimethylsiloxy</p></td></tr><tr><td class="NLM_term">TEG</td><td class="NLM_def"><p class="first last">triethylene glycol</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>dss</sub></td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr><tr><td class="NLM_term">Xantphos</td><td class="NLM_def"><p class="first last">4,5-bis(diphenylphosphino)-9,9-dimethylxanthene.</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i129">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25606" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25606" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 31 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Peyssonnaux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eychene, A.</span><span> </span><span class="NLM_article-title">The Raf/MEK/ERK pathway: New concepts of activation</span> <span class="citation_source-journal">Biol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1016%2FS0248-4900%2801%2901125-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=11730323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptVOju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2001&pages=53-62&author=C.+Peyssonnauxauthor=A.+Eychene&title=The+Raf%2FMEK%2FERK+pathway%3A+New+concepts+of+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Raf/MEK/ERK pathway: New concepts of activation</span></div><div class="casAuthors">Peyssonnaux, Carole; Eychene, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Biology of the Cell</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">53-62</span>CODEN:
                <span class="NLM_cas:coden">BCELDF</span>;
        ISSN:<span class="NLM_cas:issn">0248-4900</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review.  The Raf/MEK/ERK signaling was the first MAP kinase cascade to be characterized.  It is probably one of the most well known signal transduction pathways among biologists because of its implication in a wide variety of cellular functions as diverse -and occasionally contradictory- as cell proliferation, cell-cycle arrest, terminal differentiation and apoptosis.  Discovery and understanding of this pathway have benefited from the combination of both genetic studies in worms and flies and biochem. studies in mammalian cells.  However, ten years after, this field is still under debate and new mol. partners in the cascade continue to increase the complexity of its regulation.  This review deals with the emergence of new concepts in the activation and regulation of the Raf/MEK/ERK module.  In particular, the preponderant role of B-Raf is underlined, and the role of novel regulators such as KSR is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyjiXSFlBQ6rVg90H21EOLACvtfcHk0lhXlPPRpnXUJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptVOju7s%253D&md5=cde3db5b205a1305dc2e6262deea65ec</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0248-4900%2801%2901125-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0248-4900%252801%252901125-X%26sid%3Dliteratum%253Aachs%26aulast%3DPeyssonnaux%26aufirst%3DC.%26aulast%3DEychene%26aufirst%3DA.%26atitle%3DThe%2520Raf%252FMEK%252FERK%2520pathway%253A%2520New%2520concepts%2520of%2520activation%26jtitle%3DBiol.%2520Cell%26date%3D2001%26volume%3D93%26spage%3D53%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Wellbrook, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karasarides, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">The RAF proteins take centre stage</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">–</span> <span class="NLM_lpage">885</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1038%2Fnrm1498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=15520807" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=875-885&author=C.+Wellbrookauthor=M.+Karasaridesauthor=R.+Marais&title=The+RAF+proteins+take+centre+stage"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrm1498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1498%26sid%3Dliteratum%253Aachs%26aulast%3DWellbrook%26aufirst%3DC.%26aulast%3DKarasarides%26aufirst%3DM.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DThe%2520RAF%2520proteins%2520take%2520centre%2520stage%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2004%26volume%3D5%26spage%3D875%26epage%3D885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Davies, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bignell, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clegg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teague, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woffendin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottomley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dicks, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmidou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzies, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mould, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayatilake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gusterson, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargrave, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard-Jones, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maitland, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenevix-Trench, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggins, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigner, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cossu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J. W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seigler, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darrow, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futreal, P. A.</span><span> </span><span class="NLM_article-title">Mutations of the BRAF gene in human cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">417</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">954</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1038%2Fnature00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=12068308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=949-954&author=H.+Daviesauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S.+Edkinsauthor=S.+Cleggauthor=J.+Teagueauthor=H.+Woffendinauthor=M.+J.+Garnettauthor=W.+Bottomleyauthor=N.+Davisauthor=E.+Dicksauthor=R.+Ewingauthor=Y.+Floydauthor=K.+Grayauthor=S.+Hallauthor=R.+Hawesauthor=J.+Hughesauthor=V.+Kosmidouauthor=A.+Menziesauthor=C.+Mouldauthor=A.+Parkerauthor=C.+Stevensauthor=S.+Wattauthor=S.+Hooperauthor=R.+Wilsonauthor=H.+Jayatilakeauthor=B.+A.+Gustersonauthor=C.+Cooperauthor=J.+Shipleyauthor=D.+Hargraveauthor=K.+Pritchard-Jonesauthor=N.+Maitlandauthor=G.+Chenevix-Trenchauthor=G.+J.+Rigginsauthor=D.+D.+Bignerauthor=G.+Palmieriauthor=A.+Cossuauthor=A.+Flanaganauthor=A.+Nicholsonauthor=J.+W.+C.+Hoauthor=S.+Y.+Leungauthor=S.+T.+Yuenauthor=B.+L.+Weberauthor=H.+F.+Seiglerauthor=T.+L.+Darrowauthor=H.+Patersonauthor=R.+Maraisauthor=C.+J.+Marshallauthor=R.+Woosterauthor=M.+R.+Strattonauthor=P.+A.+Futreal&title=Mutations+of+the+BRAF+gene+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the BRAF gene in human cancer</span></div><div class="casAuthors">Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian; Hall, Sarah; Hawes, Rachel; Hughes, Jaime; Kosmidou, Vivian; Menzies, Andrew; Mould, Catherine; Parker, Adrian; Stevens, Claire; Watt, Stephen; Hooper, Steven; Wilson, Rebecca; Jayatilake, Hiran; Gusterson, Barry A.; Cooper, Colin; Shipley, Janet; Hargrave, Darren; Pritchard-Jones, Katherine; Maitland, Norman; Chenevix-Trench, Georgia; Riggins, Gregory J.; Bigner, Darell D.; Palmieri, Giuseppe; Cossu, Antonio; Flanagan, Adrienne; Nicholson, Andrew; Ho, Judy W. C.; Leung, Suet Y.; Yuen, Siu T.; Weber, Barbara L.; Seigler, Hilliard F.; Darrow, Timothy L.; Paterson, Hugh; Marais, Richard; Marshall, Christopher J.; Wooster, Richard; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6892</span>),
    <span class="NLM_cas:pages">949-954</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancers arise owing to the accumulation of mutations in crit. genes that alter normal programs of cell proliferation, differentiation and death.  As the first stage of a systematic genome-wide screen for these genes, we have prioritized for anal. signalling pathways in which at least one gene is mutated in human cancer.  The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular responses to growth signals.  RAS is mutated to an oncogenic form in about 15% of human cancer.  The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS.  Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers.  All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%.  Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.  Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.  As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBmhJC0GAjrVg90H21EOLACvtfcHk0lhXlPPRpnXUJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D&md5=4625be53ad9a382d51b6ee753d0c17e8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnature00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature00766%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DClegg%26aufirst%3DS.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWoffendin%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DBottomley%26aufirst%3DW.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DDicks%26aufirst%3DE.%26aulast%3DEwing%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DHawes%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DKosmidou%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DA.%26aulast%3DMould%26aufirst%3DC.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DJayatilake%26aufirst%3DH.%26aulast%3DGusterson%26aufirst%3DB.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DPritchard-Jones%26aufirst%3DK.%26aulast%3DMaitland%26aufirst%3DN.%26aulast%3DChenevix-Trench%26aufirst%3DG.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DJ.%2BW.%2BC.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSeigler%26aufirst%3DH.%2BF.%26aulast%3DDarrow%26aufirst%3DT.%2BL.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520of%2520the%2520BRAF%2520gene%2520in%2520human%2520cancer%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D949%26epage%3D954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spevak, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shellooe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span> </span><span class="NLM_article-title">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">467</span><span class="NLM_x">, </span> <span class="NLM_fpage">596</span><span class="NLM_x">–</span> <span class="NLM_lpage">599</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1038%2Fnature09454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=20823850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=596-599&author=G.+Bollagauthor=P.+Hirthauthor=J.+Tsaiauthor=J.+Zhangauthor=P.+N.+Ibrahimauthor=H.+Choauthor=W.+Spevakauthor=C.+Zhangauthor=Y.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=G.+Tsangauthor=B.+L.+Westauthor=B.+Powellauthor=R.+Shellooeauthor=A.+Marimuthuauthor=H.+Nguyenauthor=K.+Y.+J.+Zhangauthor=D.+R.+Artisauthor=J.+Schlessingerauthor=F.+Suauthor=B.+Higginsauthor=R.+Iyerauthor=K.+D%E2%80%99Andreaauthor=A.+Koehlerauthor=M.+Stummauthor=P.+S.+Linauthor=R.+J.+Leeauthor=J.+Grippoauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+B.+Chapmanauthor=K.+T.+Flahertyauthor=X.+Xuauthor=K.+L.+Nathansonauthor=K.+Nolop&title=Clinical+efficacy+of+a+RAF+inhibitor+needs+broad+target+blockade+in+BRAF-mutant+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span></div><div class="casAuthors">Bollag, Gideon; Hirth, Peter; Tsai, James; Zhang, Jiazhong; Ibrahim, Prabha N.; Cho, Hanna; Spevak, Wayne; Zhang, Chao; Zhang, Ying; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Tsang, Garson; West, Brian L.; Powell, Ben; Shellooe, Rafe; Marimuthu, Adhirai; Nguyen, Hoa; Zhang, Kam Y. J.; Artis, Dean R.; Schlessinger, Joseph; Su, Fei; Higgins, Brian; Iyer, Raman; D'Andrea, Kurt; Koehler, Astrid; Stumm, Michael; Lin, Paul S.; Lee, Richard J.; Grippo, Joseph; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; Chapman, Paul B.; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.; Nolop, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">596-599</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B-RAF is the most frequently mutated protein kinase in human cancers.  The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway, offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients.  Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity.  Preclin. expts. demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts.  Toxicol. studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clin. trials using a cryst. formulation of PLX4032 (ref. 5).  In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following 2 wk of treatment.  This anal. revealed substantial inhibition of ERK phosphorylation, yet clin. evaluation did not show tumor regressions.  At higher drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK phosphorylation in the tumors of patients correlated with clin. response.  Indeed, the Phase 1 clin. data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily.  These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYwlns1EfcLVg90H21EOLACvtfcHk0liVAYlme8x3dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK&md5=8a26d0ab41970f39a109ddafff2f17b4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnature09454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09454%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DKoehler%26aufirst%3DA.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DNolop%26aufirst%3DK.%26atitle%3DClinical%2520efficacy%2520of%2520a%2520RAF%2520inhibitor%2520needs%2520broad%2520target%2520blockade%2520in%2520BRAF-mutant%2520melanoma%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D596%26epage%3D599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span> </span><span class="NLM_article-title">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2507</span><span class="NLM_x">–</span> <span class="NLM_lpage">2516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2010&pages=2507-2516&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthur&title=Improved+survival+with+vemurafenib+in+melanoma+with+BRAF+V600E+mutation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DImproved%2520survival%2520with%2520vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D364%26spage%3D2507%26epage%3D2516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Inhibition of mutated, activated BRAF in metastatic melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">819</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1056%2FNEJMoa1002011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=20818844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=809-819&author=K.+T.+Flahertyauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+B.+Chapman&title=Inhibition+of+mutated%2C+activated+BRAF+in+metastatic+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutated, activated BRAF in metastatic melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.  Methods: We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the max. dose that could be administered without adverse effects (the recommended phase 2 dose).  Patients received PLX4032 twice daily until they had disease progression.  Pharmacokinetic anal. and tumor-response assessments were conducted in all patients.  In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.  Results: A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 addnl. patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.  The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia.  In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.  Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response.  The estd. median progression-free survival among all patients was more than 7 mo.  Conclusions: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwq1fkvEjfyLVg90H21EOLACvtfcHk0liVAYlme8x3dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M&md5=80f70df0ac490828a42e6c7c0b40067f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002011%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DInhibition%2520of%2520mutated%252C%2520activated%2520BRAF%2520in%2520metastatic%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D809%26epage%3D819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Flaherty, K.; Puzanov, I.; Sosman, J.; Kim, K.; Ribas, A.; McArthur, G.; Lee, R. J.; Grippo, J. F.; Nolop, K.; Chapman, P.</span><span> </span><span class="NLM_article-title">Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span> (15S (May 20 Supplement)),  <span class="NLM_fpage">9000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=9000&author=K.+Flaherty&author=I.+Puzanov&author=J.+Sosman&author=K.+Kim&author=A.+Ribas&author=G.+McArthur&author=R.+J.+Lee&author=J.+F.+Grippo&author=K.+Nolop&author=P.+Chapman&title=Phase+I+study+of+PLX4032%3A+Proof+of+concept+for+V600E+BRAF+mutation+as+a+therapeutic+target+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%26atitle%3DPhase%2520I%2520study%2520of%2520PLX4032%253A%2520Proof%2520of%2520concept%2520for%2520V600E%2520BRAF%2520mutation%2520as%2520a%2520therapeutic%2520target%2520in%2520human%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D9000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="note"><p class="first last">For description of dabrafenib (GSK2118436, GlaxoSmithKline), a selective B-Raf inhibitor in advanced clinical studies, see:</p></div><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rheault, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stellwagen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjabeng, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornberger, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquerre, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossanese, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnone, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitherman, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane-Carson, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorthy, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, K. G</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehling, D. E.</span><span> </span><span class="NLM_article-title">Discovery of dabrafenib: a selective inhibitor of Raf kinases with antitumor activity against B-Raf-driven tumors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1021/ml4000063</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4000063" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=T.+R.+Rheaultauthor=J.+C.+Stellwagenauthor=G.+M.+Adjabengauthor=K.+R.+Hornbergerauthor=K.+G.+Petrovauthor=A.+G.+Watersonauthor=S.+H.+Dickersonauthor=R.+A.+Mookauthor=S.+G.+Laquerreauthor=A.+J.+Kingauthor=O.+W.+Rossaneseauthor=M.+R.+Arnoneauthor=K.+N.+Smithermanauthor=L.+S.+Kane-Carsonauthor=C.+Hanauthor=G.+S.+Moorthyauthor=K.+G+Mossauthor=D.+E.+Uehling&title=Discovery+of+dabrafenib%3A+a+selective+inhibitor+of+Raf+kinases+with+antitumor+activity+against+B-Raf-driven+tumors&doi=10.1021%2Fml4000063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1021%2Fml4000063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4000063%26sid%3Dliteratum%253Aachs%26aulast%3DRheault%26aufirst%3DT.%2BR.%26aulast%3DStellwagen%26aufirst%3DJ.%2BC.%26aulast%3DAdjabeng%26aufirst%3DG.%2BM.%26aulast%3DHornberger%26aufirst%3DK.%2BR.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DLaquerre%26aufirst%3DS.%2BG.%26aulast%3DKing%26aufirst%3DA.%2BJ.%26aulast%3DRossanese%26aufirst%3DO.%2BW.%26aulast%3DArnone%26aufirst%3DM.%2BR.%26aulast%3DSmitherman%26aufirst%3DK.%2BN.%26aulast%3DKane-Carson%26aufirst%3DL.%2BS.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DMoorthy%26aufirst%3DG.%2BS.%26aulast%3DMoss%26aufirst%3DK.%2BG%26aulast%3DUehling%26aufirst%3DD.%2BE.%26atitle%3DDiscovery%2520of%2520dabrafenib%253A%2520a%2520selective%2520inhibitor%2520of%2520Raf%2520kinases%2520with%2520antitumor%2520activity%2520against%2520B-Raf-driven%2520tumors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26doi%3D10.1021%2Fml4000063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kefford, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arkenau, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millward, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebowitz, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falchook, G. S.</span><span> </span><span class="NLM_article-title">Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x"> (</span><span class="NLM_issue">15 Suppl (May 20 Supplement)</span><span class="NLM_x">) </span> <span class="NLM_fpage">8503</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=8503&issue=15+Suppl+%28May+20+Supplement%29&author=R.+Keffordauthor=H.+T.+Arkenauauthor=M.+P.+Brownauthor=M.+Millwardauthor=J.+R.+Infanteauthor=G.+V.+Longauthor=D.+Ouelletauthor=M.+Curtisauthor=P.+F.+Lebowitzauthor=G.+S.+Falchook&title=Phase+I%2FII+study+of+GSK2118436%2C+a+selective+inhibitor+of+oncogenic+mutant+BRAF+kinase%2C+in+patients+with+metastatic+melanoma+and+other+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKefford%26aufirst%3DR.%26aulast%3DArkenau%26aufirst%3DH.%2BT.%26aulast%3DBrown%26aufirst%3DM.%2BP.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DCurtis%26aufirst%3DM.%26aulast%3DLebowitz%26aufirst%3DP.%2BF.%26aulast%3DFalchook%26aufirst%3DG.%2BS.%26atitle%3DPhase%2520I%252FII%2520study%2520of%2520GSK2118436%252C%2520a%2520selective%2520inhibitor%2520of%2520oncogenic%2520mutant%2520BRAF%2520kinase%252C%2520in%2520patients%2520with%2520metastatic%2520melanoma%2520and%2520other%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26issue%3D15%2520Suppl%2520%2528May%252020%2520Supplement%2529%26spage%3D8503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="note"><p class="first last">Recent reviews of B-Raf inhibitors and B-Raf targeted therapy:</p></div><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zambon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span> </span><span class="NLM_article-title">Small molecule inhibitors of BRAF in clinical trials</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">789</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=789-792&author=A.+Zambonauthor=I.+Niculescu-Duvazauthor=D.+Niculescu-Duvazauthor=R.+Maraisauthor=C.+J.+Springer&title=Small+molecule+inhibitors+of+BRAF+in+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DNiculescu-Duvaz%26aufirst%3DI.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520BRAF%2520in%2520clinical%2520trials%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D789%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kim, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span> </span><span class="NLM_article-title">Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics</span> <span class="citation_source-journal">Arch. Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">605</span><span class="NLM_x">–</span> <span class="NLM_lpage">615</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1007%2Fs12272-012-0403-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=22553052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVGrs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=605-615&author=D.+H.+Kimauthor=T.+Sim&title=Novel+small+molecule+Raf+kinase+inhibitors+for+targeted+cancer+therapeutics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics</span></div><div class="casAuthors">Kim, Do-Hee; Sim, Taebo</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Pharmacal Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">605-615</span>CODEN:
                <span class="NLM_cas:coden">APHRDQ</span>;
        ISSN:<span class="NLM_cas:issn">0253-6269</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Korea</span>)
        </div><div class="casAbstract">A review.  Aberrant activation of Raf signaling pathway is frequently found in various human tumors, it was considered as distinct and promising mol. target for cancer therapeutics.  B-Raf is most attractive drug target out of 3 Raf isoforms (A-Raf, B-Raf, and C-Raf) because it exhibits high kinase activity due to frequent mutations in human tumors.  However, most recently, it was reported that Raf isoforms show the cross-activation in the presence of specific B-Raf inhibitors, which brings about the paradoxical p-ERK activation as well as tumor promoting effect.  According to these findings, it remains controversy whether pan-Raf kinase inhibitor is more valuable and promising rather than specific B-Raf inhibitor under certain conditions in terms of cancer therapeutics.  In this short review, novel Raf kinase inhibitors undergoing clin. investigation are introduced.  Moreover, the paradoxical p-ERK activation is discussed with specific B-Raf inhibitors, PLX4032/4720 compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobCYC4QV-h9rVg90H21EOLACvtfcHk0ljSrzlviRnMPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVGrs7c%253D&md5=ee868003285c1e9f51388145ba1111a3</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1007%2Fs12272-012-0403-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12272-012-0403-5%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DSim%26aufirst%3DT.%26atitle%3DNovel%2520small%2520molecule%2520Raf%2520kinase%2520inhibitors%2520for%2520targeted%2520cancer%2520therapeutics%26jtitle%3DArch.%2520Pharm.%2520Res.%26date%3D2012%26volume%3D35%26spage%3D605%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Nimmagadda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tawbi, H.</span><span> </span><span class="NLM_article-title">RAF kinase inhibitors for the treatment of melanoma</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslyku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=63-68&author=N.+Nimmagaddaauthor=H.+Tawbi&title=RAF+kinase+inhibitors+for+the+treatment+of+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">RAF kinase inhibitors for the treatment of melanoma</span></div><div class="casAuthors">Nimmagadda, N.; Tawbi, H.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-68</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Malignant melanoma is one of the most lethal solid tumors unless detected early.  Malignant melanoma accounts for about 75% of skin cancer-related deaths.  Around 68,700 cases of new melanoma were diagnosed in 2009 in the U.S.  According to a World Health Organization report, about 48,000 melanoma-related deaths occur worldwide per yr.  In its early stages, melanoma can be treated surgically, leading to 5-yr survival rates exceeding 90%.  However, when it becomes metastatic, it is uniformly fatal, with 5-yr survival rates of < 2% and a median survival of 6-10 mo.  Recent advances in the understanding of the mol. heterogeneity offer the promise of a better future for drug development in melanoma.  The MAP kinase pathway is known to be assocd. with several human cancers, including malignant melanoma.  The MAP kinase pathway is activated through mutations in BRAF, and BRAF V600E is the most common among these mutations.  Targeted therapy involving B-raf inhibition was thought to yield promising results.  This review provides information on various B-raf inhibitors and the clin. impact these drugs may have in patients with melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI-2F-i7SC3rVg90H21EOLACvtfcHk0ljSrzlviRnMPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslyku7g%253D&md5=03c390bcc60ed43863a53728bf7dd8bf</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNimmagadda%26aufirst%3DN.%26aulast%3DTawbi%26aufirst%3DH.%26atitle%3DRAF%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520melanoma%26jtitle%3DDrugs%2520Future%26date%3D2011%26volume%3D36%26spage%3D63%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span> </span><span class="NLM_article-title">BRAF targeted therapy changes the treatment paradigm in melanoma</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">426</span><span class="NLM_x">–</span> <span class="NLM_lpage">433</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1038%2Fnrclinonc.2011.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=21606968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotleltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=426-433&author=A.+Ribasauthor=K.+T.+Flaherty&title=BRAF+targeted+therapy+changes+the+treatment+paradigm+in+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9dR"><div class="casContent"><span class="casTitleNuber">9d</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF targeted therapy changes the treatment paradigm in melanoma</span></div><div class="casAuthors">Ribas, Antoni; Flaherty, Keith T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">426-433</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Therapeutic advances in melanoma seem on the horizon, with the identification of BRAF as a principal therapeutic target.  The authors describe the scientific basis for the targeting of BRAF mutations in cancer, the early clin. data with BRAF inhibitors, and how combinatorial therapies may address the current limitations of their use in the clinic.  After decades of stagnation, recent therapeutic advances in melanoma seem on the horizon.  The discovery of the genetic underpinnings of this historically refractory disease has exposed potential targets for therapy, BRAF mutations being principal among them.  In the 8 years following the discovery of BRAF mutations in 50-60% of advanced melanomas, only recently have potent and selective inhibitors of this intracellular signaling mol. shown efficacy from early clin. testing.  Vemurafenib (PLX4032) and GSK2118436, two orally available and well tolerated agents are on the verge of transforming the landscape of melanoma therapy based on the promising results of their resp. phase I, II, and III trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnJ5nnopldxbVg90H21EOLACvtfcHk0ljSrzlviRnMPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotleltrw%253D&md5=710ef1d3ccb02a0c80bf7f9b3fe935a7</span></div><a href="/servlet/linkout?suffix=cit9d&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2011.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2011.69%26sid%3Dliteratum%253Aachs%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DBRAF%2520targeted%2520therapy%2520changes%2520the%2520treatment%2520paradigm%2520in%2520melanoma%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D8%26spage%3D426%26epage%3D433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="note"><p class="first last">For a selection of representative recent examples of B-Raf inhibitors, see the following and references therein:</p></div><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ren, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahrendt, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newhouse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenglowsky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinkel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hastings, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rana, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasor, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturgis, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voegtli, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span> </span><span class="NLM_article-title">The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-Raf<sup>V600E</sup> kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3387</span><span class="NLM_x">–</span> <span class="NLM_lpage">3391</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3387-3391&author=L.+Renauthor=K.+A.+Ahrendtauthor=J.+Grinaauthor=E.+R.+Lairdauthor=A.+J.+Buckmelterauthor=J.+D.+Hansenauthor=B.+Newhouseauthor=D.+Morenoauthor=S.+Wenglowskyauthor=V.+Dinkelauthor=S.+L.+Gloorauthor=G.+Hastingsauthor=S.+Ranaauthor=K.+Rasorauthor=T.+Risomauthor=H.+L.+Sturgisauthor=W.+C.+Voegtliauthor=S.+Mathieu&title=The+discovery+of+potent+and+selective+pyridopyrimidin-7-one+based+inhibitors+of+B-RafV600E+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DL.%26aulast%3DAhrendt%26aufirst%3DK.%2BA.%26aulast%3DGrina%26aufirst%3DJ.%26aulast%3DLaird%26aufirst%3DE.%2BR.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DHansen%26aufirst%3DJ.%2BD.%26aulast%3DNewhouse%26aufirst%3DB.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DDinkel%26aufirst%3DV.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DHastings%26aufirst%3DG.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DRasor%26aufirst%3DK.%26aulast%3DRisom%26aufirst%3DT.%26aulast%3DSturgis%26aufirst%3DH.%2BL.%26aulast%3DVoegtli%26aufirst%3DW.%2BC.%26aulast%3DMathieu%26aufirst%3DS.%26atitle%3DThe%2520discovery%2520of%2520potent%2520and%2520selective%2520pyridopyrimidin-7-one%2520based%2520inhibitors%2520of%2520B-RafV600E%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3387%26epage%3D3391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ren, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinkel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newhouse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasor, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hastings, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradl, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, J.</span><span> </span><span class="NLM_article-title">Potent and selective pyrazolo[1,5-<i>a</i>]pyrimidine based inhibitors of B-Raf<sup>V600E</sup> kinase with favorable physicochemical and pharmacokinetic properties</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1165</span><span class="NLM_x">–</span> <span class="NLM_lpage">1168</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1165-1168&author=L.+Renauthor=E.+R.+Lairdauthor=A.+J.+Buckmelterauthor=V.+Dinkelauthor=S.+L.+Gloorauthor=J.+Grinaauthor=B.+Newhouseauthor=K.+Rasorauthor=G.+Hastingsauthor=S.+N.+Gradlauthor=J.+Rudolph&title=Potent+and+selective+pyrazolo%5B1%2C5-a%5Dpyrimidine+based+inhibitors+of+B-RafV600E+kinase+with+favorable+physicochemical+and+pharmacokinetic+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DL.%26aulast%3DLaird%26aufirst%3DE.%2BR.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DDinkel%26aufirst%3DV.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DGrina%26aufirst%3DJ.%26aulast%3DNewhouse%26aufirst%3DB.%26aulast%3DRasor%26aufirst%3DK.%26aulast%3DHastings%26aufirst%3DG.%26aulast%3DGradl%26aufirst%3DS.%2BN.%26aulast%3DRudolph%26aufirst%3DJ.%26atitle%3DPotent%2520and%2520selective%2520pyrazolo%255B1%252C5-a%255Dpyrimidine%2520based%2520inhibitors%2520of%2520B-RafV600E%2520kinase%2520with%2520favorable%2520physicochemical%2520and%2520pharmacokinetic%2520properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D1165%26epage%3D1168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradl, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner-Toste, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alicke, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinkel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hastings, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatzivassiliou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ran, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voegtli, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenglowsky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, J.</span><span> </span><span class="NLM_article-title">Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2869</span><span class="NLM_x">–</span> <span class="NLM_lpage">2881</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300016v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BC38XitlGjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2869-2881&author=S.+Mathieuauthor=S.+N.+Gradlauthor=L.+Renauthor=Z.+Wenauthor=I.+Aliagasauthor=J.+Gunzner-Tosteauthor=W.+Leeauthor=R.+Pulkauthor=G.+Zhaoauthor=B.+Alickeauthor=J.+W.+Boggsauthor=A.+J.+Buckmelterauthor=E.+F.+Chooauthor=V.+Dinkelauthor=S.+L.+Gloorauthor=S.+E.+Gouldauthor=J.+D.+Hansenauthor=G.+Hastingsauthor=G.+Hatzivassiliouauthor=E.+R.+Lairdauthor=D.+Morenoauthor=Y.+Ranauthor=W.+C.+Voegtliauthor=S.+Wenglowskyauthor=J.+Grinaauthor=J.+Rudolph&title=Potent+and+selective+aminopyrimidine-based+B-Raf+inhibitors+with+favorable+physicochemical+and+pharmacokinetic+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and Selective Aminopyrimidine-Based B-Raf Inhibitors with Favorable Physicochemical and Pharmacokinetic Properties</span></div><div class="casAuthors">Mathieu, Simon; Gradl, Stefan N.; Ren, Li; Wen, Zhaoyang; Aliagas, Ignacio; Gunzner-Toste, Janet; Lee, Wendy; Pulk, Rebecca; Zhao, Guiling; Alicke, Bruno; Boggs, Jason W.; Buckmelter, Alex J.; Choo, Edna F.; Dinkel, Victoria; Gloor, Susan L.; Gould, Stephen E.; Hansen, Joshua D.; Hastings, Gregg; Hatzivassiliou, Georgia; Laird, Ellen R.; Moreno, David; Ran, Yingqing; Voegtli, Walter C.; Wenglowsky, Steve; Grina, Jonas; Rudolph, Joachim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2869-2881</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent clin. data provided proof-of-concept for selective B-Raf inhibitors in treatment of B-RafV600E mutant melanoma.  Pyrazolopyridine-type B-Raf inhibitors previously described by the authors are potent and selective but exhibit low soly. requiring the use of amorphous dispersion-based formulation for achieving efficacious drug exposures.  Through structure-based design, a new class of highly potent aminopyrimidine-based B-Raf inhibitors was discovered with improved soly. and pharmacokinetic profiles.  The hinge binding moiety possesses a basic center imparting high soly. at gastric pH, addressing the dissoln. limitation obsd. with the previous series.  In our search for an optimal linker-hinge binding moiety system, amide-linked thieno[3,2-d]pyrimidine analogs I and II (G945), mols. with desirable physicochem. properties, emerged as lead compds. with strong efficacy in a B-RafV600E mutant mouse xenograft model.  Synthesis, SAR, lead selection, and evaluation of key compds. in animal studies will be described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos8je6g5RG6LVg90H21EOLACvtfcHk0lhCiw1irYRWxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitlGjtbw%253D&md5=53373bfc102c5dfa271c4f429d11139a</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1021%2Fjm300016v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300016v%26sid%3Dliteratum%253Aachs%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DGradl%26aufirst%3DS.%2BN.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DWen%26aufirst%3DZ.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DAlicke%26aufirst%3DB.%26aulast%3DBoggs%26aufirst%3DJ.%2BW.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DChoo%26aufirst%3DE.%2BF.%26aulast%3DDinkel%26aufirst%3DV.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DGould%26aufirst%3DS.%2BE.%26aulast%3DHansen%26aufirst%3DJ.%2BD.%26aulast%3DHastings%26aufirst%3DG.%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DLaird%26aufirst%3DE.%2BR.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DVoegtli%26aufirst%3DW.%2BC.%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DGrina%26aufirst%3DJ.%26aulast%3DRudolph%26aufirst%3DJ.%26atitle%3DPotent%2520and%2520selective%2520aminopyrimidine-based%2520B-Raf%2520inhibitors%2520with%2520favorable%2520physicochemical%2520and%2520pharmacokinetic%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2869%26epage%3D2881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Packard, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggs, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tehrani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shevlin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrin-Ninkovic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilgraf, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarrick, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leisten, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moghaddam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cathers, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakata, S.</span><span> </span><span class="NLM_article-title">Discovery and optimization of thieno[2,3-<i>d</i>]pyrimidines as B-Raf inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">747</span><span class="NLM_x">–</span> <span class="NLM_lpage">752</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=747-752&author=G.+K.+Packardauthor=P.+Papaauthor=J.+R.+Riggsauthor=P.+Erdmanauthor=L.+Tehraniauthor=D.+Robinsonauthor=R.+Harrisauthor=G.+Shevlinauthor=S.+Perrin-Ninkovicauthor=R.+Hilgrafauthor=M.+A.+McCarrickauthor=T.+Tranauthor=Y.+Flemingauthor=A.+Baiauthor=S.+Richardsonauthor=J.+Katzauthor=Y.+Tangauthor=J.+Leistenauthor=M.+Moghaddamauthor=B.+Cathersauthor=D.+Zhuauthor=S.+Sakata&title=Discovery+and+optimization+of+thieno%5B2%2C3-d%5Dpyrimidines+as+B-Raf+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPackard%26aufirst%3DG.%2BK.%26aulast%3DPapa%26aufirst%3DP.%26aulast%3DRiggs%26aufirst%3DJ.%2BR.%26aulast%3DErdman%26aufirst%3DP.%26aulast%3DTehrani%26aufirst%3DL.%26aulast%3DRobinson%26aufirst%3DD.%26aulast%3DHarris%26aufirst%3DR.%26aulast%3DShevlin%26aufirst%3DG.%26aulast%3DPerrin-Ninkovic%26aufirst%3DS.%26aulast%3DHilgraf%26aufirst%3DR.%26aulast%3DMcCarrick%26aufirst%3DM.%2BA.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DFleming%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DA.%26aulast%3DRichardson%26aufirst%3DS.%26aulast%3DKatz%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DLeisten%26aufirst%3DJ.%26aulast%3DMoghaddam%26aufirst%3DM.%26aulast%3DCathers%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DD.%26aulast%3DSakata%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520thieno%255B2%252C3-d%255Dpyrimidines%2520as%2520B-Raf%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D747%26epage%3D752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Lyne, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aquila, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ezhuthachan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ioannidis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pontz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deegan, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Custeau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poondru, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, A.</span><span> </span><span class="NLM_article-title">Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1026</span><span class="NLM_x">–</span> <span class="NLM_lpage">1029</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1026-1029&author=P.+D.+Lyneauthor=B.+Aquilaauthor=D.+J.+Cookauthor=L.+A.+Dakinauthor=J.+Ezhuthachanauthor=S.+Ioannidisauthor=T.+Pontzauthor=M.+Suauthor=Q.+Yeauthor=X.+Zhengauthor=M.+H.+Blockauthor=S.+Cowenauthor=T.+L.+Deeganauthor=J.+W.+Leeauthor=D.+A.+Scottauthor=D.+Custeauauthor=L.+Drewauthor=S.+Poondruauthor=M.+Shenauthor=A.+Wu&title=Identification+of+amidoheteroaryls+as+potent+inhibitors+of+mutant+%28V600E%29+B-Raf+kinase+with+in+vivo+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLyne%26aufirst%3DP.%2BD.%26aulast%3DAquila%26aufirst%3DB.%26aulast%3DCook%26aufirst%3DD.%2BJ.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DEzhuthachan%26aufirst%3DJ.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DPontz%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DCowen%26aufirst%3DS.%26aulast%3DDeegan%26aufirst%3DT.%2BL.%26aulast%3DLee%26aufirst%3DJ.%2BW.%26aulast%3DScott%26aufirst%3DD.%2BA.%26aulast%3DCusteau%26aufirst%3DD.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DPoondru%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520amidoheteroaryls%2520as%2520potent%2520inhibitors%2520of%2520mutant%2520%2528V600E%2529%2520B-Raf%2520kinase%2520with%2520in%2520vivo%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1026%26epage%3D1029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Shen, M.; Wu, A.; Aquila, B.; Lyne, P.; Drew, L.</span><span> </span><span class="NLM_article-title">Linking molecular characteristics to the pharmacological response of a panel of cancer cell lines to the BRAF inhibitor, AZ628. Los Angeles, CA</span>. <i>AACR 98th Meeting</i><span class="NLM_x"> (</span><span class="NLM_year">2007</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+Shen&author=A.+Wu&author=B.+Aquila&author=P.+Lyne&author=L.+Drew&title=Linking+molecular+characteristics+to+the+pharmacological+response+of+a+panel+of+cancer+cell+lines+to+the+BRAF+inhibitor%2C+AZ628.+Los+Angeles%2C+CA"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DM.%26atitle%3DLinking%2520molecular%2520characteristics%2520to%2520the%2520pharmacological%2520response%2520of%2520a%2520panel%2520of%2520cancer%2520cell%2520lines%2520to%2520the%2520BRAF%2520inhibitor%252C%2520AZ628.%2520Los%2520Angeles%252C%2520CA%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Montagut, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shioda, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulkus, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stubbs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">4853</span><span class="NLM_x">–</span> <span class="NLM_lpage">4861</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=4853-4861&author=C.+Montagutauthor=S.+V.+Sharmaauthor=S.+T.+Shiodaauthor=U.+McDermottauthor=M.+Ulmanauthor=L.+E.+Ulkusauthor=D.+Dias-Santagataauthor=H.+Stubbsauthor=D.+Y.+Leeauthor=A.+Singhauthor=L.+Drewauthor=D.+A.+Haberauthor=J.+Settleman&title=Elevated+CRAF+as+a+potential+mechanism+of+acquired+resistance+to+BRAF+inhibition+in+melanoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMontagut%26aufirst%3DC.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DShioda%26aufirst%3DS.%2BT.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DUlman%26aufirst%3DM.%26aulast%3DUlkus%26aufirst%3DL.%2BE.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DStubbs%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DD.%2BY.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DElevated%2520CRAF%2520as%2520a%2520potential%2520mechanism%2520of%2520acquired%2520resistance%2520to%2520BRAF%2520inhibition%2520in%2520melanoma%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D4853%26epage%3D4861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="note"><p class="first last">For references comparing DFG-in and DFG-out binding, see:</p></div><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+structures+of+the+kinase+domain+of+c-Abl+in+complex+with+the+small+molecule+inhibitors+PD173955+and+imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0li9CZ5AkmcmHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520kinase%2520domain%2520of%2520c-Abl%2520in%2520complex%2520with%2520the%2520small%2520molecule%2520inhibitors%2520PD173955%2520and%2520imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newitt, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittekind, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzillerri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span> </span><span class="NLM_article-title">The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">5790</span><span class="NLM_x">–</span> <span class="NLM_lpage">5797</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=5790-5797&author=J.+S.+Tokarskiauthor=J.+A.+Newittauthor=C.+Y.+J.+Changauthor=J.+D.+Chengauthor=M.+Wittekindauthor=S.+E.+Kieferauthor=K.+Kishauthor=F.+Y.+F.+Leeauthor=R.+Borzillerriauthor=L.+J.+Lombardoauthor=D.+Xieauthor=Y.+Zhangauthor=H.+E.+Klei&title=The+structure+of+dasatinib+%28BMS-354825%29+bound+to+activated+ABL+kinase+domain+elucidates+its+inhibitory+activity+against+imatinib-resistant+ABL+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DChang%26aufirst%3DC.%2BY.%2BJ.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26aulast%3DWittekind%26aufirst%3DM.%26aulast%3DKiefer%26aufirst%3DS.%2BE.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DF.%2BY.%2BF.%26aulast%3DBorzillerri%26aufirst%3DR.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26atitle%3DThe%2520structure%2520of%2520dasatinib%2520%2528BMS-354825%2529%2520bound%2520to%2520activated%2520ABL%2520kinase%2520domain%2520elucidates%2520its%2520inhibitory%2520activity%2520against%2520imatinib-resistant%2520ABL%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D5790%26epage%3D5797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="note"><p class="first last">For recent studies highlighting MAPK pathway activation in cells containing wild type B-Raf through Raf dimerization, see:</p></div><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Heidorn, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milagre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nourry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhomen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis-Filho, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">140</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1016%2Fj.cell.2009.12.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=20141835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2010&pages=209-221&author=S.+J.+Heidornauthor=C.+Milagreauthor=S.+Whittakerauthor=A.+Nourryauthor=I.+Niculescu-Duvasauthor=N.+Dhomenauthor=J.+Hussainauthor=J.+S.+Reis-Filhoauthor=C.+J.+Springerauthor=C.+Pritchardauthor=R.+Marais&title=Kinase-dead+BRAF+and+oncogenic+RAS+cooperate+to+drive+tumor+progression+through+CRAF"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span></div><div class="casAuthors">Heidorn, Sonja J.; Milagre, Carla; Whittaker, Steven; Nourry, Arnaud; Niculescu-Duvas, Ion; Dhomen, Nathalie; Hussain, Jahan; Reis-Filho, Jorge S.; Springer, Caroline J.; Pritchard, Catrin; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-221</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We describe a mechanism of tumorigenesis mediated by kinase-dead BRAF in the presence of oncogenic RAS.  We show that drugs that selectively inhibit BRAF drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling.  This does not occur when oncogenic BRAF is inhibited, demonstrating that BRAF inhibition per se does not drive pathway activation; it only occurs when BRAF is inhibited in the presence of oncogenic RAS.  Kinase-dead BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice.  Our data reveal another paradigm of BRAF-mediated signaling that promotes tumor progression.  They highlight the importance of understanding pathway signaling in clin. practice and of genotyping tumors prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMSb6ckHpR07Vg90H21EOLACvtfcHk0li9CZ5AkmcmHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D&md5=80af840cb978f5956b3d998b185115f4</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.12.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.12.040%26sid%3Dliteratum%253Aachs%26aulast%3DHeidorn%26aufirst%3DS.%2BJ.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DWhittaker%26aufirst%3DS.%26aulast%3DNourry%26aufirst%3DA.%26aulast%3DNiculescu-Duvas%26aufirst%3DI.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DHussain%26aufirst%3DJ.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DPritchard%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DKinase-dead%2520BRAF%2520and%2520oncogenic%2520RAS%2520cooperate%2520to%2520drive%2520tumor%2520progression%2520through%2520CRAF%26jtitle%3DCell%26date%3D2010%26volume%3D140%26spage%3D209%26epage%3D221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Poulikakos, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">464</span><span class="NLM_x">, </span> <span class="NLM_fpage">427</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=427-430&author=P.+I.+Poulikakosauthor=C.+Zhangauthor=G.+Bollagauthor=K.+M.+Shokatauthor=N.+Rosen&title=RAF+inhibitors+transactivate+RAF+dimers+and+ERK+signaling+in+cells+with+wild-type+BRAF"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DRAF%2520inhibitors%2520transactivate%2520RAF%2520dimers%2520and%2520ERK%2520signaling%2520in%2520cells%2520with%2520wild-type%2520BRAF%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D427%26epage%3D430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hatzivassiliou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarado, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludlam, M. J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaiswal, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seshagiri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span> </span><span class="NLM_article-title">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">464</span><span class="NLM_x">, </span> <span class="NLM_fpage">431</span><span class="NLM_x">–</span> <span class="NLM_lpage">436</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1038%2Fnature08833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=20130576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=431-436&author=G.+Hatzivassiliouauthor=K.+Songauthor=I.+Yenauthor=B.+J.+Brandhuberauthor=D.+J.+Andersonauthor=R.+Alvaradoauthor=M.+J.+C.+Ludlamauthor=D.+Stokoeauthor=S.+L.+Gloorauthor=G.+Vigersauthor=T.+Moralesauthor=I.+Aliagasauthor=B.+Liuauthor=S.+Siderisauthor=K.+P.+Hoeflichauthor=B.+S.+Jaiswalauthor=S.+Seshagiriauthor=H.+Koeppenauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=S.+Malek&title=RAF+inhibitors+prime+wild-type+RAF+to+activate+the+MAPK+pathway+and+enhance+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15cR"><div class="casContent"><span class="casTitleNuber">15c</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Song, Kyung; Yen, Ivana; Brandhuber, Barbara J.; Anderson, Daniel J.; Alvarado, Ryan; Ludlam, Mary J. C.; Stokoe, David; Gloor, Susan L.; Vigers, Guy; Morales, Tony; Aliagas, Ignacio; Liu, Bonnie; Sideris, Steve; Hoeflich, Klaus P.; Jaiswal, Bijay S.; Seshagiri, Somasekar; Koeppen, Hartmut; Belvin, Marcia; Friedman, Lori S.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">431-435</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in KRAS and BRAF are found in more than 30% of all human tumors and 40% of melanoma, resp., thus targeting this pathway could have broad therapeutic effects.  Small mol. ATP-competitive RAF kinase inhibitors have potent antitumor effects on mutant BRAF(V600E) tumors but, in contrast to mitogen-activated protein kinase kinase (MEK) inhibitors, are not potent against RAS mutant tumor models, despite RAF functioning as a key effector downstream of RAS and upstream of MEK.  Here we show that ATP-competitive RAF inhibitors have two opposing mechanisms of action depending on the cellular context.  In BRAF(V600E) tumors, RAF inhibitors effectively block the mitogen-activated protein kinase (MAPK) signalling pathway and decrease tumor growth.  Notably, in KRAS mutant and RAS/RAF wild-type tumors, RAF inhibitors activate the RAF-MEK-ERK pathway in a RAS-dependent manner, thus enhancing tumor growth in some xenograft models.  Inhibitor binding activates wild-type RAF isoforms by inducing dimerization, membrane localization and interaction with RAS-GTP.  These events occur independently of kinase inhibition and are, instead, linked to direct conformational effects of inhibitors on the RAF kinase domain.  On the basis of these findings, we demonstrate that ATP-competitive kinase inhibitors can have opposing functions as inhibitors or activators of signalling pathways, depending on the cellular context.  Furthermore, this work provides new insights into the therapeutic use of ATP-competitive RAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGounpcMETzVoLVg90H21EOLACvtfcHk0lgtZxBH-TbYDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D&md5=eb48bdf352ee9c9e182e63e38fd820a5</span></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1038%2Fnature08833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08833%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DAlvarado%26aufirst%3DR.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%2BC.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DJaiswal%26aufirst%3DB.%2BS.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DRAF%2520inhibitors%2520prime%2520wild-type%2520RAF%2520to%2520activate%2520the%2520MAPK%2520pathway%2520and%2520enhance%2520growth%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D431%26epage%3D436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Carnahan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beltran, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babij, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vonderfecht, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagapudi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broome, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kha, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmontes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, T. L.</span><span> </span><span class="NLM_article-title">Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2399</span><span class="NLM_x">–</span> <span class="NLM_lpage">2410</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15d&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1158%2F1535-7163.MCT-10-0181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15d&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=20663930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15d&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2399-2410&author=J.+Carnahanauthor=P.+J.+Beltranauthor=C.+Babijauthor=Q.+Leauthor=M.+J.+Roseauthor=S.+Vonderfechtauthor=J.+L.+Kimauthor=A.+L.+Smithauthor=K.+Nagapudiauthor=M.+A.+Broomeauthor=M.+Fernandoauthor=H.+Khaauthor=B.+Belmontesauthor=R.+Radinskyauthor=R.+Kendallauthor=T.+L.+Burgess&title=Selective+and+potent+Raf+inhibitors+paradoxically+stimulate+normal+cell+proliferation+and+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15dR"><div class="casContent"><span class="casTitleNuber">15d</span><div class="casTitle"><span class="NLM_cas:atitle">Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth</span></div><div class="casAuthors">Carnahan, Josette; Beltran, Pedro J.; Babij, Carol; Le, Quynh; Rose, Mark J.; Vonderfecht, Steven; Kim, Joseph L.; Smith, Adrian L.; Nagapudi, Karthik; Broome, Martin A.; Fernando, Manory; Kha, Hue; Belmontes, Brian; Radinsky, Robert; Kendall, Richard; Burgess, Teresa L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2399-2410</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Raf inhibitors are under clin. investigation, specifically in patients with tumor types harboring frequent activating mutations in B-Raf.  Here, we show that cell lines and tumors harboring mutant B-Raf were sensitive to a novel series of Raf inhibitors (e.g., V600EB-Raf A375, IC50 on cells = 2 nmol/L; ED50 on tumor xenografts = 1.3 mg/kg).  However, in cells and tumors with wild-type B-Raf, exposure to Raf inhibitors resulted in a dose-dependent and sustained activation of mitogen-activated protein kinase signaling.  In some of these cell lines, Raf inhibition led to entry into the cell cycle, enhanced proliferation, and significantly stimulated tumor growth in vivo.  Inhibition with structurally distinct Raf inhibitors or isoform-specific small interfering RNA knockdown of Raf showed that these effects were mediated directly through Raf.  Either A-Raf or C-Raf mediated the Raf inhibitor-induced mitogen-activated protein kinase pathway activation in an inhibitor-specific manner.  These paradoxical effects of Raf inhibition were seen in malignant and normal cells in vitro and in vivo.  Hyperplasia of normal epithelial cells in the esophagus and the stomach was evident in mice with all efficacious Raf inhibitors (n = 8) tested.  An implication of these results is that Raf inhibitors may induce unexpected normal cell and tumor tissue proliferation in patients.  Mol Cancer Ther; 9(8); 2399-410.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN5Uws5uZF4rVg90H21EOLACvtfcHk0lgtZxBH-TbYDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVOjt7g%253D&md5=c2958b3c22d623571dea9bedf6835834</span></div><a href="/servlet/linkout?suffix=cit15d&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0181%26sid%3Dliteratum%253Aachs%26aulast%3DCarnahan%26aufirst%3DJ.%26aulast%3DBeltran%26aufirst%3DP.%2BJ.%26aulast%3DBabij%26aufirst%3DC.%26aulast%3DLe%26aufirst%3DQ.%26aulast%3DRose%26aufirst%3DM.%2BJ.%26aulast%3DVonderfecht%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DSmith%26aufirst%3DA.%2BL.%26aulast%3DNagapudi%26aufirst%3DK.%26aulast%3DBroome%26aufirst%3DM.%2BA.%26aulast%3DFernando%26aufirst%3DM.%26aulast%3DKha%26aufirst%3DH.%26aulast%3DBelmontes%26aufirst%3DB.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DBurgess%26aufirst%3DT.%2BL.%26atitle%3DSelective%2520and%2520potent%2520Raf%2520inhibitors%2520paradoxically%2520stimulate%2520normal%2520cell%2520proliferation%2520and%2520tumor%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D2399%26epage%3D2410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Jones, J. D.</span><span> </span><span class="NLM_article-title">Quinazoline derivatives useful as intermediates</span>. Patent WO1992015569,<span class="NLM_x"> </span><span class="NLM_year">1992</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1992&author=J.+D.+Jones&title=Quinazoline+derivatives+useful+as+intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DJ.%2BD.%26atitle%3DQuinazoline%2520derivatives%2520useful%2520as%2520intermediates%26date%3D1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Jain, R.; Lin, X.; Ng, S. C.; Pfister, K. B.; Ramurthy, S.; Rico, A.; Subramanian, S.; Wang, X. M.</span><span> </span><span class="NLM_article-title">2-Arylaminoquinazolines for treating proliferative diseases</span>. Patent WO2009153313A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=R.+Jain&author=X.+Lin&author=S.+C.+Ng&author=K.+B.+Pfister&author=S.+Ramurthy&author=A.+Rico&author=S.+Subramanian&author=X.+M.+Wang&title=2-Arylaminoquinazolines+for+treating+proliferative+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DR.%26atitle%3D2-Arylaminoquinazolines%2520for%2520treating%2520proliferative%2520diseases%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><div class="note"><p class="first last">An EphB4 co-crystallization of <b>3</b> was readily obtained and used as a surrogate to B-Raf<sup>V600E</sup> due to its identical gatekeeper and similar binding site and selectivity pocket. We used this surrogate to guide initial hypotheses around the binding mode. Detailed protein preparation, crystallization, and freezing protocols are included in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> of the following report:</p></div><span class="NLM_contrib-group">Bardelle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davenport, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kettle, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortlock, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, E. J.</span><span> </span><span class="NLM_article-title">Inhibitors of the tyrosine kinase EphB4. Part 2: Structure-based discovery and optimization of 3,5-bis substituted anilinopyrimidines</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5717</span><span class="NLM_x">–</span> <span class="NLM_lpage">5721</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5717-5721&author=C.+Bardelleauthor=T.+Colemanauthor=D.+Crossauthor=S.+Davenportauthor=J.+G.+Kettleauthor=E.+J.+Koauthor=A.+G.+Leachauthor=A.+Mortlockauthor=J.+Readauthor=N.+J.+Robertsauthor=P.+Robinsauthor=E.+J.+Williams&title=Inhibitors+of+the+tyrosine+kinase+EphB4.+Part+2%3A+Structure-based+discovery+and+optimization+of+3%2C5-bis+substituted+anilinopyrimidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBardelle%26aufirst%3DC.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DCross%26aufirst%3DD.%26aulast%3DDavenport%26aufirst%3DS.%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DKo%26aufirst%3DE.%2BJ.%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DMortlock%26aufirst%3DA.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DN.%2BJ.%26aulast%3DRobins%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DE.%2BJ.%26atitle%3DInhibitors%2520of%2520the%2520tyrosine%2520kinase%2520EphB4.%2520Part%25202%253A%2520Structure-based%2520discovery%2520and%2520optimization%2520of%25203%252C5-bis%2520substituted%2520anilinopyrimidines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5717%26epage%3D5721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="note"><p class="first last">The KinaseProfiler panel testing was performed at Millipore, with data overlaid against the kinome phylogenetic tree using Millipore’s DART visualization tool.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="note"><p class="first last">For additional information around the biochemical profiles of <b>2</b> and <b>3</b>, cell line background, and tumor type, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><div class="note"><p class="first last">For a recent paper describing the concern around aromatic anilines and potential mutagenic concerns, see the following and references therein:</p></div><span class="NLM_contrib-group">Birch, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groombridge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mee, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schramm, C.</span><span> </span><span class="NLM_article-title">Rationally designing safer anilines: The challenging case of 4-aminobiphenyls</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">3923</span><span class="NLM_x">–</span> <span class="NLM_lpage">3933</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3001295" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3923-3933&author=A.+M.+Birchauthor=S.+Groombridgeauthor=R.+Lawauthor=A.+G.+Leachauthor=C.+D.+Meeauthor=C.+Schramm&title=Rationally+designing+safer+anilines%3A+The+challenging+case+of+4-aminobiphenyls"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm3001295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3001295%26sid%3Dliteratum%253Aachs%26aulast%3DBirch%26aufirst%3DA.%2BM.%26aulast%3DGroombridge%26aufirst%3DS.%26aulast%3DLaw%26aufirst%3DR.%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DMee%26aufirst%3DC.%2BD.%26aulast%3DSchramm%26aufirst%3DC.%26atitle%3DRationally%2520designing%2520safer%2520anilines%253A%2520The%2520challenging%2520case%2520of%25204-aminobiphenyls%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3923%26epage%3D3933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="note"><p class="first last">Chiral resolution of the enantiomers of <b>53</b> was performed and there was a 2-fold difference in cellular potency between the two enantiomers. Absolute confirmation of (<i>R</i>)- and (<i>S</i>)-enantiomers was not determined.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="note"><p class="first last">The (<i>S</i>)-enantiomer of <b>57</b> (not shown) had an IC<sub>50</sub> = 190 nM in the A375 pERK cell assay.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><div class="note"><p class="first last">We chose to switch to screening at 5 mM ATP concentration in the B-Raf<sup>V600E</sup> enzyme assay as we continued our lead optimization of the aminoquinazoline series and discontinued screening at <i>K</i><sub>m</sub> ATP concentrations (as reported by enzyme potencies shown in Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). We believed the higher ATP concentration was more representative of cellular ATP levels and provided a more robust enzyme-cell correlation. For additional details around the advantages of screening kinase inhibitors at various ATP concentrations, see the following paper and references therein:</p></div><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Features of selective kinase inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">621</span><span class="NLM_x">–</span> <span class="NLM_lpage">637</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1016%2Fj.chembiol.2005.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=15975507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=621-637&author=Z.+A.+Knightauthor=K.+M.+Shokat&title=Features+of+selective+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Features of Selective Kinase Inhibitors</span></div><div class="casAuthors">Knight, Zachary A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">621-637</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Summary: Small-mol. inhibitors of protein and lipid kinases have emerged as indispensable tools for studying signal transduction.  Despite the widespread use of these reagents, there is little consensus about the biochem. criteria that define their potency and selectivity in cells.  We discuss some of the features that det. the cellular activity of kinase inhibitors and propose a framework for interpreting inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAJWhVxtSrCLVg90H21EOLACvtfcHk0lg07wkxb2EmPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D&md5=ce5b3505a0326b04479172ec05573152</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2005.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2005.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DFeatures%2520of%2520selective%2520kinase%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2005%26volume%3D12%26spage%3D621%26epage%3D637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Morgenthaler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweizer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann-Röder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaeschke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foischer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendels, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diederich, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, K.</span><span> </span><span class="NLM_article-title">Predicting and tuning physicochemical properties in lead optimization: Amine basicities</span> <span class="citation_source-journal">Chem. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1100</span><span class="NLM_x">–</span> <span class="NLM_lpage">1115</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1002%2Fcmdc.200700059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=17530727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1100-1115&author=M.+Morgenthalerauthor=E.+Schweizerauthor=A.+Hoffmann-R%C3%B6derauthor=F.+Beniniauthor=R.+E.+Martinauthor=G.+Jaeschkeauthor=B.+Wagnerauthor=H.+Foischerauthor=S.+Bendelsauthor=D.+Zimmerliauthor=J.+Schneiderauthor=F.+Diederichauthor=M.+Kansyauthor=K.+M%C3%BCller&title=Predicting+and+tuning+physicochemical+properties+in+lead+optimization%3A+Amine+basicities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span></div><div class="casAuthors">Morgenthaler, Martin; Schweizer, Eliane; Hoffmann-Roder, Anja; Benini, Fausta; Martin, Rainer E.; Jaeschke, Georg; Wagner, Bjorn; Fischer, Holger; Bendels, Stefanie; Zimmerli, Daniel; Schneider, Josef; Diederich, Francois; Kansy, Manfred; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1100-1115</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This review describes simple and useful concepts for predicting and tuning the pKa values of basic amine centers, a crucial step in the optimization of phys. and ADME properties of many lead structures in drug-discovery research.  The article starts with a case study of tricyclic thrombin inhibitors featuring a tertiary amine center with pKa values that can be tuned over a wide range, from the usual value of around 10 to below 2 by (remote) neighboring functionalities commonly encountered in medicinal chem.  Next, the changes in pKa of acyclic and cyclic amines upon substitution by fluorine, oxygen, nitrogen, and sulfur functionalities, as well as carbonyl and carboxyl derivs. are systematically analyzed, leading to the derivation of simple rules for pKa prediction.  Electronic and stereoelectronic effects in cyclic amines are discussed, and the emerging computational methods for pKa predictions are briefly surveyed.  The rules for tuning amine basicities should not only be of interest in drug-discovery research, but also to the development of new crop-protection agents, new amine ligands for organometallic complexes, and in particular, to the growing field of amine-based organocatalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodsWRMtrxWPbVg90H21EOLACvtfcHk0lg07wkxb2EmPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D&md5=478b70744312c01d3a43cf435d9598de</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700059%26sid%3Dliteratum%253Aachs%26aulast%3DMorgenthaler%26aufirst%3DM.%26aulast%3DSchweizer%26aufirst%3DE.%26aulast%3DHoffmann-R%25C3%25B6der%26aufirst%3DA.%26aulast%3DBenini%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DR.%2BE.%26aulast%3DJaeschke%26aufirst%3DG.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFoischer%26aufirst%3DH.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DZimmerli%26aufirst%3DD.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DDiederich%26aufirst%3DF.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26atitle%3DPredicting%2520and%2520tuning%2520physicochemical%2520properties%2520in%2520lead%2520optimization%253A%2520Amine%2520basicities%26jtitle%3DChem.%2520Med.%2520Chem.%26date%3D2007%26volume%3D2%26spage%3D1100%26epage%3D1115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="note"><p class="first last">Work was done to identify the stereochemical preference at the carboxamide stereogenic center and in each instance the more potent diastereomer is represented in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. We were unable to separate the diastereomers of compound <b>76</b> and data shown is for the mixture of diastereomers.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Lin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVita, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eid, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chicchi, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurtz, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsao, K-L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeldon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargreavesd, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S. G.</span><span> </span><span class="NLM_article-title">The discovery of potent, selective, and orally bioavailable hNK1 antagonists derived from pyrrolidine</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5191</span><span class="NLM_x">–</span> <span class="NLM_lpage">5198</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=5191-5198&author=P.+Linauthor=L.+Changauthor=R.+J.+DeVitaauthor=J.+R.+Youngauthor=R.+Eidauthor=X.+Tongauthor=S.+Zhengauthor=R.+G.+Ballauthor=N.+N.+Tsouauthor=G.+G.+Chicchiauthor=M.+M.+Kurtzauthor=K-L.+C.+Tsaoauthor=A.+Wheeldonauthor=E.+J.+Carlsonauthor=W.+Engauthor=H.+D.+Burnsauthor=R.+J.+Hargreavesdauthor=S.+G.+Mills&title=The+discovery+of+potent%2C+selective%2C+and+orally+bioavailable+hNK1+antagonists+derived+from+pyrrolidine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26aulast%3DYoung%26aufirst%3DJ.%2BR.%26aulast%3DEid%26aufirst%3DR.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DBall%26aufirst%3DR.%2BG.%26aulast%3DTsou%26aufirst%3DN.%2BN.%26aulast%3DChicchi%26aufirst%3DG.%2BG.%26aulast%3DKurtz%26aufirst%3DM.%2BM.%26aulast%3DTsao%26aufirst%3DK-L.%2BC.%26aulast%3DWheeldon%26aufirst%3DA.%26aulast%3DCarlson%26aufirst%3DE.%2BJ.%26aulast%3DEng%26aufirst%3DW.%26aulast%3DBurns%26aufirst%3DH.%2BD.%26aulast%3DHargreavesd%26aufirst%3DR.%2BJ.%26aulast%3DMills%26aufirst%3DS.%2BG.%26atitle%3DThe%2520discovery%2520of%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520hNK1%2520antagonists%2520derived%2520from%2520pyrrolidine%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D5191%26epage%3D5198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><div class="note"><p class="first last">For additional information on <b>102</b>, see the following and references therein:</p></div><span class="NLM_contrib-group">Haura, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricart, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stella, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bazhenova, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selaru, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadgeel, S. M.</span><span> </span><span class="NLM_article-title">A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non–small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">2450</span><span class="NLM_x">–</span> <span class="NLM_lpage">2457</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1158%2F1078-0432.CCR-09-1920" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=20332327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkslSlsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=2450-2457&author=E.+B.+Hauraauthor=A.+D.+Ricartauthor=T.+G.+Larsonauthor=P.+J.+Stellaauthor=L.+Bazhenovaauthor=V.+A.+Millerauthor=R.+B.+Cohenauthor=P.+D.+Eisenbergauthor=P.+Selaruauthor=K.+D.+Wilnerauthor=S.+M.+Gadgeel&title=A+phase+II+study+of+PD-0325901%2C+an+oral+MEK+inhibitor%2C+in+previously+treated+patients+with+advanced+non%E2%80%93small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Haura, Eric B.; Ricart, Alejandro D.; Larson, Timothy G.; Stella, Philip J.; Bazhenova, Lyudmila; Miller, Vincent A.; Cohen, Roger B.; Eisenberg, Peter D.; Selaru, Paulina; Wilner, Keith D.; Gadgeel, Shirish M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2450-2457</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To evaluate the efficacy of mitogen-activated protein kinase/extracellular signal-related kinase kinase inhibitor PD-0325901 in advanced non-small cell lung cancer patients who had experienced treatment failure after, or were refractory to, std. systemic therapy.  This open-label, phase II study initially evaluated 15 mg PD-0325901 twice daily administered intermittently (3 wk on/1 wk off; schedule A).  As this schedule was not well tolerated, a second schedule was introduced as follows: 5 days on/2 days off for 3 wk, followed by 1 wk off (schedule B).  The primary end point was objective response.  All patients had received prior systemic therapy (median of two regimens, including epidermal growth factor receptor inhibitors in 26%).  Of 13 patients treated on schedule A, three discontinued due to adverse events (blurred vision, fatigue, and hallucinations, resp.).  Twenty-one patients received schedule B. Main toxicities included diarrhea, fatigue, rash, vomiting, nausea, and reversible visual disturbances.  Hematol. toxicity consisted mainly of mild-to-moderate anemia, without neutropenia.  Chem. abnormalities were rare.  Mean (coeff. of variation) PD-0325901 trough plasma concns. were 100 ng/mL (52%) and 173 ng/mL (73%) for schedules A and B, resp., above the min. target concn. established in preclin. studies (16.5 ng/mL).  There were no objective responses.  Seven patients had stable disease.  Median (95% confidence interval) progression-free survival was 1.8 mo (1.5-1.9) and overall survival was 7.8 mo (4.5-13.9).  PD-0325901 did not meet its primary efficacy end point.  Future studies should focus on PD-0325901 schedule, rational combination strategies, and enrichment of patient selection based on mode of action.  Clin Cancer Res; 16(8); 2450-7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOnKzkhzjxz7Vg90H21EOLACvtfcHk0lgdQIX-AkRi4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkslSlsbo%253D&md5=e790d14c045ba5f18b857dfdda501a1b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-1920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-1920%26sid%3Dliteratum%253Aachs%26aulast%3DHaura%26aufirst%3DE.%2BB.%26aulast%3DRicart%26aufirst%3DA.%2BD.%26aulast%3DLarson%26aufirst%3DT.%2BG.%26aulast%3DStella%26aufirst%3DP.%2BJ.%26aulast%3DBazhenova%26aufirst%3DL.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DCohen%26aufirst%3DR.%2BB.%26aulast%3DEisenberg%26aufirst%3DP.%2BD.%26aulast%3DSelaru%26aufirst%3DP.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520PD-0325901%252C%2520an%2520oral%2520MEK%2520inhibitor%252C%2520in%2520previously%2520treated%2520patients%2520with%2520advanced%2520non%25E2%2580%2593small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D2450%26epage%3D2457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span> </span><span class="NLM_article-title">Conformation-specific effects on Raf kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7332</span><span class="NLM_x">–</span> <span class="NLM_lpage">7341</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300613w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7332-7341&author=X.+Wangauthor=J.+Kim&title=Conformation-specific+effects+on+Raf+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm300613w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300613w%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DJ.%26atitle%3DConformation-specific%2520effects%2520on%2520Raf%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7332%26epage%3D7341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="note"><p class="first last">The kinase selectivity profile of <b>58</b> was similar to that of <b>3</b> with S(10) selectivity score of 0.01. For a full listing of the kinase panel data, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="note"><p class="first last">Additional details around compound <b>2</b> will be reported in a future manuscript.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8a','cit8'],'ref9':['cit9a','cit9b','cit9c','cit9d'],'ref10':['cit10a','cit10b','cit10c','cit10d'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14a','cit14b'],'ref15':['cit15a','cit15b','cit15c','cit15d'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':[],'ref20':[],'ref21':['cit21'],'ref22':[],'ref23':[],'ref24':['cit24'],'ref25':['cit25'],'ref26':[],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':[],'ref31':[]}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 22 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Andrea I. Krahn, Carrow Wells, David H. Drewry, Lenore K. Beitel, Thomas M. Durcan, <span class="NLM_string-name hlFld-ContribAuthor">Alison D. Axtman</span>. </span><span class="cited-content_cbyCitation_article-title">Defining the Neural Kinome: Strategies and Opportunities for Small Molecule Drug Discovery to Target Neurodegenerative Diseases. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2020,</strong> <em>11 </em>
                                    (13)
                                     , 1871-1886. <a href="https://doi.org/10.1021/acschemneuro.0c00176" title="DOI URL">https://doi.org/10.1021/acschemneuro.0c00176</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.0c00176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.0c00176%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DDefining%252Bthe%252BNeural%252BKinome%25253A%252BStrategies%252Band%252BOpportunities%252Bfor%252BSmall%252BMolecule%252BDrug%252BDiscovery%252Bto%252BTarget%252BNeurodegenerative%252BDiseases%26aulast%3DKrahn%26aufirst%3DAndrea%2BI.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D01042020%26date%3D28052020%26date%3D11062020%26date%3D28052020%26volume%3D11%26issue%3D13%26spage%3D1871%26epage%3D1886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paula  Ruiz-Castillo</span> and <span class="hlFld-ContribAuthor ">Stephen L.  Buchwald</span>  . </span><span class="cited-content_cbyCitation_article-title">Applications of Palladium-Catalyzed C–N Cross-Coupling Reactions. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2016,</strong> <em>116 </em>
                                    (19)
                                     , 12564-12649. <a href="https://doi.org/10.1021/acs.chemrev.6b00512" title="DOI URL">https://doi.org/10.1021/acs.chemrev.6b00512</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.6b00512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.6b00512%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DApplications%252Bof%252BPalladium-Catalyzed%252BC%2525E2%252580%252593N%252BCross-Coupling%252BReactions%26aulast%3DRuiz-Castillo%26aufirst%3DPaula%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D03082016%26date%3D30092016%26date%3D12102016%26volume%3D116%26issue%3D19%26spage%3D12564%26epage%3D12649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nash D.  Rochman</span>, <span class="hlFld-ContribAuthor ">Yuri I.  Wolf</span>, <span class="hlFld-ContribAuthor ">Eugene V.  Koonin</span>. </span><span class="cited-content_cbyCitation_article-title">Deep phylogeny of cancer drivers and compensatory mutations. </span><span class="cited-content_cbyCitation_journal-name">Communications Biology</span><span> <strong>2020,</strong> <em>3 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s42003-020-01276-7" title="DOI URL">https://doi.org/10.1038/s42003-020-01276-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s42003-020-01276-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs42003-020-01276-7%26sid%3Dliteratum%253Aachs%26jtitle%3DCommunications%2520Biology%26atitle%3DDeep%252Bphylogeny%252Bof%252Bcancer%252Bdrivers%252Band%252Bcompensatory%252Bmutations%26aulast%3DRochman%26aufirst%3DNash%2BD.%26date%3D2020%26date%3D2020%26volume%3D3%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jaydeepsinh  Chavda</span>, <span class="hlFld-ContribAuthor ">Hardik  Bhatt</span>. </span><span class="cited-content_cbyCitation_article-title">Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>206 </em>, 112675. <a href="https://doi.org/10.1016/j.ejmech.2020.112675" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112675%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSystemic%252Breview%252Bon%252BB-RafV600E%252Bmutation%252Bas%252Bpotential%252Btherapeutic%252Btarget%252Bfor%252Bthe%252Btreatment%252Bof%252Bcancer%26aulast%3DChavda%26aufirst%3DJaydeepsinh%26date%3D2020%26volume%3D206%26spage%3D112675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Chen</span>, <span class="hlFld-ContribAuthor ">Jie  Wu</span>, <span class="hlFld-ContribAuthor ">Hongfei  Yan</span>, <span class="hlFld-ContribAuthor ">Yang  Cheng</span>, <span class="hlFld-ContribAuthor ">Yizhe  Wang</span>, <span class="hlFld-ContribAuthor ">Yi  Yang</span>, <span class="hlFld-ContribAuthor ">Mingming  Deng</span>, <span class="hlFld-ContribAuthor ">Xiaofang  Che</span>, <span class="hlFld-ContribAuthor ">Kezuo  Hou</span>, <span class="hlFld-ContribAuthor ">Xiujuan  Qu</span>, <span class="hlFld-ContribAuthor ">Dan  Zou</span>, <span class="hlFld-ContribAuthor ">Yunpeng  Liu</span>, <span class="hlFld-ContribAuthor ">Ye  Zhang</span>, <span class="hlFld-ContribAuthor ">Xuejun  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Lymecycline reverses acquired EGFR-TKI resistance in non–small-cell lung cancer by targeting GRB2. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2020,</strong> <em>159 </em>, 105007. <a href="https://doi.org/10.1016/j.phrs.2020.105007" title="DOI URL">https://doi.org/10.1016/j.phrs.2020.105007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2020.105007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2020.105007%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DLymecycline%252Breverses%252Bacquired%252BEGFR-TKI%252Bresistance%252Bin%252Bnon%2525E2%252580%252593small-cell%252Blung%252Bcancer%252Bby%252Btargeting%252BGRB2%26aulast%3DChen%26aufirst%3DYang%26date%3D2020%26volume%3D159%26spage%3D105007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vitalii V.  Solomin</span>, <span class="hlFld-ContribAuthor ">Alberts  Seins</span>, <span class="hlFld-ContribAuthor ">Aigars  Jirgensons</span>. </span><span class="cited-content_cbyCitation_article-title">2-Aminoquinazolines by Chan–Evans–Lam Coupling of Guanidines with (2-Formylphenyl)boronic Acids. </span><span class="cited-content_cbyCitation_journal-name">Synlett</span><span> <strong>2020,</strong> <em>31 </em>
                                    (15)
                                     , 1507-1510. <a href="https://doi.org/10.1055/s-0040-1707080" title="DOI URL">https://doi.org/10.1055/s-0040-1707080</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/s-0040-1707080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fs-0040-1707080%26sid%3Dliteratum%253Aachs%26jtitle%3DSynlett%26atitle%3D2-Aminoquinazolines%252Bby%252BChan%2525E2%252580%252593Evans%2525E2%252580%252593Lam%252BCoupling%252Bof%252BGuanidines%252Bwith%252B%2525282-Formylphenyl%252529boronic%252BAcids%26aulast%3DSolomin%26aufirst%3DVitalii%2BV.%26date%3D2020%26date%3D2020%26volume%3D31%26issue%3D15%26spage%3D1507%26epage%3D1510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mallika  Iyer</span>, <span class="hlFld-ContribAuthor ">Zhanwen  Li</span>, <span class="hlFld-ContribAuthor ">Lukasz  Jaroszewski</span>, <span class="hlFld-ContribAuthor ">Mayya  Sedova</span>, <span class="hlFld-ContribAuthor ">Adam  Godzik</span>, . </span><span class="cited-content_cbyCitation_article-title">Difference contact maps: From what to why in the analysis of the conformational flexibility of proteins. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2020,</strong> <em>15 </em>
                                    (3)
                                     , e0226702. <a href="https://doi.org/10.1371/journal.pone.0226702" title="DOI URL">https://doi.org/10.1371/journal.pone.0226702</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0226702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0226702%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DDifference%252Bcontact%252Bmaps%25253A%252BFrom%252Bwhat%252Bto%252Bwhy%252Bin%252Bthe%252Banalysis%252Bof%252Bthe%252Bconformational%252Bflexibility%252Bof%252Bproteins%26aulast%3DIyer%26aufirst%3DMallika%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D3%26spage%3De0226702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui-Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Ying  Shen</span>, <span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Hei</span>, <span class="hlFld-ContribAuthor ">Hong-Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">She-Min  Lu</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-(aminopyrimidin-5-yl)-4-(morpholin-4-yl)-6- substituted triazine as PI3K and BRAF dual inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2018,</strong> <em>10 </em>
                                    (20)
                                     , 2445-2455. <a href="https://doi.org/10.4155/fmc-2018-0145" title="DOI URL">https://doi.org/10.4155/fmc-2018-0145</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2018-0145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2018-0145%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-%252528aminopyrimidin-5-yl%252529-4-%252528morpholin-4-yl%252529-6-%252Bsubstituted%252Btriazine%252Bas%252BPI3K%252Band%252BBRAF%252Bdual%252Binhibitor%26aulast%3DWang%26aufirst%3DHui-Yan%26date%3D2018%26volume%3D10%26issue%3D20%26spage%3D2445%26epage%3D2455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rui  Ma</span>, <span class="hlFld-ContribAuthor ">Ling  Xu</span>, <span class="hlFld-ContribAuthor ">Xiujuan  Qu</span>, <span class="hlFld-ContribAuthor ">Xiaofang  Che</span>, <span class="hlFld-ContribAuthor ">Ye  Zhang</span>, <span class="hlFld-ContribAuthor ">Yibo  Fan</span>, <span class="hlFld-ContribAuthor ">Ce  Li</span>, <span class="hlFld-ContribAuthor ">Tianshu  Guo</span>, <span class="hlFld-ContribAuthor ">Kezuo  Hou</span>, <span class="hlFld-ContribAuthor ">Xuejun  Hu</span>, <span class="hlFld-ContribAuthor ">Lisa  Drew</span>, <span class="hlFld-ContribAuthor ">Minhui  Shen</span>, <span class="hlFld-ContribAuthor ">Tony  Cheung</span>, <span class="hlFld-ContribAuthor ">Yunpeng  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Cancer</span><span> <strong>2018,</strong> <em>118 </em>
                                    (11)
                                     , 1453-1463. <a href="https://doi.org/10.1038/s41416-018-0086-x" title="DOI URL">https://doi.org/10.1038/s41416-018-0086-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41416-018-0086-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41416-018-0086-x%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Cancer%26atitle%3DAZ304%25252C%252Ba%252Bnovel%252Bdual%252BBRAF%252Binhibitor%25252C%252Bexerts%252Banti-tumour%252Beffects%252Bin%252Bcolorectal%252Bcancer%252Bindependently%252Bof%252BBRAF%252Bgenetic%252Bstatus%26aulast%3DMa%26aufirst%3DRui%26date%3D2018%26date%3D2018%26volume%3D118%26issue%3D11%26spage%3D1453%26epage%3D1463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Shan</span>, <span class="hlFld-ContribAuthor ">Chuansheng  Li</span>, <span class="hlFld-ContribAuthor ">Ying  Sun</span>, <span class="hlFld-ContribAuthor ">Ping  Su</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Wang</span>, <span class="hlFld-ContribAuthor ">Lisha  Li</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Pan</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel anti-angiogenesis agents. Part 6: Multi-targeted RTK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>127 </em>, 275-285. <a href="https://doi.org/10.1016/j.ejmech.2016.12.059" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.12.059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.12.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.12.059%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Banti-angiogenesis%252Bagents.%252BPart%252B6%25253A%252BMulti-targeted%252BRTK%252Binhibitors%26aulast%3DZhang%26aufirst%3DLin%26date%3D2017%26volume%3D127%26spage%3D275%26epage%3D285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chun-Qi  Hu</span>, <span class="hlFld-ContribAuthor ">Kang  Li</span>, <span class="hlFld-ContribAuthor ">Ting-Ting  Yao</span>, <span class="hlFld-ContribAuthor ">Yong-Zhou  Hu</span>, <span class="hlFld-ContribAuthor ">Hua-Zhou  Ying</span>, <span class="hlFld-ContribAuthor ">Xiao-Wu  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Integrating docking scores and key interaction profiles to improve the accuracy of molecular docking: towards novel B-Raf
              V600E
              inhibitors. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2017,</strong> <em>8 </em>
                                    (9)
                                     , 1835-1844. <a href="https://doi.org/10.1039/C7MD00229G" title="DOI URL">https://doi.org/10.1039/C7MD00229G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7MD00229G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7MD00229G%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DIntegrating%252Bdocking%252Bscores%252Band%252Bkey%252Binteraction%252Bprofiles%252Bto%252Bimprove%252Bthe%252Baccuracy%252Bof%252Bmolecular%252Bdocking%25253A%252Btowards%252Bnovel%252BB-Raf%252BV600E%252Binhibitors%26aulast%3DHu%26aufirst%3DChun-Qi%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D9%26spage%3D1835%26epage%3D1844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huazhou  Ying</span>, <span class="hlFld-ContribAuthor ">Jiangfeng  Xie</span>, <span class="hlFld-ContribAuthor ">Xingguo  Liu</span>, <span class="hlFld-ContribAuthor ">Tingting  Yao</span>, <span class="hlFld-ContribAuthor ">Xiaowu  Dong</span>, <span class="hlFld-ContribAuthor ">Chunqi  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Discriminatory analysis based molecular docking study for in silico identification of epigallocatechin-3-gallate (EGCG) derivatives as B-Raf
              V600E
              inhibitors. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2017,</strong> <em>7 </em>
                                    (71)
                                     , 44820-44826. <a href="https://doi.org/10.1039/C7RA04788F" title="DOI URL">https://doi.org/10.1039/C7RA04788F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7RA04788F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7RA04788F%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DDiscriminatory%252Banalysis%252Bbased%252Bmolecular%252Bdocking%252Bstudy%252Bfor%252Bin%252Bsilico%252Bidentification%252Bof%252Bepigallocatechin-3-gallate%252B%252528EGCG%252529%252Bderivatives%252Bas%252BB-Raf%252BV600E%252Binhibitors%26aulast%3DYing%26aufirst%3DHuazhou%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D71%26spage%3D44820%26epage%3D44826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E. V.  Koroleva</span>, <span class="hlFld-ContribAuthor ">Zh. I.  Ignatovich</span>, <span class="hlFld-ContribAuthor ">Yu. V.  Sinyutich</span>, <span class="hlFld-ContribAuthor ">K. N.  Gusak</span>. </span><span class="cited-content_cbyCitation_article-title">Aminopyrimidine derivatives as protein kinases inhibitors. Molecular design, synthesis, and biologic activity. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>52 </em>
                                    (2)
                                     , 139-177. <a href="https://doi.org/10.1134/S1070428016020019" title="DOI URL">https://doi.org/10.1134/S1070428016020019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428016020019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428016020019%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAminopyrimidine%252Bderivatives%252Bas%252Bprotein%252Bkinases%252Binhibitors.%252BMolecular%252Bdesign%25252C%252Bsynthesis%25252C%252Band%252Bbiologic%252Bactivity%26aulast%3DKoroleva%26aufirst%3DE.%2BV.%26date%3D2016%26date%3D2016%26volume%3D52%26issue%3D2%26spage%3D139%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">G. M.  Verkhivker</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular dynamics simulations and modelling of the residue interaction networks in the BRAF kinase complexes with small molecule inhibitors: probing the allosteric effects of ligand-induced kinase dimerization and paradoxical activation. </span><span class="cited-content_cbyCitation_journal-name">Molecular BioSystems</span><span> <strong>2016,</strong> <em>12 </em>
                                    (10)
                                     , 3146-3165. <a href="https://doi.org/10.1039/C6MB00298F" title="DOI URL">https://doi.org/10.1039/C6MB00298F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6MB00298F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6MB00298F%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520BioSystems%26atitle%3DMolecular%252Bdynamics%252Bsimulations%252Band%252Bmodelling%252Bof%252Bthe%252Bresidue%252Binteraction%252Bnetworks%252Bin%252Bthe%252BBRAF%252Bkinase%252Bcomplexes%252Bwith%252Bsmall%252Bmolecule%252Binhibitors%25253A%252Bprobing%252Bthe%252Ballosteric%252Beffects%252Bof%252Bligand-induced%252Bkinase%252Bdimerization%252Band%252Bparadoxical%252Bactivation%26aulast%3DVerkhivker%26aufirst%3DG.%2BM.%26date%3D2016%26date%3D2016%26volume%3D12%26issue%3D10%26spage%3D3146%26epage%3D3165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao-Meng  Wang</span>, <span class="hlFld-ContribAuthor ">Min-Hang  Xin</span>, <span class="hlFld-ContribAuthor ">Jing  Xu</span>, <span class="hlFld-ContribAuthor ">Bo-Rui  Kang</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">She-Min  Lu</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>96 </em>, 382-395. <a href="https://doi.org/10.1016/j.ejmech.2015.04.037" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.04.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.04.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.04.037%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bantitumor%252Bactivities%252Bevaluation%252Bof%252Bm-%2525284-morpholinoquinazolin-2-yl%252529benzamides%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%26aulast%3DWang%26aufirst%3DXiao-Meng%26date%3D2015%26volume%3D96%26spage%3D382%26epage%3D395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy J.  Snape</span>, <span class="hlFld-ContribAuthor ">Tracy  Warr</span>. </span><span class="cited-content_cbyCitation_article-title">Approaches Toward Improving the Prognosis of Pediatric Patients With Glioma: Pursuing Mutant Drug Targets With Emerging Small Molecules. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Pediatric Neurology</span><span> <strong>2015,</strong> <em>22 </em>
                                    (1)
                                     , 28-34. <a href="https://doi.org/10.1016/j.spen.2014.12.003" title="DOI URL">https://doi.org/10.1016/j.spen.2014.12.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.spen.2014.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.spen.2014.12.003%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Pediatric%2520Neurology%26atitle%3DApproaches%252BToward%252BImproving%252Bthe%252BPrognosis%252Bof%252BPediatric%252BPatients%252BWith%252BGlioma%25253A%252BPursuing%252BMutant%252BDrug%252BTargets%252BWith%252BEmerging%252BSmall%252BMolecules%26aulast%3DSnape%26aufirst%3DTimothy%2BJ.%26date%3D2015%26volume%3D22%26issue%3D1%26spage%3D28%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maurizio  Pulici</span>, <span class="hlFld-ContribAuthor ">Gabriella  Traquandi</span>, <span class="hlFld-ContribAuthor ">Chiara  Marchionni</span>, <span class="hlFld-ContribAuthor ">Michele  Modugno</span>, <span class="hlFld-ContribAuthor ">Rosita  Lupi</span>, <span class="hlFld-ContribAuthor ">Nadia  Amboldi</span>, <span class="hlFld-ContribAuthor ">Elena  Casale</span>, <span class="hlFld-ContribAuthor ">Nicoletta  Colombo</span>, <span class="hlFld-ContribAuthor ">Luca  Corti</span>, <span class="hlFld-ContribAuthor ">Marina  Fasolini</span>, <span class="hlFld-ContribAuthor ">Fabio  Gasparri</span>, <span class="hlFld-ContribAuthor ">Wilma  Pastori</span>, <span class="hlFld-ContribAuthor ">Alessandra  Scolaro</span>, <span class="hlFld-ContribAuthor ">Daniele  Donati</span>, <span class="hlFld-ContribAuthor ">Eduard  Felder</span>, <span class="hlFld-ContribAuthor ">Arturo  Galvani</span>, <span class="hlFld-ContribAuthor ">Antonella  Isacchi</span>, <span class="hlFld-ContribAuthor ">Enrico  Pesenti</span>, <span class="hlFld-ContribAuthor ">Marina  Ciomei</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization of Diarylthiazole B-Raf Inhibitors: Identification of a Compound Endowed with High Oral Antitumor Activity, Mitigated hERG Inhibition, and Low Paradoxical Effect. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2015,</strong> <em>10 </em>
                                    (2)
                                     , 276-295. <a href="https://doi.org/10.1002/cmdc.201402424" title="DOI URL">https://doi.org/10.1002/cmdc.201402424</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201402424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201402424%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DOptimization%252Bof%252BDiarylthiazole%252BB-Raf%252BInhibitors%25253A%252BIdentification%252Bof%252Ba%252BCompound%252BEndowed%252Bwith%252BHigh%252BOral%252BAntitumor%252BActivity%25252C%252BMitigated%252BhERG%252BInhibition%25252C%252Band%252BLow%252BParadoxical%252BEffect%26aulast%3DPulici%26aufirst%3DMaurizio%26date%3D2015%26date%3D2014%26volume%3D10%26issue%3D2%26spage%3D276%26epage%3D295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D. Suresh  Babu</span>, <span class="hlFld-ContribAuthor ">Doddaga  Srinivasulu</span>, <span class="hlFld-ContribAuthor ">Venkata S.  Kotakadi</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of novel N-aryl-4-[6-(2-fluoropyridin-3-yl)quinazolin-2-yl]-piperazine-1-carboxamide or -carbothioamide derivatives and their antimicrobial activity. </span><span class="cited-content_cbyCitation_journal-name">Chemistry of Heterocyclic Compounds</span><span> <strong>2015,</strong> <em>51 </em>
                                    (1)
                                     , 60-66. <a href="https://doi.org/10.1007/s10593-015-1660-2" title="DOI URL">https://doi.org/10.1007/s10593-015-1660-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10593-015-1660-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10593-015-1660-2%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520of%2520Heterocyclic%2520Compounds%26atitle%3DSynthesis%252Bof%252Bnovel%252BN-aryl-4-%25255B6-%2525282-fluoropyridin-3-yl%252529quinazolin-2-yl%25255D-piperazine-1-carboxamide%252Bor%252B-carbothioamide%252Bderivatives%252Band%252Btheir%252Bantimicrobial%252Bactivity%26aulast%3DBabu%26aufirst%3DD.%2BSuresh%26date%3D2015%26date%3D2015%26volume%3D51%26issue%3D1%26spage%3D60%26epage%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weimin  Yang</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, <span class="hlFld-ContribAuthor ">Xiang  Zhou</span>, <span class="hlFld-ContribAuthor ">Yazhou  Gu</span>, <span class="hlFld-ContribAuthor ">Wenqi  Qian</span>, <span class="hlFld-ContribAuthor ">Fan  Zhang</span>, <span class="hlFld-ContribAuthor ">Wei  Han</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Weifang  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>89 </em>, 581-596. <a href="https://doi.org/10.1016/j.ejmech.2014.10.039" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.10.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.10.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.10.039%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bbis-aryl%252Bureas%252Band%252Bamides%252Bbased%252Bon%252B2-amino-3-purinylpyridine%252Bscaffold%252Bas%252BDFG-out%252BB-Raf%252Bkinase%252Binhibitors%26aulast%3DYang%26aufirst%3DWeimin%26date%3D2015%26volume%3D89%26spage%3D581%26epage%3D596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo  Chao</span>, <span class="hlFld-ContribAuthor ">Bingbing X.  Li</span>, <span class="hlFld-ContribAuthor ">Xiangshu  Xiao</span>. </span><span class="cited-content_cbyCitation_article-title">The chemistry and pharmacology of privileged pyrroloquinazolines. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2015,</strong> <em>6 </em>
                                    (4)
                                     , 510-520. <a href="https://doi.org/10.1039/C4MD00485J" title="DOI URL">https://doi.org/10.1039/C4MD00485J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4MD00485J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4MD00485J%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DThe%252Bchemistry%252Band%252Bpharmacology%252Bof%252Bprivileged%252Bpyrroloquinazolines%26aulast%3DChao%26aufirst%3DBo%26date%3D2015%26date%3D2015%26volume%3D6%26issue%3D4%26spage%3D510%26epage%3D520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Imtiaz  Khan</span>, <span class="hlFld-ContribAuthor ">Aliya  Ibrar</span>, <span class="hlFld-ContribAuthor ">Naeem  Abbas</span>, <span class="hlFld-ContribAuthor ">Aamer  Saeed</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the structural library of functionalized quinazoline and quinazolinone scaffolds: Synthetic approaches and multifarious applications. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>76 </em>, 193-244. <a href="https://doi.org/10.1016/j.ejmech.2014.02.005" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.02.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.02.005%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bstructural%252Blibrary%252Bof%252Bfunctionalized%252Bquinazoline%252Band%252Bquinazolinone%252Bscaffolds%25253A%252BSynthetic%252Bapproaches%252Band%252Bmultifarious%252Bapplications%26aulast%3DKhan%26aufirst%3DImtiaz%26date%3D2014%26volume%3D76%26spage%3D193%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hala Bakr  El-Nassan</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress in the identification of BRAF inhibitors as anti-cancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>72 </em>, 170-205. <a href="https://doi.org/10.1016/j.ejmech.2013.11.018" title="DOI URL">https://doi.org/10.1016/j.ejmech.2013.11.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2013.11.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2013.11.018%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bin%252Bthe%252Bidentification%252Bof%252BBRAF%252Binhibitors%252Bas%252Banti-cancer%252Bagents%26aulast%3DEl-Nassan%26aufirst%3DHala%2BBakr%26date%3D2014%26volume%3D72%26spage%3D170%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. AstraZeneca B-Raf inhibitors <b>1</b>–<b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0011.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Aminoquinazolines <b>3</b> and <b>24</b>–<b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) guanidine carbonate, DMA, 140 °C; (b) Pd(PPh<sub>3</sub>)<sub>4</sub> (20 mol %), K<sub>2</sub>CO<sub>3</sub>, ArB(OH)<sub>2</sub>, DME/water, 90 °C; (c) <b>17</b>–<b>23</b>, Pd<sub>2</sub>(dba)<sub>3</sub> (5 mol %), BINAP (10 mol %), Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 100 °C.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0012.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Aminoquinazolines <b>48</b>–<b>50</b> and <b>51</b>–<b>58</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd<sub>2</sub>(dba)<sub>3</sub> (10 mol %), BINAP (20 mol %), Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 100 °C; (b) amine (1.1 equiv), MeOH, 3 Å MS, HOAc (catalytic amount), NaBH<sub>3</sub>CN (1.6 equiv), rt, 12 h then 1 N NaOH; (c) <b>41–47</b>, Xantphos (10 mol %), Cs<sub>2</sub>CO<sub>3</sub> (3.0 equiv), dioxane, Pd(OAc)<sub>2</sub>,160 °C, microwave. For preparation of <b>51</b> and <b>53</b>, see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. 1-[2-(4-Bromophenoxy)ethyl]pyrrolidine was commercially available.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0013.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Aminoquinazolines <b>67</b>–<b>71</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) method A or B [method A, <i>N</i>-(4-aminophenyl)-<i>N</i>-methylacetamide or <i>N</i>-(4-aminophenyl)acetamide (1.5 equiv), MeCN, 125 °C, microwave, 30 min; method B, <b>59–61</b>, propan-2-ol, 100 °C, 2 h]; (b) 4-pyridinylboronic acid (1.5 equiv), Cs<sub>2</sub>CO<sub>3</sub> or K<sub>2</sub>CO<sub>3</sub> (3.0 equiv), dioxane/water or DME/water (4/1), Pd(PPh<sub>3</sub>)<sub>4</sub>or PdCI<sub>2</sub>(dppf)-CH<sub>2</sub>CI<sub>2</sub> (0.1 equiv), 100 °C.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0014.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Aminoquinazoline Analogues <b>75</b>–<b>84</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) <b>72</b>, Xantphos (10 mol %), Cs<sub>2</sub>CO<sub>3</sub> (3.0 equiv), dioxane, Pd(OAc)<sub>2</sub> (5 mol %), 100 °C, 4 h; (ii) 2 N HCl in ether. (b) For compounds <b>75</b>–<b>76</b> and <b>78–80</b>, (i) carboxylic acid, DIPEA, HATU, DMF, 60 °C; (ii) 4 M HCl in dioxane or 2 N HCl in ether, rt; for compounds <b>81</b>, <b>82</b>, cyclohexane- or cyclopentane-1,3-dione (3 equiv), HOAc, DIPEA, MeOH, 60 °C, 12 h; for compound <b>83</b>, piperidine-2,4-dione, DMF, microwave, 150 °C; for preparation of <b>77</b>, see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. (c) (i) NaBH<sub>4</sub> (1.8 equiv), MeCN, benzyl carbonochloridate (1.2 equiv), 0 °C, dioxane; (ii) 4 M HCl in dioxane, rt. (d) (i) <b>73</b>, HOAc, NMP, 105 °C, 6 h; (ii) Pearlman’s catalyst (15 mol %), MeOH, rt, H<sub>2</sub>, 1 atm.</p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0015.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Preparation of Aminoquinazolines <b>87</b> and <b>97</b>–<b>101</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>85</b>, propan-2-ol, reflux, 3 h then DIPEA, reflux. (b) Pd(PPh<sub>3</sub>)<sub>4</sub>, Cs<sub>2</sub>CO<sub>3</sub>, 4-pyridinylboronic acid, dioxane/water (2/1), 90 °C. (c) <b>72</b>, Pd(OAc)<sub>2</sub> (5 mol %), Xantphos (10 mol %), Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 100 °C. (d) (i) HCl/THF or 4 N HCl/dioxane; (ii) NEt<sub>3</sub>, Ac<sub>2</sub>O, rt. (e) (i) <b>95</b>, <b>96</b>, methyl boronic acid, K<sub>2</sub>CO<sub>3</sub> (3.0 equiv), dioxane, Pd(OAc)<sub>2</sub>(4 mol %), PCy<sub>3</sub>-HBF<sub>4</sub> (10 mol %), 100 °C, 12 h; (ii) HCl/THF; (iii) NEt<sub>3</sub>, Ac<sub>2</sub>O, rt.</p></p></figure><figure data-id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Cocrystallization of <b>3</b> in EphB4, which was used as a surrogate to mutant B-Raf, illustrates the compound binding in a DFG-in manner in the ATP site of the kinase domain of the protein. The structure has been deposited in the Protein Data Bank (reference code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4bb4">4bb4</a>). (B) Proposed plan for aminoquinazoline exploration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Millipore KinaseProfiler selectivity screening of a diverse kinase set (<i>n</i> = 83) at 1 μM of <b>3</b> and <b>30</b>, with hits overlaid on the kinome phylogenetic tree. Red circles indicate active hits ≤35% of control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Biochemical inhibitory profile of <b>2</b> and <b>3</b>. For a more detailed description of the biochemical differences of <b>2</b> and <b>3</b> with regard to substrate ATP concentration, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>. (B) Antiproliferative activity of B-Raf inhibitors <b>2</b> and <b>3</b> against a panel of various cell lines. Cells were incubated with DMSO or compounds <b>2</b> or <b>3</b> for 72 h and cell growth was determined by MTS assay, represented as log mean GI<sub>50</sub> (average of three replicates). Cell lines denoted with an asterisk (*) harbor the B-Raf<sup>V600E</sup> mutation. For a complete listing of cell line type, further observations around the proliferation profile, and additional MTS assay details, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0007.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray structure of <b>48</b> bound to the kinase domain of mutant B-Raf<sup>V600E</sup>. The structure has been deposited in the Protein Data Bank (reference code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4H58">4H58</a>), and detailed protein preparation, crystallization, and freezing protocols are included in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0008.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Evaluation of pERK in A549 cell lines. Cells were collected following a 75 min treatment with DMSO or compound at the indicated doses (0.1-, 1-, 10-, and 100-fold the A375 pERK IC<sub>50</sub>). pERK refers to phospho-ERK levels and tERK represents total-ERK levels. Western blotting analyses were performed using antibodies against the indicated proteins. <b>102</b> was used as a positive control in this study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0009.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vitro pERK evaluation in multiple nonmutant B-Raf cell lines. Cells were collected following 75 min treatment with DMSO or compound at the indicated doses (1-, 10-, and 100-fold the A375 pERK IC<sub>50</sub>). Western blotting analysis was performed using antibodies against the indicated proteins. pERK refers to phospho-ERK levels and tERK represents total-ERK levels. <b>102</b> was used as a positive control in this study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/medium/jm-2012-01658d_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0010.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) A375 xenograft dose–response mouse PD of compound <b>58</b> at 2 h post po single dose. Tumors and plasma were harvested 2 h after dosing. Western blotting was performed on tumor samples to determine pERK inhibition. An equal amount of protein was loaded into each well and total ERK (tERK) was used for further normalization. (B) Percent reduction in pERK from the A375 xenograft dose–response mouse PD. For additional details including plasma concentration information, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>. (C) A375 mouse xenograft tumor growth inhibition study with <b>58</b> (<i>n</i> = 5) dosed at 25 mg/kg po BID for 10.5 days. The vehicle group (<i>n</i> = 8) received 0.5% HPMC. Tumor volume and body weights were measured twice weekly. For additional details, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301658d/production/images/large/jm-2012-01658d_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301658d&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i129">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78626" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78626" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 31 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Peyssonnaux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eychene, A.</span><span> </span><span class="NLM_article-title">The Raf/MEK/ERK pathway: New concepts of activation</span> <span class="citation_source-journal">Biol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1016%2FS0248-4900%2801%2901125-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=11730323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptVOju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2001&pages=53-62&author=C.+Peyssonnauxauthor=A.+Eychene&title=The+Raf%2FMEK%2FERK+pathway%3A+New+concepts+of+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Raf/MEK/ERK pathway: New concepts of activation</span></div><div class="casAuthors">Peyssonnaux, Carole; Eychene, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Biology of the Cell</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">53-62</span>CODEN:
                <span class="NLM_cas:coden">BCELDF</span>;
        ISSN:<span class="NLM_cas:issn">0248-4900</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review.  The Raf/MEK/ERK signaling was the first MAP kinase cascade to be characterized.  It is probably one of the most well known signal transduction pathways among biologists because of its implication in a wide variety of cellular functions as diverse -and occasionally contradictory- as cell proliferation, cell-cycle arrest, terminal differentiation and apoptosis.  Discovery and understanding of this pathway have benefited from the combination of both genetic studies in worms and flies and biochem. studies in mammalian cells.  However, ten years after, this field is still under debate and new mol. partners in the cascade continue to increase the complexity of its regulation.  This review deals with the emergence of new concepts in the activation and regulation of the Raf/MEK/ERK module.  In particular, the preponderant role of B-Raf is underlined, and the role of novel regulators such as KSR is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyjiXSFlBQ6rVg90H21EOLACvtfcHk0ljW4jV0iMQJhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptVOju7s%253D&md5=cde3db5b205a1305dc2e6262deea65ec</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0248-4900%2801%2901125-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0248-4900%252801%252901125-X%26sid%3Dliteratum%253Aachs%26aulast%3DPeyssonnaux%26aufirst%3DC.%26aulast%3DEychene%26aufirst%3DA.%26atitle%3DThe%2520Raf%252FMEK%252FERK%2520pathway%253A%2520New%2520concepts%2520of%2520activation%26jtitle%3DBiol.%2520Cell%26date%3D2001%26volume%3D93%26spage%3D53%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Wellbrook, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karasarides, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">The RAF proteins take centre stage</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">–</span> <span class="NLM_lpage">885</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1038%2Fnrm1498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=15520807" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=875-885&author=C.+Wellbrookauthor=M.+Karasaridesauthor=R.+Marais&title=The+RAF+proteins+take+centre+stage"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrm1498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1498%26sid%3Dliteratum%253Aachs%26aulast%3DWellbrook%26aufirst%3DC.%26aulast%3DKarasarides%26aufirst%3DM.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DThe%2520RAF%2520proteins%2520take%2520centre%2520stage%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2004%26volume%3D5%26spage%3D875%26epage%3D885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Davies, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bignell, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clegg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teague, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woffendin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottomley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dicks, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmidou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzies, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mould, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayatilake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gusterson, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargrave, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard-Jones, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maitland, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenevix-Trench, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggins, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigner, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cossu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J. W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seigler, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darrow, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futreal, P. A.</span><span> </span><span class="NLM_article-title">Mutations of the BRAF gene in human cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">417</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">954</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1038%2Fnature00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=12068308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=949-954&author=H.+Daviesauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S.+Edkinsauthor=S.+Cleggauthor=J.+Teagueauthor=H.+Woffendinauthor=M.+J.+Garnettauthor=W.+Bottomleyauthor=N.+Davisauthor=E.+Dicksauthor=R.+Ewingauthor=Y.+Floydauthor=K.+Grayauthor=S.+Hallauthor=R.+Hawesauthor=J.+Hughesauthor=V.+Kosmidouauthor=A.+Menziesauthor=C.+Mouldauthor=A.+Parkerauthor=C.+Stevensauthor=S.+Wattauthor=S.+Hooperauthor=R.+Wilsonauthor=H.+Jayatilakeauthor=B.+A.+Gustersonauthor=C.+Cooperauthor=J.+Shipleyauthor=D.+Hargraveauthor=K.+Pritchard-Jonesauthor=N.+Maitlandauthor=G.+Chenevix-Trenchauthor=G.+J.+Rigginsauthor=D.+D.+Bignerauthor=G.+Palmieriauthor=A.+Cossuauthor=A.+Flanaganauthor=A.+Nicholsonauthor=J.+W.+C.+Hoauthor=S.+Y.+Leungauthor=S.+T.+Yuenauthor=B.+L.+Weberauthor=H.+F.+Seiglerauthor=T.+L.+Darrowauthor=H.+Patersonauthor=R.+Maraisauthor=C.+J.+Marshallauthor=R.+Woosterauthor=M.+R.+Strattonauthor=P.+A.+Futreal&title=Mutations+of+the+BRAF+gene+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the BRAF gene in human cancer</span></div><div class="casAuthors">Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian; Hall, Sarah; Hawes, Rachel; Hughes, Jaime; Kosmidou, Vivian; Menzies, Andrew; Mould, Catherine; Parker, Adrian; Stevens, Claire; Watt, Stephen; Hooper, Steven; Wilson, Rebecca; Jayatilake, Hiran; Gusterson, Barry A.; Cooper, Colin; Shipley, Janet; Hargrave, Darren; Pritchard-Jones, Katherine; Maitland, Norman; Chenevix-Trench, Georgia; Riggins, Gregory J.; Bigner, Darell D.; Palmieri, Giuseppe; Cossu, Antonio; Flanagan, Adrienne; Nicholson, Andrew; Ho, Judy W. C.; Leung, Suet Y.; Yuen, Siu T.; Weber, Barbara L.; Seigler, Hilliard F.; Darrow, Timothy L.; Paterson, Hugh; Marais, Richard; Marshall, Christopher J.; Wooster, Richard; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6892</span>),
    <span class="NLM_cas:pages">949-954</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancers arise owing to the accumulation of mutations in crit. genes that alter normal programs of cell proliferation, differentiation and death.  As the first stage of a systematic genome-wide screen for these genes, we have prioritized for anal. signalling pathways in which at least one gene is mutated in human cancer.  The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular responses to growth signals.  RAS is mutated to an oncogenic form in about 15% of human cancer.  The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS.  Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers.  All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%.  Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.  Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.  As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBmhJC0GAjrVg90H21EOLACvtfcHk0ljW4jV0iMQJhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D&md5=4625be53ad9a382d51b6ee753d0c17e8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnature00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature00766%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DClegg%26aufirst%3DS.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWoffendin%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DBottomley%26aufirst%3DW.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DDicks%26aufirst%3DE.%26aulast%3DEwing%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DHawes%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DKosmidou%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DA.%26aulast%3DMould%26aufirst%3DC.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DJayatilake%26aufirst%3DH.%26aulast%3DGusterson%26aufirst%3DB.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DPritchard-Jones%26aufirst%3DK.%26aulast%3DMaitland%26aufirst%3DN.%26aulast%3DChenevix-Trench%26aufirst%3DG.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DJ.%2BW.%2BC.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSeigler%26aufirst%3DH.%2BF.%26aulast%3DDarrow%26aufirst%3DT.%2BL.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520of%2520the%2520BRAF%2520gene%2520in%2520human%2520cancer%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D949%26epage%3D954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spevak, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shellooe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span> </span><span class="NLM_article-title">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">467</span><span class="NLM_x">, </span> <span class="NLM_fpage">596</span><span class="NLM_x">–</span> <span class="NLM_lpage">599</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1038%2Fnature09454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=20823850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=596-599&author=G.+Bollagauthor=P.+Hirthauthor=J.+Tsaiauthor=J.+Zhangauthor=P.+N.+Ibrahimauthor=H.+Choauthor=W.+Spevakauthor=C.+Zhangauthor=Y.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=G.+Tsangauthor=B.+L.+Westauthor=B.+Powellauthor=R.+Shellooeauthor=A.+Marimuthuauthor=H.+Nguyenauthor=K.+Y.+J.+Zhangauthor=D.+R.+Artisauthor=J.+Schlessingerauthor=F.+Suauthor=B.+Higginsauthor=R.+Iyerauthor=K.+D%E2%80%99Andreaauthor=A.+Koehlerauthor=M.+Stummauthor=P.+S.+Linauthor=R.+J.+Leeauthor=J.+Grippoauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+B.+Chapmanauthor=K.+T.+Flahertyauthor=X.+Xuauthor=K.+L.+Nathansonauthor=K.+Nolop&title=Clinical+efficacy+of+a+RAF+inhibitor+needs+broad+target+blockade+in+BRAF-mutant+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span></div><div class="casAuthors">Bollag, Gideon; Hirth, Peter; Tsai, James; Zhang, Jiazhong; Ibrahim, Prabha N.; Cho, Hanna; Spevak, Wayne; Zhang, Chao; Zhang, Ying; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Tsang, Garson; West, Brian L.; Powell, Ben; Shellooe, Rafe; Marimuthu, Adhirai; Nguyen, Hoa; Zhang, Kam Y. J.; Artis, Dean R.; Schlessinger, Joseph; Su, Fei; Higgins, Brian; Iyer, Raman; D'Andrea, Kurt; Koehler, Astrid; Stumm, Michael; Lin, Paul S.; Lee, Richard J.; Grippo, Joseph; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; Chapman, Paul B.; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.; Nolop, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">596-599</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B-RAF is the most frequently mutated protein kinase in human cancers.  The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway, offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients.  Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity.  Preclin. expts. demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts.  Toxicol. studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clin. trials using a cryst. formulation of PLX4032 (ref. 5).  In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following 2 wk of treatment.  This anal. revealed substantial inhibition of ERK phosphorylation, yet clin. evaluation did not show tumor regressions.  At higher drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK phosphorylation in the tumors of patients correlated with clin. response.  Indeed, the Phase 1 clin. data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily.  These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYwlns1EfcLVg90H21EOLACvtfcHk0lipzsZ3hEo_DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK&md5=8a26d0ab41970f39a109ddafff2f17b4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnature09454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09454%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DKoehler%26aufirst%3DA.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DNolop%26aufirst%3DK.%26atitle%3DClinical%2520efficacy%2520of%2520a%2520RAF%2520inhibitor%2520needs%2520broad%2520target%2520blockade%2520in%2520BRAF-mutant%2520melanoma%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D596%26epage%3D599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span> </span><span class="NLM_article-title">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2507</span><span class="NLM_x">–</span> <span class="NLM_lpage">2516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2010&pages=2507-2516&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthur&title=Improved+survival+with+vemurafenib+in+melanoma+with+BRAF+V600E+mutation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DImproved%2520survival%2520with%2520vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D364%26spage%3D2507%26epage%3D2516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Inhibition of mutated, activated BRAF in metastatic melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">819</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1056%2FNEJMoa1002011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=20818844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=809-819&author=K.+T.+Flahertyauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+B.+Chapman&title=Inhibition+of+mutated%2C+activated+BRAF+in+metastatic+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutated, activated BRAF in metastatic melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.  Methods: We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the max. dose that could be administered without adverse effects (the recommended phase 2 dose).  Patients received PLX4032 twice daily until they had disease progression.  Pharmacokinetic anal. and tumor-response assessments were conducted in all patients.  In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.  Results: A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 addnl. patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.  The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia.  In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.  Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response.  The estd. median progression-free survival among all patients was more than 7 mo.  Conclusions: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwq1fkvEjfyLVg90H21EOLACvtfcHk0liuT44M3SBKcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M&md5=80f70df0ac490828a42e6c7c0b40067f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002011%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DInhibition%2520of%2520mutated%252C%2520activated%2520BRAF%2520in%2520metastatic%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D809%26epage%3D819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Flaherty, K.; Puzanov, I.; Sosman, J.; Kim, K.; Ribas, A.; McArthur, G.; Lee, R. J.; Grippo, J. F.; Nolop, K.; Chapman, P.</span><span> </span><span class="NLM_article-title">Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span> (15S (May 20 Supplement)),  <span class="NLM_fpage">9000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=9000&author=K.+Flaherty&author=I.+Puzanov&author=J.+Sosman&author=K.+Kim&author=A.+Ribas&author=G.+McArthur&author=R.+J.+Lee&author=J.+F.+Grippo&author=K.+Nolop&author=P.+Chapman&title=Phase+I+study+of+PLX4032%3A+Proof+of+concept+for+V600E+BRAF+mutation+as+a+therapeutic+target+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%26atitle%3DPhase%2520I%2520study%2520of%2520PLX4032%253A%2520Proof%2520of%2520concept%2520for%2520V600E%2520BRAF%2520mutation%2520as%2520a%2520therapeutic%2520target%2520in%2520human%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D9000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="note"><p class="first last">For description of dabrafenib (GSK2118436, GlaxoSmithKline), a selective B-Raf inhibitor in advanced clinical studies, see:</p></div><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rheault, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stellwagen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjabeng, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornberger, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquerre, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossanese, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnone, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitherman, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane-Carson, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorthy, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, K. G</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehling, D. E.</span><span> </span><span class="NLM_article-title">Discovery of dabrafenib: a selective inhibitor of Raf kinases with antitumor activity against B-Raf-driven tumors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1021/ml4000063</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4000063" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=T.+R.+Rheaultauthor=J.+C.+Stellwagenauthor=G.+M.+Adjabengauthor=K.+R.+Hornbergerauthor=K.+G.+Petrovauthor=A.+G.+Watersonauthor=S.+H.+Dickersonauthor=R.+A.+Mookauthor=S.+G.+Laquerreauthor=A.+J.+Kingauthor=O.+W.+Rossaneseauthor=M.+R.+Arnoneauthor=K.+N.+Smithermanauthor=L.+S.+Kane-Carsonauthor=C.+Hanauthor=G.+S.+Moorthyauthor=K.+G+Mossauthor=D.+E.+Uehling&title=Discovery+of+dabrafenib%3A+a+selective+inhibitor+of+Raf+kinases+with+antitumor+activity+against+B-Raf-driven+tumors&doi=10.1021%2Fml4000063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1021%2Fml4000063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4000063%26sid%3Dliteratum%253Aachs%26aulast%3DRheault%26aufirst%3DT.%2BR.%26aulast%3DStellwagen%26aufirst%3DJ.%2BC.%26aulast%3DAdjabeng%26aufirst%3DG.%2BM.%26aulast%3DHornberger%26aufirst%3DK.%2BR.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DLaquerre%26aufirst%3DS.%2BG.%26aulast%3DKing%26aufirst%3DA.%2BJ.%26aulast%3DRossanese%26aufirst%3DO.%2BW.%26aulast%3DArnone%26aufirst%3DM.%2BR.%26aulast%3DSmitherman%26aufirst%3DK.%2BN.%26aulast%3DKane-Carson%26aufirst%3DL.%2BS.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DMoorthy%26aufirst%3DG.%2BS.%26aulast%3DMoss%26aufirst%3DK.%2BG%26aulast%3DUehling%26aufirst%3DD.%2BE.%26atitle%3DDiscovery%2520of%2520dabrafenib%253A%2520a%2520selective%2520inhibitor%2520of%2520Raf%2520kinases%2520with%2520antitumor%2520activity%2520against%2520B-Raf-driven%2520tumors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26doi%3D10.1021%2Fml4000063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kefford, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arkenau, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millward, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebowitz, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falchook, G. S.</span><span> </span><span class="NLM_article-title">Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x"> (</span><span class="NLM_issue">15 Suppl (May 20 Supplement)</span><span class="NLM_x">) </span> <span class="NLM_fpage">8503</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=8503&issue=15+Suppl+%28May+20+Supplement%29&author=R.+Keffordauthor=H.+T.+Arkenauauthor=M.+P.+Brownauthor=M.+Millwardauthor=J.+R.+Infanteauthor=G.+V.+Longauthor=D.+Ouelletauthor=M.+Curtisauthor=P.+F.+Lebowitzauthor=G.+S.+Falchook&title=Phase+I%2FII+study+of+GSK2118436%2C+a+selective+inhibitor+of+oncogenic+mutant+BRAF+kinase%2C+in+patients+with+metastatic+melanoma+and+other+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKefford%26aufirst%3DR.%26aulast%3DArkenau%26aufirst%3DH.%2BT.%26aulast%3DBrown%26aufirst%3DM.%2BP.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DCurtis%26aufirst%3DM.%26aulast%3DLebowitz%26aufirst%3DP.%2BF.%26aulast%3DFalchook%26aufirst%3DG.%2BS.%26atitle%3DPhase%2520I%252FII%2520study%2520of%2520GSK2118436%252C%2520a%2520selective%2520inhibitor%2520of%2520oncogenic%2520mutant%2520BRAF%2520kinase%252C%2520in%2520patients%2520with%2520metastatic%2520melanoma%2520and%2520other%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26issue%3D15%2520Suppl%2520%2528May%252020%2520Supplement%2529%26spage%3D8503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="note"><p class="first last">Recent reviews of B-Raf inhibitors and B-Raf targeted therapy:</p></div><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zambon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span> </span><span class="NLM_article-title">Small molecule inhibitors of BRAF in clinical trials</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">789</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=789-792&author=A.+Zambonauthor=I.+Niculescu-Duvazauthor=D.+Niculescu-Duvazauthor=R.+Maraisauthor=C.+J.+Springer&title=Small+molecule+inhibitors+of+BRAF+in+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DNiculescu-Duvaz%26aufirst%3DI.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520BRAF%2520in%2520clinical%2520trials%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D789%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kim, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span> </span><span class="NLM_article-title">Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics</span> <span class="citation_source-journal">Arch. Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">605</span><span class="NLM_x">–</span> <span class="NLM_lpage">615</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1007%2Fs12272-012-0403-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=22553052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVGrs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=605-615&author=D.+H.+Kimauthor=T.+Sim&title=Novel+small+molecule+Raf+kinase+inhibitors+for+targeted+cancer+therapeutics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics</span></div><div class="casAuthors">Kim, Do-Hee; Sim, Taebo</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Pharmacal Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">605-615</span>CODEN:
                <span class="NLM_cas:coden">APHRDQ</span>;
        ISSN:<span class="NLM_cas:issn">0253-6269</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Korea</span>)
        </div><div class="casAbstract">A review.  Aberrant activation of Raf signaling pathway is frequently found in various human tumors, it was considered as distinct and promising mol. target for cancer therapeutics.  B-Raf is most attractive drug target out of 3 Raf isoforms (A-Raf, B-Raf, and C-Raf) because it exhibits high kinase activity due to frequent mutations in human tumors.  However, most recently, it was reported that Raf isoforms show the cross-activation in the presence of specific B-Raf inhibitors, which brings about the paradoxical p-ERK activation as well as tumor promoting effect.  According to these findings, it remains controversy whether pan-Raf kinase inhibitor is more valuable and promising rather than specific B-Raf inhibitor under certain conditions in terms of cancer therapeutics.  In this short review, novel Raf kinase inhibitors undergoing clin. investigation are introduced.  Moreover, the paradoxical p-ERK activation is discussed with specific B-Raf inhibitors, PLX4032/4720 compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobCYC4QV-h9rVg90H21EOLACvtfcHk0ljVL4Wkw5lcDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVGrs7c%253D&md5=ee868003285c1e9f51388145ba1111a3</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1007%2Fs12272-012-0403-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12272-012-0403-5%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DSim%26aufirst%3DT.%26atitle%3DNovel%2520small%2520molecule%2520Raf%2520kinase%2520inhibitors%2520for%2520targeted%2520cancer%2520therapeutics%26jtitle%3DArch.%2520Pharm.%2520Res.%26date%3D2012%26volume%3D35%26spage%3D605%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Nimmagadda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tawbi, H.</span><span> </span><span class="NLM_article-title">RAF kinase inhibitors for the treatment of melanoma</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslyku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=63-68&author=N.+Nimmagaddaauthor=H.+Tawbi&title=RAF+kinase+inhibitors+for+the+treatment+of+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">RAF kinase inhibitors for the treatment of melanoma</span></div><div class="casAuthors">Nimmagadda, N.; Tawbi, H.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-68</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Malignant melanoma is one of the most lethal solid tumors unless detected early.  Malignant melanoma accounts for about 75% of skin cancer-related deaths.  Around 68,700 cases of new melanoma were diagnosed in 2009 in the U.S.  According to a World Health Organization report, about 48,000 melanoma-related deaths occur worldwide per yr.  In its early stages, melanoma can be treated surgically, leading to 5-yr survival rates exceeding 90%.  However, when it becomes metastatic, it is uniformly fatal, with 5-yr survival rates of < 2% and a median survival of 6-10 mo.  Recent advances in the understanding of the mol. heterogeneity offer the promise of a better future for drug development in melanoma.  The MAP kinase pathway is known to be assocd. with several human cancers, including malignant melanoma.  The MAP kinase pathway is activated through mutations in BRAF, and BRAF V600E is the most common among these mutations.  Targeted therapy involving B-raf inhibition was thought to yield promising results.  This review provides information on various B-raf inhibitors and the clin. impact these drugs may have in patients with melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI-2F-i7SC3rVg90H21EOLACvtfcHk0ljVL4Wkw5lcDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslyku7g%253D&md5=03c390bcc60ed43863a53728bf7dd8bf</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNimmagadda%26aufirst%3DN.%26aulast%3DTawbi%26aufirst%3DH.%26atitle%3DRAF%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520melanoma%26jtitle%3DDrugs%2520Future%26date%3D2011%26volume%3D36%26spage%3D63%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span> </span><span class="NLM_article-title">BRAF targeted therapy changes the treatment paradigm in melanoma</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">426</span><span class="NLM_x">–</span> <span class="NLM_lpage">433</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1038%2Fnrclinonc.2011.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=21606968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotleltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=426-433&author=A.+Ribasauthor=K.+T.+Flaherty&title=BRAF+targeted+therapy+changes+the+treatment+paradigm+in+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9dR"><div class="casContent"><span class="casTitleNuber">9d</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF targeted therapy changes the treatment paradigm in melanoma</span></div><div class="casAuthors">Ribas, Antoni; Flaherty, Keith T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">426-433</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Therapeutic advances in melanoma seem on the horizon, with the identification of BRAF as a principal therapeutic target.  The authors describe the scientific basis for the targeting of BRAF mutations in cancer, the early clin. data with BRAF inhibitors, and how combinatorial therapies may address the current limitations of their use in the clinic.  After decades of stagnation, recent therapeutic advances in melanoma seem on the horizon.  The discovery of the genetic underpinnings of this historically refractory disease has exposed potential targets for therapy, BRAF mutations being principal among them.  In the 8 years following the discovery of BRAF mutations in 50-60% of advanced melanomas, only recently have potent and selective inhibitors of this intracellular signaling mol. shown efficacy from early clin. testing.  Vemurafenib (PLX4032) and GSK2118436, two orally available and well tolerated agents are on the verge of transforming the landscape of melanoma therapy based on the promising results of their resp. phase I, II, and III trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnJ5nnopldxbVg90H21EOLACvtfcHk0ljwhX_WmcXwsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotleltrw%253D&md5=710ef1d3ccb02a0c80bf7f9b3fe935a7</span></div><a href="/servlet/linkout?suffix=cit9d&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2011.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2011.69%26sid%3Dliteratum%253Aachs%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DBRAF%2520targeted%2520therapy%2520changes%2520the%2520treatment%2520paradigm%2520in%2520melanoma%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D8%26spage%3D426%26epage%3D433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="note"><p class="first last">For a selection of representative recent examples of B-Raf inhibitors, see the following and references therein:</p></div><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ren, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahrendt, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newhouse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenglowsky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinkel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hastings, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rana, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasor, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturgis, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voegtli, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span> </span><span class="NLM_article-title">The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-Raf<sup>V600E</sup> kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3387</span><span class="NLM_x">–</span> <span class="NLM_lpage">3391</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3387-3391&author=L.+Renauthor=K.+A.+Ahrendtauthor=J.+Grinaauthor=E.+R.+Lairdauthor=A.+J.+Buckmelterauthor=J.+D.+Hansenauthor=B.+Newhouseauthor=D.+Morenoauthor=S.+Wenglowskyauthor=V.+Dinkelauthor=S.+L.+Gloorauthor=G.+Hastingsauthor=S.+Ranaauthor=K.+Rasorauthor=T.+Risomauthor=H.+L.+Sturgisauthor=W.+C.+Voegtliauthor=S.+Mathieu&title=The+discovery+of+potent+and+selective+pyridopyrimidin-7-one+based+inhibitors+of+B-RafV600E+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DL.%26aulast%3DAhrendt%26aufirst%3DK.%2BA.%26aulast%3DGrina%26aufirst%3DJ.%26aulast%3DLaird%26aufirst%3DE.%2BR.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DHansen%26aufirst%3DJ.%2BD.%26aulast%3DNewhouse%26aufirst%3DB.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DDinkel%26aufirst%3DV.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DHastings%26aufirst%3DG.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DRasor%26aufirst%3DK.%26aulast%3DRisom%26aufirst%3DT.%26aulast%3DSturgis%26aufirst%3DH.%2BL.%26aulast%3DVoegtli%26aufirst%3DW.%2BC.%26aulast%3DMathieu%26aufirst%3DS.%26atitle%3DThe%2520discovery%2520of%2520potent%2520and%2520selective%2520pyridopyrimidin-7-one%2520based%2520inhibitors%2520of%2520B-RafV600E%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3387%26epage%3D3391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ren, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinkel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newhouse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasor, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hastings, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradl, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, J.</span><span> </span><span class="NLM_article-title">Potent and selective pyrazolo[1,5-<i>a</i>]pyrimidine based inhibitors of B-Raf<sup>V600E</sup> kinase with favorable physicochemical and pharmacokinetic properties</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1165</span><span class="NLM_x">–</span> <span class="NLM_lpage">1168</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1165-1168&author=L.+Renauthor=E.+R.+Lairdauthor=A.+J.+Buckmelterauthor=V.+Dinkelauthor=S.+L.+Gloorauthor=J.+Grinaauthor=B.+Newhouseauthor=K.+Rasorauthor=G.+Hastingsauthor=S.+N.+Gradlauthor=J.+Rudolph&title=Potent+and+selective+pyrazolo%5B1%2C5-a%5Dpyrimidine+based+inhibitors+of+B-RafV600E+kinase+with+favorable+physicochemical+and+pharmacokinetic+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DL.%26aulast%3DLaird%26aufirst%3DE.%2BR.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DDinkel%26aufirst%3DV.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DGrina%26aufirst%3DJ.%26aulast%3DNewhouse%26aufirst%3DB.%26aulast%3DRasor%26aufirst%3DK.%26aulast%3DHastings%26aufirst%3DG.%26aulast%3DGradl%26aufirst%3DS.%2BN.%26aulast%3DRudolph%26aufirst%3DJ.%26atitle%3DPotent%2520and%2520selective%2520pyrazolo%255B1%252C5-a%255Dpyrimidine%2520based%2520inhibitors%2520of%2520B-RafV600E%2520kinase%2520with%2520favorable%2520physicochemical%2520and%2520pharmacokinetic%2520properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D1165%26epage%3D1168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradl, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner-Toste, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alicke, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinkel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hastings, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatzivassiliou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ran, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voegtli, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenglowsky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, J.</span><span> </span><span class="NLM_article-title">Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2869</span><span class="NLM_x">–</span> <span class="NLM_lpage">2881</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300016v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BC38XitlGjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2869-2881&author=S.+Mathieuauthor=S.+N.+Gradlauthor=L.+Renauthor=Z.+Wenauthor=I.+Aliagasauthor=J.+Gunzner-Tosteauthor=W.+Leeauthor=R.+Pulkauthor=G.+Zhaoauthor=B.+Alickeauthor=J.+W.+Boggsauthor=A.+J.+Buckmelterauthor=E.+F.+Chooauthor=V.+Dinkelauthor=S.+L.+Gloorauthor=S.+E.+Gouldauthor=J.+D.+Hansenauthor=G.+Hastingsauthor=G.+Hatzivassiliouauthor=E.+R.+Lairdauthor=D.+Morenoauthor=Y.+Ranauthor=W.+C.+Voegtliauthor=S.+Wenglowskyauthor=J.+Grinaauthor=J.+Rudolph&title=Potent+and+selective+aminopyrimidine-based+B-Raf+inhibitors+with+favorable+physicochemical+and+pharmacokinetic+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and Selective Aminopyrimidine-Based B-Raf Inhibitors with Favorable Physicochemical and Pharmacokinetic Properties</span></div><div class="casAuthors">Mathieu, Simon; Gradl, Stefan N.; Ren, Li; Wen, Zhaoyang; Aliagas, Ignacio; Gunzner-Toste, Janet; Lee, Wendy; Pulk, Rebecca; Zhao, Guiling; Alicke, Bruno; Boggs, Jason W.; Buckmelter, Alex J.; Choo, Edna F.; Dinkel, Victoria; Gloor, Susan L.; Gould, Stephen E.; Hansen, Joshua D.; Hastings, Gregg; Hatzivassiliou, Georgia; Laird, Ellen R.; Moreno, David; Ran, Yingqing; Voegtli, Walter C.; Wenglowsky, Steve; Grina, Jonas; Rudolph, Joachim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2869-2881</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent clin. data provided proof-of-concept for selective B-Raf inhibitors in treatment of B-RafV600E mutant melanoma.  Pyrazolopyridine-type B-Raf inhibitors previously described by the authors are potent and selective but exhibit low soly. requiring the use of amorphous dispersion-based formulation for achieving efficacious drug exposures.  Through structure-based design, a new class of highly potent aminopyrimidine-based B-Raf inhibitors was discovered with improved soly. and pharmacokinetic profiles.  The hinge binding moiety possesses a basic center imparting high soly. at gastric pH, addressing the dissoln. limitation obsd. with the previous series.  In our search for an optimal linker-hinge binding moiety system, amide-linked thieno[3,2-d]pyrimidine analogs I and II (G945), mols. with desirable physicochem. properties, emerged as lead compds. with strong efficacy in a B-RafV600E mutant mouse xenograft model.  Synthesis, SAR, lead selection, and evaluation of key compds. in animal studies will be described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos8je6g5RG6LVg90H21EOLACvtfcHk0ljwhX_WmcXwsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitlGjtbw%253D&md5=53373bfc102c5dfa271c4f429d11139a</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1021%2Fjm300016v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300016v%26sid%3Dliteratum%253Aachs%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DGradl%26aufirst%3DS.%2BN.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DWen%26aufirst%3DZ.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DAlicke%26aufirst%3DB.%26aulast%3DBoggs%26aufirst%3DJ.%2BW.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DChoo%26aufirst%3DE.%2BF.%26aulast%3DDinkel%26aufirst%3DV.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DGould%26aufirst%3DS.%2BE.%26aulast%3DHansen%26aufirst%3DJ.%2BD.%26aulast%3DHastings%26aufirst%3DG.%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DLaird%26aufirst%3DE.%2BR.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DVoegtli%26aufirst%3DW.%2BC.%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DGrina%26aufirst%3DJ.%26aulast%3DRudolph%26aufirst%3DJ.%26atitle%3DPotent%2520and%2520selective%2520aminopyrimidine-based%2520B-Raf%2520inhibitors%2520with%2520favorable%2520physicochemical%2520and%2520pharmacokinetic%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2869%26epage%3D2881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Packard, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggs, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tehrani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shevlin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrin-Ninkovic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilgraf, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarrick, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leisten, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moghaddam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cathers, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakata, S.</span><span> </span><span class="NLM_article-title">Discovery and optimization of thieno[2,3-<i>d</i>]pyrimidines as B-Raf inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">747</span><span class="NLM_x">–</span> <span class="NLM_lpage">752</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=747-752&author=G.+K.+Packardauthor=P.+Papaauthor=J.+R.+Riggsauthor=P.+Erdmanauthor=L.+Tehraniauthor=D.+Robinsonauthor=R.+Harrisauthor=G.+Shevlinauthor=S.+Perrin-Ninkovicauthor=R.+Hilgrafauthor=M.+A.+McCarrickauthor=T.+Tranauthor=Y.+Flemingauthor=A.+Baiauthor=S.+Richardsonauthor=J.+Katzauthor=Y.+Tangauthor=J.+Leistenauthor=M.+Moghaddamauthor=B.+Cathersauthor=D.+Zhuauthor=S.+Sakata&title=Discovery+and+optimization+of+thieno%5B2%2C3-d%5Dpyrimidines+as+B-Raf+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPackard%26aufirst%3DG.%2BK.%26aulast%3DPapa%26aufirst%3DP.%26aulast%3DRiggs%26aufirst%3DJ.%2BR.%26aulast%3DErdman%26aufirst%3DP.%26aulast%3DTehrani%26aufirst%3DL.%26aulast%3DRobinson%26aufirst%3DD.%26aulast%3DHarris%26aufirst%3DR.%26aulast%3DShevlin%26aufirst%3DG.%26aulast%3DPerrin-Ninkovic%26aufirst%3DS.%26aulast%3DHilgraf%26aufirst%3DR.%26aulast%3DMcCarrick%26aufirst%3DM.%2BA.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DFleming%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DA.%26aulast%3DRichardson%26aufirst%3DS.%26aulast%3DKatz%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DLeisten%26aufirst%3DJ.%26aulast%3DMoghaddam%26aufirst%3DM.%26aulast%3DCathers%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DD.%26aulast%3DSakata%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520thieno%255B2%252C3-d%255Dpyrimidines%2520as%2520B-Raf%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D747%26epage%3D752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Lyne, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aquila, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ezhuthachan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ioannidis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pontz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deegan, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Custeau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poondru, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, A.</span><span> </span><span class="NLM_article-title">Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1026</span><span class="NLM_x">–</span> <span class="NLM_lpage">1029</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1026-1029&author=P.+D.+Lyneauthor=B.+Aquilaauthor=D.+J.+Cookauthor=L.+A.+Dakinauthor=J.+Ezhuthachanauthor=S.+Ioannidisauthor=T.+Pontzauthor=M.+Suauthor=Q.+Yeauthor=X.+Zhengauthor=M.+H.+Blockauthor=S.+Cowenauthor=T.+L.+Deeganauthor=J.+W.+Leeauthor=D.+A.+Scottauthor=D.+Custeauauthor=L.+Drewauthor=S.+Poondruauthor=M.+Shenauthor=A.+Wu&title=Identification+of+amidoheteroaryls+as+potent+inhibitors+of+mutant+%28V600E%29+B-Raf+kinase+with+in+vivo+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLyne%26aufirst%3DP.%2BD.%26aulast%3DAquila%26aufirst%3DB.%26aulast%3DCook%26aufirst%3DD.%2BJ.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DEzhuthachan%26aufirst%3DJ.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DPontz%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DCowen%26aufirst%3DS.%26aulast%3DDeegan%26aufirst%3DT.%2BL.%26aulast%3DLee%26aufirst%3DJ.%2BW.%26aulast%3DScott%26aufirst%3DD.%2BA.%26aulast%3DCusteau%26aufirst%3DD.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DPoondru%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520amidoheteroaryls%2520as%2520potent%2520inhibitors%2520of%2520mutant%2520%2528V600E%2529%2520B-Raf%2520kinase%2520with%2520in%2520vivo%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1026%26epage%3D1029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Shen, M.; Wu, A.; Aquila, B.; Lyne, P.; Drew, L.</span><span> </span><span class="NLM_article-title">Linking molecular characteristics to the pharmacological response of a panel of cancer cell lines to the BRAF inhibitor, AZ628. Los Angeles, CA</span>. <i>AACR 98th Meeting</i><span class="NLM_x"> (</span><span class="NLM_year">2007</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+Shen&author=A.+Wu&author=B.+Aquila&author=P.+Lyne&author=L.+Drew&title=Linking+molecular+characteristics+to+the+pharmacological+response+of+a+panel+of+cancer+cell+lines+to+the+BRAF+inhibitor%2C+AZ628.+Los+Angeles%2C+CA"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DM.%26atitle%3DLinking%2520molecular%2520characteristics%2520to%2520the%2520pharmacological%2520response%2520of%2520a%2520panel%2520of%2520cancer%2520cell%2520lines%2520to%2520the%2520BRAF%2520inhibitor%252C%2520AZ628.%2520Los%2520Angeles%252C%2520CA%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Montagut, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shioda, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulkus, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stubbs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">4853</span><span class="NLM_x">–</span> <span class="NLM_lpage">4861</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=4853-4861&author=C.+Montagutauthor=S.+V.+Sharmaauthor=S.+T.+Shiodaauthor=U.+McDermottauthor=M.+Ulmanauthor=L.+E.+Ulkusauthor=D.+Dias-Santagataauthor=H.+Stubbsauthor=D.+Y.+Leeauthor=A.+Singhauthor=L.+Drewauthor=D.+A.+Haberauthor=J.+Settleman&title=Elevated+CRAF+as+a+potential+mechanism+of+acquired+resistance+to+BRAF+inhibition+in+melanoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMontagut%26aufirst%3DC.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DShioda%26aufirst%3DS.%2BT.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DUlman%26aufirst%3DM.%26aulast%3DUlkus%26aufirst%3DL.%2BE.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DStubbs%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DD.%2BY.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DElevated%2520CRAF%2520as%2520a%2520potential%2520mechanism%2520of%2520acquired%2520resistance%2520to%2520BRAF%2520inhibition%2520in%2520melanoma%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D4853%26epage%3D4861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="note"><p class="first last">For references comparing DFG-in and DFG-out binding, see:</p></div><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+structures+of+the+kinase+domain+of+c-Abl+in+complex+with+the+small+molecule+inhibitors+PD173955+and+imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0lgeMsvsm9QnQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520kinase%2520domain%2520of%2520c-Abl%2520in%2520complex%2520with%2520the%2520small%2520molecule%2520inhibitors%2520PD173955%2520and%2520imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newitt, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittekind, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzillerri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span> </span><span class="NLM_article-title">The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">5790</span><span class="NLM_x">–</span> <span class="NLM_lpage">5797</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=5790-5797&author=J.+S.+Tokarskiauthor=J.+A.+Newittauthor=C.+Y.+J.+Changauthor=J.+D.+Chengauthor=M.+Wittekindauthor=S.+E.+Kieferauthor=K.+Kishauthor=F.+Y.+F.+Leeauthor=R.+Borzillerriauthor=L.+J.+Lombardoauthor=D.+Xieauthor=Y.+Zhangauthor=H.+E.+Klei&title=The+structure+of+dasatinib+%28BMS-354825%29+bound+to+activated+ABL+kinase+domain+elucidates+its+inhibitory+activity+against+imatinib-resistant+ABL+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DChang%26aufirst%3DC.%2BY.%2BJ.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26aulast%3DWittekind%26aufirst%3DM.%26aulast%3DKiefer%26aufirst%3DS.%2BE.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DF.%2BY.%2BF.%26aulast%3DBorzillerri%26aufirst%3DR.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26atitle%3DThe%2520structure%2520of%2520dasatinib%2520%2528BMS-354825%2529%2520bound%2520to%2520activated%2520ABL%2520kinase%2520domain%2520elucidates%2520its%2520inhibitory%2520activity%2520against%2520imatinib-resistant%2520ABL%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D5790%26epage%3D5797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="note"><p class="first last">For recent studies highlighting MAPK pathway activation in cells containing wild type B-Raf through Raf dimerization, see:</p></div><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Heidorn, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milagre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nourry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhomen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis-Filho, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">140</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1016%2Fj.cell.2009.12.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=20141835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2010&pages=209-221&author=S.+J.+Heidornauthor=C.+Milagreauthor=S.+Whittakerauthor=A.+Nourryauthor=I.+Niculescu-Duvasauthor=N.+Dhomenauthor=J.+Hussainauthor=J.+S.+Reis-Filhoauthor=C.+J.+Springerauthor=C.+Pritchardauthor=R.+Marais&title=Kinase-dead+BRAF+and+oncogenic+RAS+cooperate+to+drive+tumor+progression+through+CRAF"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span></div><div class="casAuthors">Heidorn, Sonja J.; Milagre, Carla; Whittaker, Steven; Nourry, Arnaud; Niculescu-Duvas, Ion; Dhomen, Nathalie; Hussain, Jahan; Reis-Filho, Jorge S.; Springer, Caroline J.; Pritchard, Catrin; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-221</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We describe a mechanism of tumorigenesis mediated by kinase-dead BRAF in the presence of oncogenic RAS.  We show that drugs that selectively inhibit BRAF drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling.  This does not occur when oncogenic BRAF is inhibited, demonstrating that BRAF inhibition per se does not drive pathway activation; it only occurs when BRAF is inhibited in the presence of oncogenic RAS.  Kinase-dead BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice.  Our data reveal another paradigm of BRAF-mediated signaling that promotes tumor progression.  They highlight the importance of understanding pathway signaling in clin. practice and of genotyping tumors prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMSb6ckHpR07Vg90H21EOLACvtfcHk0lhodz4XbC3DHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D&md5=80af840cb978f5956b3d998b185115f4</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.12.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.12.040%26sid%3Dliteratum%253Aachs%26aulast%3DHeidorn%26aufirst%3DS.%2BJ.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DWhittaker%26aufirst%3DS.%26aulast%3DNourry%26aufirst%3DA.%26aulast%3DNiculescu-Duvas%26aufirst%3DI.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DHussain%26aufirst%3DJ.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DPritchard%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DKinase-dead%2520BRAF%2520and%2520oncogenic%2520RAS%2520cooperate%2520to%2520drive%2520tumor%2520progression%2520through%2520CRAF%26jtitle%3DCell%26date%3D2010%26volume%3D140%26spage%3D209%26epage%3D221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Poulikakos, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">464</span><span class="NLM_x">, </span> <span class="NLM_fpage">427</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=427-430&author=P.+I.+Poulikakosauthor=C.+Zhangauthor=G.+Bollagauthor=K.+M.+Shokatauthor=N.+Rosen&title=RAF+inhibitors+transactivate+RAF+dimers+and+ERK+signaling+in+cells+with+wild-type+BRAF"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DRAF%2520inhibitors%2520transactivate%2520RAF%2520dimers%2520and%2520ERK%2520signaling%2520in%2520cells%2520with%2520wild-type%2520BRAF%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D427%26epage%3D430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hatzivassiliou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarado, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludlam, M. J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaiswal, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seshagiri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span> </span><span class="NLM_article-title">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">464</span><span class="NLM_x">, </span> <span class="NLM_fpage">431</span><span class="NLM_x">–</span> <span class="NLM_lpage">436</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1038%2Fnature08833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=20130576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=431-436&author=G.+Hatzivassiliouauthor=K.+Songauthor=I.+Yenauthor=B.+J.+Brandhuberauthor=D.+J.+Andersonauthor=R.+Alvaradoauthor=M.+J.+C.+Ludlamauthor=D.+Stokoeauthor=S.+L.+Gloorauthor=G.+Vigersauthor=T.+Moralesauthor=I.+Aliagasauthor=B.+Liuauthor=S.+Siderisauthor=K.+P.+Hoeflichauthor=B.+S.+Jaiswalauthor=S.+Seshagiriauthor=H.+Koeppenauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=S.+Malek&title=RAF+inhibitors+prime+wild-type+RAF+to+activate+the+MAPK+pathway+and+enhance+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15cR"><div class="casContent"><span class="casTitleNuber">15c</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Song, Kyung; Yen, Ivana; Brandhuber, Barbara J.; Anderson, Daniel J.; Alvarado, Ryan; Ludlam, Mary J. C.; Stokoe, David; Gloor, Susan L.; Vigers, Guy; Morales, Tony; Aliagas, Ignacio; Liu, Bonnie; Sideris, Steve; Hoeflich, Klaus P.; Jaiswal, Bijay S.; Seshagiri, Somasekar; Koeppen, Hartmut; Belvin, Marcia; Friedman, Lori S.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">431-435</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in KRAS and BRAF are found in more than 30% of all human tumors and 40% of melanoma, resp., thus targeting this pathway could have broad therapeutic effects.  Small mol. ATP-competitive RAF kinase inhibitors have potent antitumor effects on mutant BRAF(V600E) tumors but, in contrast to mitogen-activated protein kinase kinase (MEK) inhibitors, are not potent against RAS mutant tumor models, despite RAF functioning as a key effector downstream of RAS and upstream of MEK.  Here we show that ATP-competitive RAF inhibitors have two opposing mechanisms of action depending on the cellular context.  In BRAF(V600E) tumors, RAF inhibitors effectively block the mitogen-activated protein kinase (MAPK) signalling pathway and decrease tumor growth.  Notably, in KRAS mutant and RAS/RAF wild-type tumors, RAF inhibitors activate the RAF-MEK-ERK pathway in a RAS-dependent manner, thus enhancing tumor growth in some xenograft models.  Inhibitor binding activates wild-type RAF isoforms by inducing dimerization, membrane localization and interaction with RAS-GTP.  These events occur independently of kinase inhibition and are, instead, linked to direct conformational effects of inhibitors on the RAF kinase domain.  On the basis of these findings, we demonstrate that ATP-competitive kinase inhibitors can have opposing functions as inhibitors or activators of signalling pathways, depending on the cellular context.  Furthermore, this work provides new insights into the therapeutic use of ATP-competitive RAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGounpcMETzVoLVg90H21EOLACvtfcHk0lhXU1sR49-RuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D&md5=eb48bdf352ee9c9e182e63e38fd820a5</span></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1038%2Fnature08833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08833%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DAlvarado%26aufirst%3DR.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%2BC.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DJaiswal%26aufirst%3DB.%2BS.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DRAF%2520inhibitors%2520prime%2520wild-type%2520RAF%2520to%2520activate%2520the%2520MAPK%2520pathway%2520and%2520enhance%2520growth%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D431%26epage%3D436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Carnahan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beltran, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babij, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vonderfecht, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagapudi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broome, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kha, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmontes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, T. L.</span><span> </span><span class="NLM_article-title">Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2399</span><span class="NLM_x">–</span> <span class="NLM_lpage">2410</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15d&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1158%2F1535-7163.MCT-10-0181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15d&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=20663930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15d&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2399-2410&author=J.+Carnahanauthor=P.+J.+Beltranauthor=C.+Babijauthor=Q.+Leauthor=M.+J.+Roseauthor=S.+Vonderfechtauthor=J.+L.+Kimauthor=A.+L.+Smithauthor=K.+Nagapudiauthor=M.+A.+Broomeauthor=M.+Fernandoauthor=H.+Khaauthor=B.+Belmontesauthor=R.+Radinskyauthor=R.+Kendallauthor=T.+L.+Burgess&title=Selective+and+potent+Raf+inhibitors+paradoxically+stimulate+normal+cell+proliferation+and+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15dR"><div class="casContent"><span class="casTitleNuber">15d</span><div class="casTitle"><span class="NLM_cas:atitle">Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth</span></div><div class="casAuthors">Carnahan, Josette; Beltran, Pedro J.; Babij, Carol; Le, Quynh; Rose, Mark J.; Vonderfecht, Steven; Kim, Joseph L.; Smith, Adrian L.; Nagapudi, Karthik; Broome, Martin A.; Fernando, Manory; Kha, Hue; Belmontes, Brian; Radinsky, Robert; Kendall, Richard; Burgess, Teresa L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2399-2410</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Raf inhibitors are under clin. investigation, specifically in patients with tumor types harboring frequent activating mutations in B-Raf.  Here, we show that cell lines and tumors harboring mutant B-Raf were sensitive to a novel series of Raf inhibitors (e.g., V600EB-Raf A375, IC50 on cells = 2 nmol/L; ED50 on tumor xenografts = 1.3 mg/kg).  However, in cells and tumors with wild-type B-Raf, exposure to Raf inhibitors resulted in a dose-dependent and sustained activation of mitogen-activated protein kinase signaling.  In some of these cell lines, Raf inhibition led to entry into the cell cycle, enhanced proliferation, and significantly stimulated tumor growth in vivo.  Inhibition with structurally distinct Raf inhibitors or isoform-specific small interfering RNA knockdown of Raf showed that these effects were mediated directly through Raf.  Either A-Raf or C-Raf mediated the Raf inhibitor-induced mitogen-activated protein kinase pathway activation in an inhibitor-specific manner.  These paradoxical effects of Raf inhibition were seen in malignant and normal cells in vitro and in vivo.  Hyperplasia of normal epithelial cells in the esophagus and the stomach was evident in mice with all efficacious Raf inhibitors (n = 8) tested.  An implication of these results is that Raf inhibitors may induce unexpected normal cell and tumor tissue proliferation in patients.  Mol Cancer Ther; 9(8); 2399-410.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN5Uws5uZF4rVg90H21EOLACvtfcHk0lhXU1sR49-RuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVOjt7g%253D&md5=c2958b3c22d623571dea9bedf6835834</span></div><a href="/servlet/linkout?suffix=cit15d&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0181%26sid%3Dliteratum%253Aachs%26aulast%3DCarnahan%26aufirst%3DJ.%26aulast%3DBeltran%26aufirst%3DP.%2BJ.%26aulast%3DBabij%26aufirst%3DC.%26aulast%3DLe%26aufirst%3DQ.%26aulast%3DRose%26aufirst%3DM.%2BJ.%26aulast%3DVonderfecht%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DSmith%26aufirst%3DA.%2BL.%26aulast%3DNagapudi%26aufirst%3DK.%26aulast%3DBroome%26aufirst%3DM.%2BA.%26aulast%3DFernando%26aufirst%3DM.%26aulast%3DKha%26aufirst%3DH.%26aulast%3DBelmontes%26aufirst%3DB.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DBurgess%26aufirst%3DT.%2BL.%26atitle%3DSelective%2520and%2520potent%2520Raf%2520inhibitors%2520paradoxically%2520stimulate%2520normal%2520cell%2520proliferation%2520and%2520tumor%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D2399%26epage%3D2410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Jones, J. D.</span><span> </span><span class="NLM_article-title">Quinazoline derivatives useful as intermediates</span>. Patent WO1992015569,<span class="NLM_x"> </span><span class="NLM_year">1992</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1992&author=J.+D.+Jones&title=Quinazoline+derivatives+useful+as+intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DJ.%2BD.%26atitle%3DQuinazoline%2520derivatives%2520useful%2520as%2520intermediates%26date%3D1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Jain, R.; Lin, X.; Ng, S. C.; Pfister, K. B.; Ramurthy, S.; Rico, A.; Subramanian, S.; Wang, X. M.</span><span> </span><span class="NLM_article-title">2-Arylaminoquinazolines for treating proliferative diseases</span>. Patent WO2009153313A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=R.+Jain&author=X.+Lin&author=S.+C.+Ng&author=K.+B.+Pfister&author=S.+Ramurthy&author=A.+Rico&author=S.+Subramanian&author=X.+M.+Wang&title=2-Arylaminoquinazolines+for+treating+proliferative+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DR.%26atitle%3D2-Arylaminoquinazolines%2520for%2520treating%2520proliferative%2520diseases%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><div class="note"><p class="first last">An EphB4 co-crystallization of <b>3</b> was readily obtained and used as a surrogate to B-Raf<sup>V600E</sup> due to its identical gatekeeper and similar binding site and selectivity pocket. We used this surrogate to guide initial hypotheses around the binding mode. Detailed protein preparation, crystallization, and freezing protocols are included in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> of the following report:</p></div><span class="NLM_contrib-group">Bardelle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davenport, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kettle, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortlock, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, E. J.</span><span> </span><span class="NLM_article-title">Inhibitors of the tyrosine kinase EphB4. Part 2: Structure-based discovery and optimization of 3,5-bis substituted anilinopyrimidines</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5717</span><span class="NLM_x">–</span> <span class="NLM_lpage">5721</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5717-5721&author=C.+Bardelleauthor=T.+Colemanauthor=D.+Crossauthor=S.+Davenportauthor=J.+G.+Kettleauthor=E.+J.+Koauthor=A.+G.+Leachauthor=A.+Mortlockauthor=J.+Readauthor=N.+J.+Robertsauthor=P.+Robinsauthor=E.+J.+Williams&title=Inhibitors+of+the+tyrosine+kinase+EphB4.+Part+2%3A+Structure-based+discovery+and+optimization+of+3%2C5-bis+substituted+anilinopyrimidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBardelle%26aufirst%3DC.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DCross%26aufirst%3DD.%26aulast%3DDavenport%26aufirst%3DS.%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DKo%26aufirst%3DE.%2BJ.%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DMortlock%26aufirst%3DA.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DN.%2BJ.%26aulast%3DRobins%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DE.%2BJ.%26atitle%3DInhibitors%2520of%2520the%2520tyrosine%2520kinase%2520EphB4.%2520Part%25202%253A%2520Structure-based%2520discovery%2520and%2520optimization%2520of%25203%252C5-bis%2520substituted%2520anilinopyrimidines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5717%26epage%3D5721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="note"><p class="first last">The KinaseProfiler panel testing was performed at Millipore, with data overlaid against the kinome phylogenetic tree using Millipore’s DART visualization tool.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="note"><p class="first last">For additional information around the biochemical profiles of <b>2</b> and <b>3</b>, cell line background, and tumor type, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><div class="note"><p class="first last">For a recent paper describing the concern around aromatic anilines and potential mutagenic concerns, see the following and references therein:</p></div><span class="NLM_contrib-group">Birch, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groombridge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mee, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schramm, C.</span><span> </span><span class="NLM_article-title">Rationally designing safer anilines: The challenging case of 4-aminobiphenyls</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">3923</span><span class="NLM_x">–</span> <span class="NLM_lpage">3933</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3001295" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3923-3933&author=A.+M.+Birchauthor=S.+Groombridgeauthor=R.+Lawauthor=A.+G.+Leachauthor=C.+D.+Meeauthor=C.+Schramm&title=Rationally+designing+safer+anilines%3A+The+challenging+case+of+4-aminobiphenyls"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm3001295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3001295%26sid%3Dliteratum%253Aachs%26aulast%3DBirch%26aufirst%3DA.%2BM.%26aulast%3DGroombridge%26aufirst%3DS.%26aulast%3DLaw%26aufirst%3DR.%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DMee%26aufirst%3DC.%2BD.%26aulast%3DSchramm%26aufirst%3DC.%26atitle%3DRationally%2520designing%2520safer%2520anilines%253A%2520The%2520challenging%2520case%2520of%25204-aminobiphenyls%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3923%26epage%3D3933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="note"><p class="first last">Chiral resolution of the enantiomers of <b>53</b> was performed and there was a 2-fold difference in cellular potency between the two enantiomers. Absolute confirmation of (<i>R</i>)- and (<i>S</i>)-enantiomers was not determined.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="note"><p class="first last">The (<i>S</i>)-enantiomer of <b>57</b> (not shown) had an IC<sub>50</sub> = 190 nM in the A375 pERK cell assay.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><div class="note"><p class="first last">We chose to switch to screening at 5 mM ATP concentration in the B-Raf<sup>V600E</sup> enzyme assay as we continued our lead optimization of the aminoquinazoline series and discontinued screening at <i>K</i><sub>m</sub> ATP concentrations (as reported by enzyme potencies shown in Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). We believed the higher ATP concentration was more representative of cellular ATP levels and provided a more robust enzyme-cell correlation. For additional details around the advantages of screening kinase inhibitors at various ATP concentrations, see the following paper and references therein:</p></div><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Features of selective kinase inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">621</span><span class="NLM_x">–</span> <span class="NLM_lpage">637</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1016%2Fj.chembiol.2005.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=15975507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=621-637&author=Z.+A.+Knightauthor=K.+M.+Shokat&title=Features+of+selective+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Features of Selective Kinase Inhibitors</span></div><div class="casAuthors">Knight, Zachary A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">621-637</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Summary: Small-mol. inhibitors of protein and lipid kinases have emerged as indispensable tools for studying signal transduction.  Despite the widespread use of these reagents, there is little consensus about the biochem. criteria that define their potency and selectivity in cells.  We discuss some of the features that det. the cellular activity of kinase inhibitors and propose a framework for interpreting inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAJWhVxtSrCLVg90H21EOLACvtfcHk0liBENv9iOlxfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D&md5=ce5b3505a0326b04479172ec05573152</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2005.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2005.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DFeatures%2520of%2520selective%2520kinase%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2005%26volume%3D12%26spage%3D621%26epage%3D637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Morgenthaler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweizer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann-Röder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaeschke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foischer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendels, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diederich, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, K.</span><span> </span><span class="NLM_article-title">Predicting and tuning physicochemical properties in lead optimization: Amine basicities</span> <span class="citation_source-journal">Chem. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1100</span><span class="NLM_x">–</span> <span class="NLM_lpage">1115</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1002%2Fcmdc.200700059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=17530727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1100-1115&author=M.+Morgenthalerauthor=E.+Schweizerauthor=A.+Hoffmann-R%C3%B6derauthor=F.+Beniniauthor=R.+E.+Martinauthor=G.+Jaeschkeauthor=B.+Wagnerauthor=H.+Foischerauthor=S.+Bendelsauthor=D.+Zimmerliauthor=J.+Schneiderauthor=F.+Diederichauthor=M.+Kansyauthor=K.+M%C3%BCller&title=Predicting+and+tuning+physicochemical+properties+in+lead+optimization%3A+Amine+basicities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span></div><div class="casAuthors">Morgenthaler, Martin; Schweizer, Eliane; Hoffmann-Roder, Anja; Benini, Fausta; Martin, Rainer E.; Jaeschke, Georg; Wagner, Bjorn; Fischer, Holger; Bendels, Stefanie; Zimmerli, Daniel; Schneider, Josef; Diederich, Francois; Kansy, Manfred; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1100-1115</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This review describes simple and useful concepts for predicting and tuning the pKa values of basic amine centers, a crucial step in the optimization of phys. and ADME properties of many lead structures in drug-discovery research.  The article starts with a case study of tricyclic thrombin inhibitors featuring a tertiary amine center with pKa values that can be tuned over a wide range, from the usual value of around 10 to below 2 by (remote) neighboring functionalities commonly encountered in medicinal chem.  Next, the changes in pKa of acyclic and cyclic amines upon substitution by fluorine, oxygen, nitrogen, and sulfur functionalities, as well as carbonyl and carboxyl derivs. are systematically analyzed, leading to the derivation of simple rules for pKa prediction.  Electronic and stereoelectronic effects in cyclic amines are discussed, and the emerging computational methods for pKa predictions are briefly surveyed.  The rules for tuning amine basicities should not only be of interest in drug-discovery research, but also to the development of new crop-protection agents, new amine ligands for organometallic complexes, and in particular, to the growing field of amine-based organocatalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodsWRMtrxWPbVg90H21EOLACvtfcHk0lhxarkhYX7w1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D&md5=478b70744312c01d3a43cf435d9598de</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700059%26sid%3Dliteratum%253Aachs%26aulast%3DMorgenthaler%26aufirst%3DM.%26aulast%3DSchweizer%26aufirst%3DE.%26aulast%3DHoffmann-R%25C3%25B6der%26aufirst%3DA.%26aulast%3DBenini%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DR.%2BE.%26aulast%3DJaeschke%26aufirst%3DG.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFoischer%26aufirst%3DH.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DZimmerli%26aufirst%3DD.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DDiederich%26aufirst%3DF.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26atitle%3DPredicting%2520and%2520tuning%2520physicochemical%2520properties%2520in%2520lead%2520optimization%253A%2520Amine%2520basicities%26jtitle%3DChem.%2520Med.%2520Chem.%26date%3D2007%26volume%3D2%26spage%3D1100%26epage%3D1115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="note"><p class="first last">Work was done to identify the stereochemical preference at the carboxamide stereogenic center and in each instance the more potent diastereomer is represented in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. We were unable to separate the diastereomers of compound <b>76</b> and data shown is for the mixture of diastereomers.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Lin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVita, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eid, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chicchi, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurtz, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsao, K-L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeldon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargreavesd, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S. G.</span><span> </span><span class="NLM_article-title">The discovery of potent, selective, and orally bioavailable hNK1 antagonists derived from pyrrolidine</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5191</span><span class="NLM_x">–</span> <span class="NLM_lpage">5198</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=5191-5198&author=P.+Linauthor=L.+Changauthor=R.+J.+DeVitaauthor=J.+R.+Youngauthor=R.+Eidauthor=X.+Tongauthor=S.+Zhengauthor=R.+G.+Ballauthor=N.+N.+Tsouauthor=G.+G.+Chicchiauthor=M.+M.+Kurtzauthor=K-L.+C.+Tsaoauthor=A.+Wheeldonauthor=E.+J.+Carlsonauthor=W.+Engauthor=H.+D.+Burnsauthor=R.+J.+Hargreavesdauthor=S.+G.+Mills&title=The+discovery+of+potent%2C+selective%2C+and+orally+bioavailable+hNK1+antagonists+derived+from+pyrrolidine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26aulast%3DYoung%26aufirst%3DJ.%2BR.%26aulast%3DEid%26aufirst%3DR.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DBall%26aufirst%3DR.%2BG.%26aulast%3DTsou%26aufirst%3DN.%2BN.%26aulast%3DChicchi%26aufirst%3DG.%2BG.%26aulast%3DKurtz%26aufirst%3DM.%2BM.%26aulast%3DTsao%26aufirst%3DK-L.%2BC.%26aulast%3DWheeldon%26aufirst%3DA.%26aulast%3DCarlson%26aufirst%3DE.%2BJ.%26aulast%3DEng%26aufirst%3DW.%26aulast%3DBurns%26aufirst%3DH.%2BD.%26aulast%3DHargreavesd%26aufirst%3DR.%2BJ.%26aulast%3DMills%26aufirst%3DS.%2BG.%26atitle%3DThe%2520discovery%2520of%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520hNK1%2520antagonists%2520derived%2520from%2520pyrrolidine%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D5191%26epage%3D5198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><div class="note"><p class="first last">For additional information on <b>102</b>, see the following and references therein:</p></div><span class="NLM_contrib-group">Haura, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricart, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stella, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bazhenova, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selaru, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadgeel, S. M.</span><span> </span><span class="NLM_article-title">A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non–small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">2450</span><span class="NLM_x">–</span> <span class="NLM_lpage">2457</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm301658d&amp;key=10.1158%2F1078-0432.CCR-09-1920" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm301658d&amp;key=20332327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm301658d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkslSlsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=2450-2457&author=E.+B.+Hauraauthor=A.+D.+Ricartauthor=T.+G.+Larsonauthor=P.+J.+Stellaauthor=L.+Bazhenovaauthor=V.+A.+Millerauthor=R.+B.+Cohenauthor=P.+D.+Eisenbergauthor=P.+Selaruauthor=K.+D.+Wilnerauthor=S.+M.+Gadgeel&title=A+phase+II+study+of+PD-0325901%2C+an+oral+MEK+inhibitor%2C+in+previously+treated+patients+with+advanced+non%E2%80%93small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Haura, Eric B.; Ricart, Alejandro D.; Larson, Timothy G.; Stella, Philip J.; Bazhenova, Lyudmila; Miller, Vincent A.; Cohen, Roger B.; Eisenberg, Peter D.; Selaru, Paulina; Wilner, Keith D.; Gadgeel, Shirish M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2450-2457</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To evaluate the efficacy of mitogen-activated protein kinase/extracellular signal-related kinase kinase inhibitor PD-0325901 in advanced non-small cell lung cancer patients who had experienced treatment failure after, or were refractory to, std. systemic therapy.  This open-label, phase II study initially evaluated 15 mg PD-0325901 twice daily administered intermittently (3 wk on/1 wk off; schedule A).  As this schedule was not well tolerated, a second schedule was introduced as follows: 5 days on/2 days off for 3 wk, followed by 1 wk off (schedule B).  The primary end point was objective response.  All patients had received prior systemic therapy (median of two regimens, including epidermal growth factor receptor inhibitors in 26%).  Of 13 patients treated on schedule A, three discontinued due to adverse events (blurred vision, fatigue, and hallucinations, resp.).  Twenty-one patients received schedule B. Main toxicities included diarrhea, fatigue, rash, vomiting, nausea, and reversible visual disturbances.  Hematol. toxicity consisted mainly of mild-to-moderate anemia, without neutropenia.  Chem. abnormalities were rare.  Mean (coeff. of variation) PD-0325901 trough plasma concns. were 100 ng/mL (52%) and 173 ng/mL (73%) for schedules A and B, resp., above the min. target concn. established in preclin. studies (16.5 ng/mL).  There were no objective responses.  Seven patients had stable disease.  Median (95% confidence interval) progression-free survival was 1.8 mo (1.5-1.9) and overall survival was 7.8 mo (4.5-13.9).  PD-0325901 did not meet its primary efficacy end point.  Future studies should focus on PD-0325901 schedule, rational combination strategies, and enrichment of patient selection based on mode of action.  Clin Cancer Res; 16(8); 2450-7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOnKzkhzjxz7Vg90H21EOLACvtfcHk0lhxarkhYX7w1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkslSlsbo%253D&md5=e790d14c045ba5f18b857dfdda501a1b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-1920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-1920%26sid%3Dliteratum%253Aachs%26aulast%3DHaura%26aufirst%3DE.%2BB.%26aulast%3DRicart%26aufirst%3DA.%2BD.%26aulast%3DLarson%26aufirst%3DT.%2BG.%26aulast%3DStella%26aufirst%3DP.%2BJ.%26aulast%3DBazhenova%26aufirst%3DL.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DCohen%26aufirst%3DR.%2BB.%26aulast%3DEisenberg%26aufirst%3DP.%2BD.%26aulast%3DSelaru%26aufirst%3DP.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520PD-0325901%252C%2520an%2520oral%2520MEK%2520inhibitor%252C%2520in%2520previously%2520treated%2520patients%2520with%2520advanced%2520non%25E2%2580%2593small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D2450%26epage%3D2457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span> </span><span class="NLM_article-title">Conformation-specific effects on Raf kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7332</span><span class="NLM_x">–</span> <span class="NLM_lpage">7341</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300613w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7332-7341&author=X.+Wangauthor=J.+Kim&title=Conformation-specific+effects+on+Raf+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm300613w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300613w%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DJ.%26atitle%3DConformation-specific%2520effects%2520on%2520Raf%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7332%26epage%3D7341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="note"><p class="first last">The kinase selectivity profile of <b>58</b> was similar to that of <b>3</b> with S(10) selectivity score of 0.01. For a full listing of the kinase panel data, see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="note"><p class="first last">Additional details around compound <b>2</b> will be reported in a future manuscript.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4bb4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4bb4','PDB','4bb4'); return false;">PDB: 4bb4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4H58" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4H58','PDB','4H58'); return false;">PDB: 4H58</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i122"><a href="/doi/suppl/10.1021/jm301658d">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_32106"></div></div></div></div></div><hr /></hr><p class="last">Tables SI1–SI4, Figure SI1, protein expression, purification, crystallization, and structure determination for <b>3</b> and <b>48</b>, biological and DMPK assay details, pharmacodynamic protocol, and A375 mouse xenograft assay protocol details. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm301658d/suppl_file/jm301658d_si_001.pdf">jm301658d_si_001.pdf (571.51 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm301658d&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm301658d%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-5%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm301658d" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a97946acf3cd0","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
